{"_links":{"first":[{"href":"/gidprojects/All?Page=0&PageSize=2048"}],"last":[{"href":"/gidprojects/All?Page=0&PageSize=2048"}],"self":[{"href":"/gidprojects/All?Page=0&PageSize=2048"}]},"_embedded":{"nice.indev:indevelopment-project":[{"_links":{"self":[{"href":"/project/GID-TAG377"}]},"ETag":"01000000-0000-001B-0000-000000005402","Reference":"GID-TAG377","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Atrial fibrillation - ximelagatran [ID376]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG415"}]},"ETag":"01000000-0000-001B-0000-00000000540A","Reference":"GID-TAG415","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Clinically isolated syndrome - beta interferons and glatiramer acetate [ID109]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IP1197"}]},"ETag":"01000000-0000-001B-0000-000000005494","Reference":"GID-IP1197","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Degradable surgical implant","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-08-30T14:59:34.4037121","FirstGoLiveDate":"2016-08-30T14:59:34.4037121","CreatedDate":"2014-08-11T13:09:28","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IP1156"}]},"ETag":"01000000-0000-001B-0000-000000005495","Reference":"GID-IP1156","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Ex utero intrapartum therapy for fetal obstruction ","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-08-30T15:02:34.3688355","FirstGoLiveDate":"2016-08-30T15:02:34.3688355","CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IP1153"}]},"ETag":"01000000-0000-001B-0000-000000005496","Reference":"GID-IP1153","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Extra corporeal membrane oxygenation for acute heart failure in children","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-08-30T15:02:34.3844313","FirstGoLiveDate":"2016-08-30T15:02:34.3844313","CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IP1043"}]},"ETag":"01000000-0000-001B-0000-00000000549A","Reference":"GID-IP1043","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"MRI guided focussed ultrasound for chronic pain","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-08-30T15:11:34.3892208","FirstGoLiveDate":"2016-08-30T15:11:34.3892208","CreatedDate":"2014-08-11T16:06:44","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IP1229"}]},"ETag":"01000000-0000-001B-0000-00000000549B","Reference":"GID-IP1229","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Peroral endoscopic myotomy (POEM) for achalasia ","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-08-30T15:11:34.404835","FirstGoLiveDate":"2016-08-30T15:11:34.404835","CreatedDate":"2014-08-11T15:11:16","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IP1170"}]},"ETag":"01000000-0000-001B-0000-00000000549C","Reference":"GID-IP1170","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Spineform Hemibridge endoscopic vertebral stapling to reduce curvature in the growing scoliotic spine in children ","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-08-30T15:14:34.3855836","FirstGoLiveDate":"2016-08-30T15:14:34.3855836","CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10197"}]},"ETag":"01000000-0000-001B-0000-00000000AD18","Reference":"GID-TA10197","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Bevacizumab for untreated malignant pleural mesothelioma (ID1183)","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-07-27T09:01:12.1746696","FirstGoLiveDate":"2017-07-27T09:01:12.1746696","CreatedDate":"2017-07-20T11:17:39.9805064","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG241"}]},"ETag":"01000000-0000-001C-0000-0000000014DC","Reference":"GID-TAG241","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Kidney transplantation (rejection) - everolimus [ID117]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-11-01T15:14:44.9655931","FirstGoLiveDate":"2017-11-01T15:14:44.9655931","CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IP1151"}]},"ETag":"01000000-0000-001D-0000-0000000024BB","Reference":"GID-IP1151","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Autologous unmanipulated peripheral blood stem cell therapy for multiple sclerosis","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-08-30T14:53:34.3797032","FirstGoLiveDate":"2016-08-30T14:53:34.3797032","CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10067"}]},"ETag":"01000000-0000-001D-0000-000000005694","Reference":"GID-IPG10067","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Endoscopic bipolar radiofrequency ablation for treating biliary obstruction caused by cholangiocarcinoma or pancreatic adenocarcinoma","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-01-10T10:38:47.4430321","FirstGoLiveDate":"2018-01-10T10:38:47.4430321","CreatedDate":"2018-01-10T10:35:19.1149722","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT130"}]},"ETag":"01000000-0000-001E-0000-000000000065","Reference":"GID-MT130","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"Levitronix CentriMag for treatment of refractory cardiogenic shock or severe cardiopulmonary insufficiency (discontinued)","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-02-06T12:22:24.0402664","FirstGoLiveDate":"2017-03-27T11:01:41.622957","CreatedDate":"2015-06-10T16:00:10","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10207"}]},"ETag":"01000000-0000-001E-0000-0000000009F4","Reference":"GID-TA10207","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Selumetinib for treating differentiated thyroid cancer ID1079","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-02-13T12:09:17.1834284","FirstGoLiveDate":"2017-08-02T15:01:42.0169899","CreatedDate":"2017-08-02T15:00:10.700693","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10249"}]},"ETag":"01000000-0000-001E-0000-0000000009FC","Reference":"GID-TA10249","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Talacotuzumab for untreated acute myeloid leukaemia [ID1262]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-02-13T12:18:17.126336","FirstGoLiveDate":"2017-09-28T10:03:13.7871025","CreatedDate":"2017-09-28T10:01:03.7022662","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10205"}]},"ETag":"01000000-0000-001E-0000-000000000AD7","Reference":"GID-TA10205","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"NY-ESO-1 T-cells for treating synovial sarcoma ID1286","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-02-13T14:48:17.2839173","FirstGoLiveDate":"2017-07-27T14:58:14.9814655","CreatedDate":"2017-07-27T14:57:33.6979111","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10251"}]},"ETag":"01000000-0000-001E-0000-000000000ADF","Reference":"GID-TA10251","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Doxorubicin nanoparticles for previously treated advanced hepatocellular carcinoma [ID1314]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-02-13T15:48:17.2890572","FirstGoLiveDate":"2017-09-28T10:03:55.8377295","CreatedDate":"2017-09-28T10:03:49.2858605","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10284"}]},"ETag":"01000000-0000-001E-0000-000000003162","Reference":"GID-TA10284","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Eltrombopag for untreated severe aplastic anaemia ID1198","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-03-13T11:11:11.4485172","FirstGoLiveDate":"2018-03-13T11:11:11.4485172","CreatedDate":"2017-12-22T10:48:19.3382432","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-DT9"}]},"ETag":"01000000-0000-001E-0000-000000004F61","Reference":"GID-DT9","ProjectType":"DG","ProductTypeName":"Diagnostics guidance","Process":"DT","Title":"Xpert MTB/RIF assay for the detection of active pulmonary tuberculosis and multi-drug resistant tuberculosis","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-05-09T09:05:14.4825768","FirstGoLiveDate":"2016-02-18T15:32:34.2328899","CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT163"}]},"ETag":"01000000-0000-001E-0000-0000000061A2","Reference":"GID-MT163","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"Clinitek Microalbumin 9 reagent strips for the early detection and monitoring of kidney disease (discontinued)","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-05-26T09:42:21.2722418","FirstGoLiveDate":"2016-05-26T09:42:21.2722418","CreatedDate":"2015-06-10T15:51:20","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10330"}]},"ETag":"01000000-0000-001E-0000-000000008D89","Reference":"GID-TA10330","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Pembrolizumab with epacadostat for untreated malignant melanoma ID1423","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-05-11T09:07:41.6204935","FirstGoLiveDate":"2018-03-14T10:37:14.9885141","CreatedDate":"2018-03-14T10:36:24.037136","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10203"}]},"ETag":"01000000-0000-001E-0000-00000000A9AF","Reference":"GID-TA10203","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Nivolumab with ipilimumab for previously treated extensive stage small-cell lung cancer ID1228","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-05-31T15:21:11.2345189","FirstGoLiveDate":"2017-07-27T14:44:53.6761962","CreatedDate":"2017-07-27T14:43:37.3542304","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10149"}]},"ETag":"01000000-0000-001E-0000-00000000BFA8","Reference":"GID-TA10149","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Bevacizumab as monotherapy or in combination with lomustine for glioblastoma – second line [ID978]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-01-23T15:44:08.4980634","FirstGoLiveDate":"2017-01-23T15:44:08.4980634","CreatedDate":"2017-01-23T15:42:24.4962324","DevelopedAs":null,"RelevantTo":null,"IdNumber":"978","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG410"}]},"ETag":"01000000-0000-001E-0000-00000000BFAA","Reference":"GID-TAG410","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Breast cancer (advanced and/or metastatic) - sunitinib (in combination with capecitabine) [ID319]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG389"}]},"ETag":"01000000-0000-001E-0000-00000000BFAB","Reference":"GID-TAG389","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Clostridium difficile associated diarrhoea - tolevamer [ID378]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG405"}]},"ETag":"01000000-0000-001E-0000-00000000BFAC","Reference":"GID-TAG405","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Lung cancer (non-small-cell, second line treatment) - vandetanib [ID46]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG232"}]},"ETag":"01000000-0000-001E-0000-00000000BFAE","Reference":"GID-TAG232","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Cardiac transplantation (rejection) - everolimus [ID114]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG376"}]},"ETag":"01000000-0000-001E-0000-00000000BFAF","Reference":"GID-TAG376","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Heart failure (acute decompensated) - nesiritide [ID384]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG383"}]},"ETag":"01000000-0000-001E-0000-00000000BFB0","Reference":"GID-TAG383","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Atrial fibrillation - idraparinux sodium [ID375]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG384"}]},"ETag":"01000000-0000-001E-0000-00000000BFB1","Reference":"GID-TAG384","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Venous thromboembolism (recurrent) - idraparinux sodium [ID395]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG385"}]},"ETag":"01000000-0000-001E-0000-00000000BFB2","Reference":"GID-TAG385","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Psoriatic arthritis (moderate to severe) - leflunomide [ID391]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG388"}]},"ETag":"01000000-0000-001E-0000-00000000BFB4","Reference":"GID-TAG388","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Lung cancer (non-small-cell, advanced or metastatic maintenance treatment) - erlotinib (in combination with bevacizumab) [ID44]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG391"}]},"ETag":"01000000-0000-001E-0000-00000000BFB5","Reference":"GID-TAG391","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Breast cancer (first line treatment) - sunitinib (in combination with a taxane) [ID58]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG400"}]},"ETag":"01000000-0000-001E-0000-00000000BFB6","Reference":"GID-TAG400","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Juvenile idiopathic arthritis - adalimumab [ID385]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG416"}]},"ETag":"01000000-0000-001E-0000-00000000BFB7","Reference":"GID-TAG416","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Atrial fibrillation - clopidogrel (in combination with aspirin) [ID95]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG408"}]},"ETag":"01000000-0000-001E-0000-00000000BFB8","Reference":"GID-TAG408","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Leukaemia (chronic myeloid) - nilotinib (discontinued) [ID79]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":"2011-05-01T00:00:00","LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG394"}]},"ETag":"01000000-0000-001E-0000-00000000BFB9","Reference":"GID-TAG394","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Pancreatic cancer - capecitabine [ID389]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-02-12T10:38:02.6782141","FirstGoLiveDate":"2016-02-12T10:38:02.6782141","CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":"389","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG401"}]},"ETag":"01000000-0000-001E-0000-00000000BFBA","Reference":"GID-TAG401","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Melanoma (advanced and metastatic) - temozolomide [ID316]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10138"}]},"ETag":"01000000-0000-001E-0000-00000000BFBB","Reference":"GID-TA10138","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Nintedanib for previously treated metastatic colorectal cancer [ID1030]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-11-29T01:01:40.8824949","FirstGoLiveDate":"2016-11-29T01:01:40.8824949","CreatedDate":"2016-11-22T12:24:45.6959983","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1030","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10140"}]},"ETag":"01000000-0000-001E-0000-00000000BFBF","Reference":"GID-TA10140","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Nivolumab for treating relapsed or refractory diffuse large B-cell lymphoma [ID986]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-12-08T01:01:13.9632003","FirstGoLiveDate":"2016-12-08T01:01:13.9632003","CreatedDate":"2016-12-01T18:32:36.9424264","DevelopedAs":null,"RelevantTo":null,"IdNumber":"986","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10144"}]},"ETag":"01000000-0000-001E-0000-00000000BFC0","Reference":"GID-TA10144","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma after autologous stem cell transplant [ID1103]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-06-21T14:08:41.0080345","FirstGoLiveDate":"2016-12-29T01:01:46.8578164","CreatedDate":"2016-12-22T13:33:06.5481772","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1103","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG406"}]},"ETag":"01000000-0000-001E-0000-00000000BFC3","Reference":"GID-TAG406","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Lung cancer (non-small-cell, advanced or metastatic second line) - erlotinib (in combination with bevacizumab) [ID43]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10183"}]},"ETag":"01000000-0000-001E-0000-00000000BFC4","Reference":"GID-TA10183","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"NGR-TNF for previously treated advanced malignant pleural mesothelioma (ID655)","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-07-20T10:53:51.0436172","FirstGoLiveDate":"2017-06-23T11:35:42.8297939","CreatedDate":"2017-06-23T11:29:35.5703948","DevelopedAs":null,"RelevantTo":null,"IdNumber":"655","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10126"}]},"ETag":"01000000-0000-001E-0000-00000000C097","Reference":"GID-TA10126","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Nivolumab for treating recurrent glioblastoma [ID998]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-05-10T09:59:15.6719787","FirstGoLiveDate":"2016-10-19T00:01:32.7344323","CreatedDate":"2016-10-12T12:35:45.6432991","DevelopedAs":null,"RelevantTo":null,"IdNumber":"998","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG221"}]},"ETag":"01000000-0000-001E-0000-00000000C099","Reference":"GID-TAG221","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Multiple sclerosis (primary-progressive) - fingolimod [ID62]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2015-10-08T08:40:37.750051","FirstGoLiveDate":"2015-10-08T08:40:37.750051","CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10185"}]},"ETag":"01000000-0000-001E-0000-00000000D0A6","Reference":"GID-TA10185","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Ibrutinib for untreated mantle cell lymphoma (ID1221)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-06-19T12:13:47.0569349","FirstGoLiveDate":"2017-06-26T09:17:42.5398091","CreatedDate":"2017-06-26T09:08:54.3286678","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1221","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10036"}]},"ETag":"01000000-0000-001E-0000-0000000106E4","Reference":"GID-QS10036","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Acne","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-24T13:30:32.3137214","FirstGoLiveDate":"2016-08-22T07:40:25.5693041","CreatedDate":"2016-08-22T07:37:47.1809737","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10038"}]},"ETag":"01000000-0000-001E-0000-000000010703","Reference":"GID-QS10038","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Adrenal dysfunction","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-24T14:15:32.3657352","FirstGoLiveDate":"2016-08-22T07:48:33.1434288","CreatedDate":"2016-08-22T07:47:04.6109088","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10093"}]},"ETag":"01000000-0000-001E-0000-000000010782","Reference":"GID-QS10093","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Pain management (young people and adults)","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-24T15:09:32.6062035","FirstGoLiveDate":"2018-07-24T15:09:32.6062035","CreatedDate":"2018-07-24T15:06:49.0623913","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10085"}]},"ETag":"01000000-0000-001E-0000-0000000107A5","Reference":"GID-QS10085","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Pancreatitis (including acute pancreatitis)","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-24T15:15:32.3920515","FirstGoLiveDate":"2018-07-24T14:36:32.3012064","CreatedDate":"2018-07-24T14:34:12.613815","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10088"}]},"ETag":"01000000-0000-001E-0000-0000000107BA","Reference":"GID-QS10088","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Thyroid disease","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-24T15:18:32.3611194","FirstGoLiveDate":"2018-07-24T14:57:32.6202382","CreatedDate":"2018-07-24T14:53:59.7462374","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10089"}]},"ETag":"01000000-0000-001E-0000-0000000107BD","Reference":"GID-QS10089","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Primary hyperparathyroidism","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-24T15:18:32.371119","FirstGoLiveDate":"2018-07-24T15:00:32.6337387","CreatedDate":"2018-07-24T14:57:24.0541143","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10096"}]},"ETag":"01000000-0000-001E-0000-0000000107E1","Reference":"GID-QS10096","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Sleep disordered breathing","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-24T15:24:32.6927015","FirstGoLiveDate":"2018-07-24T15:24:32.6927015","CreatedDate":"2018-07-24T15:23:10.4135526","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10103"}]},"ETag":"01000000-0000-001E-0000-00000001086A","Reference":"GID-QS10103","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Managing symptoms with an uncertain cause","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-24T16:09:58.1995433","FirstGoLiveDate":"2018-07-24T16:09:58.1995433","CreatedDate":"2018-07-24T16:07:42.4665892","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10105"}]},"ETag":"01000000-0000-001E-0000-000000010880","Reference":"GID-QS10105","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Readmission to ICU within 48hrs","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-24T16:18:32.774608","FirstGoLiveDate":"2018-07-24T16:18:32.774608","CreatedDate":"2018-07-24T16:16:38.4505608","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10107"}]},"ETag":"01000000-0000-001E-0000-00000001088E","Reference":"GID-QS10107","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Secondary care management of malignant hypertension","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-24T16:27:32.8290942","FirstGoLiveDate":"2018-07-24T16:27:32.8290942","CreatedDate":"2018-07-24T16:25:56.8452096","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10109"}]},"ETag":"01000000-0000-001E-0000-0000000108A4","Reference":"GID-QS10109","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Prevention of dementia","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-24T16:33:58.5994356","FirstGoLiveDate":"2018-07-24T16:33:58.5994356","CreatedDate":"2018-07-24T16:33:13.7992813","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10099"}]},"ETag":"01000000-0000-001E-0000-000000010A9E","Reference":"GID-QS10099","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Gambling","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-25T14:44:59.5495536","FirstGoLiveDate":"2018-07-25T14:44:59.5495536","CreatedDate":"2018-07-24T15:50:59.6196947","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10124"}]},"ETag":"01000000-0000-001E-0000-000000010AC5","Reference":"GID-QS10124","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Vulnerable populations: strategies for tackling inequalities","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-25T14:56:59.8617875","FirstGoLiveDate":"2018-07-25T14:56:59.8617875","CreatedDate":"2018-07-25T14:53:56.3048246","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10100"}]},"ETag":"01000000-0000-001E-0000-000000010D6E","Reference":"GID-QS10100","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Gout","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-26T15:53:00.203295","FirstGoLiveDate":"2018-07-24T16:00:32.7106392","CreatedDate":"2018-07-24T15:57:51.6714606","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10204"}]},"ETag":"01000000-0000-001E-0000-00000001138F","Reference":"GID-TA10204","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"ATA129 for treating post-transplant lymphoproliferative disorder caused by the Epstein-Barr virus ID1203","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-31T10:36:51.3202326","FirstGoLiveDate":"2017-07-27T14:46:15.0495037","CreatedDate":"2017-07-27T14:44:53.675377","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT81"}]},"ETag":"01000000-0000-001E-0000-000000011C34","Reference":"GID-MT81","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"SILK artery reconstruction device (discontinued)","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-05-16T12:36:00.2473423","FirstGoLiveDate":"2016-04-28T16:05:16.158821","CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10052"}]},"ETag":"01000000-0000-001E-0000-000000013CFE","Reference":"GID-NG10052","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Assessment, referral and management of Adrenal dysfunction","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-08-30T14:45:38.2281504","FirstGoLiveDate":"2016-10-11T12:55:31.7139027","CreatedDate":"2016-10-11T12:49:14.7527304","DevelopedAs":"CG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IP267"}]},"ETag":"01000000-0000-001E-0000-000000017FDB","Reference":"GID-IP267","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Intravaginal sling for stress urinary incontinence","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-08-30T15:08:34.3928563","FirstGoLiveDate":"2016-08-30T15:08:34.3928563","CreatedDate":"2014-08-18T16:15:33","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10401"}]},"ETag":"01000000-0000-001E-0000-00000001883B","Reference":"GID-TA10401","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Carotuximab with pazopanib for treating advanced angiosarcoma ID1503","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-10-22T14:18:19.6517696","FirstGoLiveDate":"2018-10-22T14:18:19.6517696","CreatedDate":"2018-10-22T14:17:18.0191429","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10227"}]},"ETag":"01000000-0000-001E-0000-000000018DA3","Reference":"GID-TA10227","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Asunercept for treating glioblastoma [1301]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-08-11T12:08:32.2976584","FirstGoLiveDate":"2017-08-11T12:08:32.2976584","CreatedDate":"2017-08-11T12:06:08.4306124","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10289"}]},"ETag":"01000000-0000-001E-0000-000000018DA4","Reference":"GID-TA10289","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Mepolizumab for treating eosinophilic granulomatosis with polyangiitis ID1186","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-01-15T11:14:45.806376","FirstGoLiveDate":"2018-01-15T11:14:45.806376","CreatedDate":"2018-01-15T11:11:46.111171","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10225"}]},"ETag":"01000000-0000-001E-0000-000000019DCD","Reference":"GID-TA10225","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Cimavax for treating wild-type EGFR-positive non-small-cell lung cancer [1259]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-08-11T11:53:33.5262042","FirstGoLiveDate":"2017-08-11T11:53:33.5262042","CreatedDate":"2017-08-11T11:52:14.0988572","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10074"}]},"ETag":"01000000-0000-001E-0000-00000001AE96","Reference":"GID-TA10074","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Binimetinib for treating melanoma [ID833]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-06-08T10:28:29.2139307","FirstGoLiveDate":"2016-07-08T01:02:22.0499639","CreatedDate":"2016-07-01T14:01:57.2355343","DevelopedAs":null,"RelevantTo":null,"IdNumber":"833","EvidenceAssessmentGroup":"BMJ Evidence Centre, BMJ Group","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10081"}]},"ETag":"01000000-0000-001E-0000-00000001AE98","Reference":"GID-TA10081","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Clofarabine for treating acute lymphoblastic leukaemia in children after 2 therapies [ID1033] ","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-12-08T01:01:13.9163046","FirstGoLiveDate":"2016-07-15T01:02:39.7016913","CreatedDate":"2016-07-08T15:01:38.1519961","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1033","EvidenceAssessmentGroup":"Warwick Evidence","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10087"}]},"ETag":"01000000-0000-001E-0000-00000001AE9A","Reference":"GID-TA10087","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Nelarabine for treating refractory T-cell lymphoblastic non-Hodgkin’s lymphoma [ID1044]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":"2017-12-27T00:00:00","LastModifiedDate":"2016-12-08T01:01:13.9475737","FirstGoLiveDate":"2016-08-05T14:07:46.3096651","CreatedDate":"2016-07-22T14:43:19.7869813","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1044","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10130"}]},"ETag":"01000000-0000-001E-0000-00000001B8F3","Reference":"GID-QS10130","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Pernicious anaemia","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-11-16T16:12:58.0031343","FirstGoLiveDate":"2018-10-17T15:36:20.0964819","CreatedDate":"2018-10-17T15:24:12.0629774","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10057"}]},"ETag":"01000000-0000-001E-0000-00000001BF19","Reference":"GID-QS10057","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Depression in adults (update)","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-11-20T16:35:51.7388032","FirstGoLiveDate":"2017-09-28T19:36:56.5650832","CreatedDate":"2017-09-28T19:32:39.4075164","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10035"}]},"ETag":"01000000-0000-001E-0000-00000001BF1A","Reference":"GID-QS10035","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Abdominal aortic aneurysm","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-11-20T16:35:51.7508109","FirstGoLiveDate":"2016-08-22T07:36:33.2458508","CreatedDate":"2016-08-22T07:33:07.6457159","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10437"}]},"ETag":"01000000-0000-001E-0000-00000001C0D5","Reference":"GID-TA10437","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Ofatumumab (Arzerra) in combination with chemotherapy for follicular lymphoma; second line - refractory to rituximab ID1487","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-11-21T15:18:02.6443468","FirstGoLiveDate":"2018-11-21T15:18:02.6443468","CreatedDate":"2018-11-21T15:15:24.2931465","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10426"}]},"ETag":"01000000-0000-001E-0000-00000001C821","Reference":"GID-TA10426","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Dabigatran etexilate for the secondary prevention of stroke after an embolic stroke of undetermined source (ID1417)","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-11-26T16:34:08.9409384","FirstGoLiveDate":"2018-11-20T06:00:21.82196","CreatedDate":"2018-11-13T15:32:22.1991008","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1417","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10166"}]},"ETag":"01000000-0000-001E-0000-00000001EEA2","Reference":"GID-TA10166","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Renal cell carcinoma - sunitinib [ID1076]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-12-20T09:00:24.5847097","FirstGoLiveDate":"2017-05-11T12:11:48.3049068","CreatedDate":"2017-05-11T12:07:18.4531563","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1076","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG250"}]},"ETag":"01000000-0000-001E-0000-00000001F0B2","Reference":"GID-TAG250","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Osteoarthritis - diacerein [ID332]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-12-21T11:18:23.8372915","FirstGoLiveDate":"2018-12-21T11:18:23.8372915","CreatedDate":"2015-04-09T10:57:22","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10091"}]},"ETag":"01000000-0000-001E-0000-00000001F138","Reference":"GID-QS10091","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Tinnitus","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-24T15:03:32.34079","FirstGoLiveDate":"2018-07-24T15:03:32.34079","CreatedDate":"2018-07-24T15:01:11.8606695","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10394"}]},"ETag":"01000000-0000-001E-0000-00000001F180","Reference":"GID-TA10394","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Durvalumab for treating metastatic urothelial bladder cancer after chemotherapy ID1172","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-09-28T11:05:06.6990861","FirstGoLiveDate":"2018-09-28T11:05:06.6990861","CreatedDate":"2018-09-28T11:03:24.2756781","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10446"}]},"ETag":"01000000-0000-001E-0000-0000000203DE","Reference":"GID-TA10446","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Cositecan for treating platinum or taxane resistant advanced, mucinous, epithelial ovarian cancer [ID826]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-01-04T10:38:49.663873","FirstGoLiveDate":"2019-01-04T10:38:49.663873","CreatedDate":"2019-01-04T10:36:14.5487108","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10101"}]},"ETag":"01000000-0000-001E-0000-000000020B95","Reference":"GID-QS10101","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Heart valve disease in adults","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-24T16:00:32.7476405","FirstGoLiveDate":"2018-07-24T16:00:32.7476405","CreatedDate":"2018-07-24T15:59:07.6923689","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10445"}]},"ETag":"01000000-0000-001E-0000-0000000217EB","Reference":"GID-TA10445","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"ATIR101 with haploidentical haematopoietic stem cell transplantation for haematological cancers  [ID1093]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-01-17T14:19:29.1345124","FirstGoLiveDate":"2019-01-04T10:33:28.1424573","CreatedDate":"2019-01-04T10:27:54.659975","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1093","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10086"}]},"ETag":"01000000-0000-001E-0000-0000000241AD","Reference":"GID-QS10086","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Diverticular disease","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-24T15:15:32.4020511","FirstGoLiveDate":"2018-07-24T14:39:32.3142855","CreatedDate":"2018-07-24T14:37:20.3329055","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT117"}]},"ETag":"01000000-0000-001E-0000-000000024937","Reference":"GID-MT117","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"OraQuick® HCV Rapid Antibody Test (discontinued)","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-03-27T13:28:41.6601071","FirstGoLiveDate":"2016-04-08T11:34:28.234191","CreatedDate":"2014-08-13T13:45:58","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10210"}]},"ETag":"01000000-0000-001E-0000-000000027AF6","Reference":"GID-TA10210","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Avelumab for treating gastric or gastro-oesophageal junction cancer after 2 therapies ID1289","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-02-13T14:03:17.3025096","FirstGoLiveDate":"2017-08-03T09:02:54.9273111","CreatedDate":"2017-08-03T09:02:29.7569651","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10326"}]},"ETag":"01000000-0000-001E-0000-000000027AF8","Reference":"GID-TA10326","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Taselisib for previously treated ER-positive, HER2-negative, PIK3CA-positive breast cancer in postmenopausal women ID1401","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-06-12T08:40:38.2946959","FirstGoLiveDate":"2018-03-14T10:31:14.9998254","CreatedDate":"2018-03-14T10:30:15.6333975","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10252"}]},"ETag":"01000000-0000-001E-0000-000000028D25","Reference":"GID-TA10252","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer [ID1333]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-04-03T09:45:55.750786","FirstGoLiveDate":"2017-09-28T10:18:13.3766004","CreatedDate":"2017-09-28T10:16:29.9161361","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10102"}]},"ETag":"01000000-0000-001E-0000-0000000294DE","Reference":"GID-QS10102","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Infant, children and young people's experience of health care","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-24T16:09:32.3112416","FirstGoLiveDate":"2018-07-24T16:09:32.3112416","CreatedDate":"2018-07-24T16:05:54.2890859","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10473"}]},"ETag":"01000000-0000-001E-0000-000000029A60","Reference":"GID-TA10473","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer after platinum-based chemotherapy [ID1231]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-04-11T00:02:26.0229051","FirstGoLiveDate":"2019-04-11T00:02:26.0229051","CreatedDate":"2019-04-04T16:28:33.7504376","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10223"}]},"ETag":"01000000-0000-001E-0000-00000002BD49","Reference":"GID-TA10223","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Ibrutinib for treating relapsed or refractory follicular lymphoma [1251]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-08-11T11:20:56.8376213","FirstGoLiveDate":"2017-08-11T11:20:56.8376213","CreatedDate":"2017-08-11T11:20:28.2302038","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IP1112"}]},"ETag":"01000000-0000-001E-0000-00000002C473","Reference":"GID-IP1112","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Cutting blocks for total knee arthroplasty\n","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-08-30T14:59:34.3881076","FirstGoLiveDate":"2016-08-30T14:59:34.3881076","CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10486"}]},"ETag":"01000000-0000-001E-0000-00000002C5EC","Reference":"GID-TA10486","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pegargiminase with pemetrexed and cisplatin for untreated advanced malignant pleural\r\nmesothelioma [ID1575]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-05-08T16:06:59.2881317","FirstGoLiveDate":"2019-05-02T10:25:11.0441244","CreatedDate":"2019-05-02T10:14:59.7436094","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1575","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10108"}]},"ETag":"01000000-0000-001E-0000-00000002D08C","Reference":"GID-QS10108","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Seven day working","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-05-15T11:51:45.9070301","FirstGoLiveDate":"2018-07-24T16:30:32.8295903","CreatedDate":"2018-07-24T16:28:12.4015598","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10355"}]},"ETag":"01000000-0000-001E-0000-00000002F029","Reference":"GID-TA10355","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Depatuxizumab mafodotin in combination for untreated EGFR-amplified glioblastoma ID1466","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-06-04T15:54:30.7814407","FirstGoLiveDate":"2018-06-08T12:38:09.4151716","CreatedDate":"2018-06-08T12:37:37.5895248","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1466","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG412"}]},"ETag":"01000000-0000-001E-0000-00000002FDD2","Reference":"GID-TAG412","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Psoriasis - briakinumab (suspended) [ID65]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10248"}]},"ETag":"01000000-0000-001E-0000-0000000333D9","Reference":"GID-TA10248","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Veliparib with carboplatin and paclitaxel for untreated non-squamous non-small-cell lung cancer [ID1277]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-02-13T14:33:17.1335241","FirstGoLiveDate":"2017-09-28T10:00:13.4415677","CreatedDate":"2017-09-28T09:57:54.2156243","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10148"}]},"ETag":"01000000-0000-001E-0000-0000000333DB","Reference":"GID-TA10148","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Nivolumab monotherapy for non-small-cell lung cancer [ID1088]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-01-23T10:52:55.6175681","FirstGoLiveDate":"2017-01-23T10:52:55.6175681","CreatedDate":"2017-01-23T10:44:56.3587804","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1088","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10097"}]},"ETag":"01000000-0000-001E-0000-000000033A96","Reference":"GID-QS10097","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Shared decision-making: practical guidance for health and social care professionals","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-24T15:33:32.7072081","FirstGoLiveDate":"2018-07-24T15:33:32.7072081","CreatedDate":"2018-07-24T15:29:59.3232188","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10354"}]},"ETag":"01000000-0000-001E-0000-0000000361A2","Reference":"GID-TA10354","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Atezolizumab with cobimetinib for untreated BRAF wild-type metastatic melanoma ID1470","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-08-15T00:01:19.2950038","FirstGoLiveDate":"2018-06-08T12:37:29.1657795","CreatedDate":"2018-06-08T12:36:53.252767","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10152"}]},"ETag":"01000000-0000-001E-0000-0000000396D0","Reference":"GID-NG10152","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Diabetes update","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-09-18T09:04:04.3321745","FirstGoLiveDate":"2019-07-31T09:15:58.2745087","CreatedDate":"2019-07-31T09:09:37.0675672","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10480"}]},"ETag":"01000000-0000-001E-0000-000000039A66","Reference":"GID-TA10480","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-09-19T16:10:08.2970371","FirstGoLiveDate":"2019-05-01T14:57:46.840424","CreatedDate":"2019-05-01T14:00:03.8380183","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1611","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10546"}]},"ETag":"01000000-0000-001E-0000-00000003BE29","Reference":"GID-TA10546","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-10-11T13:32:26.0837135","FirstGoLiveDate":"2019-10-11T13:32:26.0837135","CreatedDate":"2019-10-11T13:30:44.2571518","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-DT28"}]},"ETag":"01000000-0000-001E-0000-00000003D1AE","Reference":"GID-DT28","ProjectType":"DG","ProductTypeName":"Diagnostics guidance","Process":"DT","Title":"Multiple myeloma and related disorders - Freelite assays (and alternative technologies identified during scoping) for diagnosis in primary care","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-01-04T08:23:36.366229","FirstGoLiveDate":"2016-02-10T00:01:58.6682272","CreatedDate":"2015-05-22T17:01:44","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10542"}]},"ETag":"01000000-0000-001E-0000-00000003D8CD","Reference":"GID-TA10542","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-10-28T08:47:33.4330092","FirstGoLiveDate":"2019-10-02T12:11:16.8144337","CreatedDate":"2019-10-02T12:09:53.2796427","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10129"}]},"ETag":"01000000-0000-001E-0000-0000000420A3","Reference":"GID-QS10129","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Pelvic floor dysfunction","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-12-10T17:33:37.5346009","FirstGoLiveDate":"2018-10-12T11:14:21.2588113","CreatedDate":"2018-10-12T11:10:30.8793502","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10163"}]},"ETag":"01000000-0000-001E-0000-000000042DBC","Reference":"GID-NG10163","ProjectType":"NG","ProductTypeName":"Antimicrobial prescribing guideline","Process":"APG","Title":"Skin abscess: antimicrobial prescribing","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-12-18T17:09:47.5244776","FirstGoLiveDate":"2019-12-18T17:09:47.5244776","CreatedDate":"2019-12-18T17:05:04.385153","DevelopedAs":"APG","RelevantTo":"APG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":["AMP"]},{"_links":{"self":[{"href":"/project/GID-TA10553"}]},"ETag":"01000000-0000-001E-0000-000000042EDD","Reference":"GID-TA10553","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Gosuranemab for treating progressive supranuclear palsy [ID1607]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-12-19T11:06:47.3904151","FirstGoLiveDate":"2019-11-21T06:00:28.2053377","CreatedDate":"2019-11-18T10:56:38.5716592","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1607","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IP1131"}]},"ETag":"01000000-0000-001E-0000-000000042FB7","Reference":"GID-IP1131","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Cervical ripening ballon for the induction of labour in women who have previously undergone cesarean section","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-12-19T17:04:38.9058667","FirstGoLiveDate":"2019-12-19T17:04:38.9058667","CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-SGWAVE0702"}]},"ETag":"01000000-0000-001E-0000-00000004484E","Reference":"GID-SGWAVE0702","ProjectType":"SG","ProductTypeName":"NICE guideline","Process":"SG","Title":"Mental health community settings","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2015-08-04T09:52:15","FirstGoLiveDate":null,"CreatedDate":"2015-08-04T09:52:15","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10208"}]},"ETag":"01000000-0000-001E-0000-00000004607D","Reference":"GID-TA10208","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Pembrolizumab for previously treated metastatic gastric or gastro-oesophageal junction cancer ID1168","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-02-13T12:03:17.3158068","FirstGoLiveDate":"2017-08-02T15:04:42.0511143","CreatedDate":"2017-08-02T15:04:12.4947135","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IP1145"}]},"ETag":"01000000-0000-001E-0000-0000000461B5","Reference":"GID-IP1145","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Implantable Vagus Nerve Stimulator in Heart Failure","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-08-30T15:05:34.3964769","FirstGoLiveDate":"2016-08-30T15:05:34.3964769","CreatedDate":"2015-05-29T16:49:41","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10211"}]},"ETag":"01000000-0000-001E-0000-0000000461E9","Reference":"GID-TA10211","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Venetoclax with ibrutinib and obinutuzumab for untreated chronic lymphocytic leukaemia ID1270","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-10-12T10:44:21.1985285","FirstGoLiveDate":"2017-08-03T09:04:48.5058391","CreatedDate":"2017-08-03T09:03:54.4999936","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10607"}]},"ETag":"01000000-0000-001E-0000-0000000461EF","Reference":"GID-TA10607","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Cediranib with olaparib for treating recurrent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer after 3 therapies [ID1639]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-01-21T13:34:27.4861","FirstGoLiveDate":"2020-01-21T13:34:27.4861","CreatedDate":"2020-01-21T13:33:31.4775633","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10589"}]},"ETag":"01000000-0000-001E-0000-0000000467E4","Reference":"GID-TA10589","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Ixazomib citrate for maintenance treatment of untreated multiple myeloma in people who cannot have autologous stem cell transplant [ID2706]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-01-24T10:44:55.7339926","FirstGoLiveDate":"2020-01-10T11:40:13.1204762","CreatedDate":"2020-01-10T11:39:04.0426622","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2706","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10573"}]},"ETag":"01000000-0000-001E-0000-0000000467ED","Reference":"GID-TA10573","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"MTX110 for untreated diffuse intrinsic pontine glioma [ID2695]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-01-24T10:46:30.3551095","FirstGoLiveDate":"2019-12-16T10:19:03.1813038","CreatedDate":"2019-12-16T10:18:00.2035857","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2695","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10568"}]},"ETag":"01000000-0000-001E-0000-000000046842","Reference":"GID-TA10568","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Belantamab mafodotin for treating relapsed or refractory multiple myeloma after 3 therapies [ID2701]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-01-24T10:56:55.7289638","FirstGoLiveDate":"2019-12-16T09:58:25.966546","CreatedDate":"2019-12-16T09:57:06.0518734","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2701","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10617"}]},"ETag":"01000000-0000-001E-0000-00000004710C","Reference":"GID-TA10617","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-01-29T10:04:36.0548657","FirstGoLiveDate":"2020-01-29T10:01:36.0401165","CreatedDate":"2020-01-29T09:59:52.6031221","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3752","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10623"}]},"ETag":"01000000-0000-001E-0000-000000047E9D","Reference":"GID-TA10623","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Atezolizumab for adjuvant treatment of resected high-risk muscle-invasive urothelial cancer [ID2730]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-02-06T14:54:23.4783361","FirstGoLiveDate":"2020-02-06T14:48:23.5234355","CreatedDate":"2020-02-06T14:46:13.0276762","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2730","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10585"}]},"ETag":"01000000-0000-001E-0000-000000047FED","Reference":"GID-TA10585","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nivolumab with ipilimumab for untreated PD-L1 mutation-positive non-small-cell lung cancer [ID1675]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-02-05T11:04:45.4079468","FirstGoLiveDate":"2019-12-18T10:30:53.4155351","CreatedDate":"2019-12-18T10:28:05.4470043","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1675","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10490"}]},"ETag":"01000000-0000-001E-0000-000000048872","Reference":"GID-TA10490","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer before chemotherapy [ID1619]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-02-12T15:22:54.1281943","FirstGoLiveDate":"2019-05-08T11:30:59.6206248","CreatedDate":"2019-05-08T11:28:32.242886","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1619","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10492"}]},"ETag":"01000000-0000-001E-0000-000000048873","Reference":"GID-TA10492","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nivolumab in combination for treating hormone-relapsed metastatic prostate cancer after chemotherapy [ID1621]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-02-12T15:22:54.1438156","FirstGoLiveDate":"2019-05-08T11:36:59.5321056","CreatedDate":"2019-05-08T11:35:12.5307464","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1621","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10590"}]},"ETag":"01000000-0000-001E-0000-000000048C6C","Reference":"GID-TA10590","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nivolumab for treating platinum-resistant advanced or recurrent ovarian cancer [ID2714]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":"2021-05-19T00:00:00","LastModifiedDate":"2020-02-14T15:29:03.8797435","FirstGoLiveDate":"2020-01-10T11:50:19.4881726","CreatedDate":"2020-01-10T11:48:36.8633398","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2714","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10160"}]},"ETag":"01000000-0000-001E-0000-000000049298","Reference":"GID-IPG10160","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Endobronchial vagal nerve ablation for chronic obstructive pulmonary disease","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-02-18T15:29:05.6462958","FirstGoLiveDate":"2020-02-18T15:29:05.6462958","CreatedDate":"2020-02-18T15:28:30.6933264","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG386"}]},"ETag":"01000000-0000-001E-0000-000000049612","Reference":"GID-TAG386","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Diabetic retinopathy - ruboxistaurin [ID382]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10625"}]},"ETag":"01000000-0000-001E-0000-00000004A078","Reference":"GID-TA10625","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Crizotinib for treating metastatic c-MET exon 14-positive non-small-cell lung cancer [ID1472]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-02-27T08:35:10.6258834","FirstGoLiveDate":"2020-02-27T08:35:10.6258834","CreatedDate":"2020-02-27T08:33:16.2028228","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1472","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10447"}]},"ETag":"01000000-0000-001E-0000-00000004A2E9","Reference":"GID-TA10447","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Ublituximab with ibrutinib for previously treated chronic lymphocytic leukaemia [ID1476]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-02-28T13:14:13.149038","FirstGoLiveDate":"2019-01-04T10:38:49.7588213","CreatedDate":"2019-01-04T10:37:14.6781593","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10628"}]},"ETag":"01000000-0000-001E-0000-00000004B204","Reference":"GID-TA10628","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Avelumab for maintenance treatment of advanced gastric or gastro-oesophageal junction cancer after platinum-based chemotherapy [ID2693]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-03-09T10:23:25.1024308","FirstGoLiveDate":"2020-03-09T10:23:25.1024308","CreatedDate":"2020-03-09T10:21:31.8447969","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2693","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10627"}]},"ETag":"01000000-0000-001E-0000-00000004B209","Reference":"GID-TA10627","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Masitinib for treating malignant melanoma that has a c-Kit juxtamembrane mutation [ID1082]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-03-09T10:20:25.1888313","FirstGoLiveDate":"2020-03-09T10:20:25.1888313","CreatedDate":"2020-03-09T10:15:49.955727","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10329"}]},"ETag":"01000000-0000-001E-0000-00000004B20E","Reference":"GID-TA10329","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Paclitaxel as albumin-bound nanoparticles with gemcitabine for adjuvant treatment of pancreatic cancer ID1413","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-03-09T10:25:29.9302897","FirstGoLiveDate":"2018-03-14T10:37:14.9464669","CreatedDate":"2018-03-14T10:35:06.7179403","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1413","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10604"}]},"ETag":"01000000-0000-001E-0000-00000004B6CB","Reference":"GID-TA10604","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Cabotegravir with rilpivirine for the oral treatment of HIV-1 [ID3731]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-01-15T09:01:47.4393943","FirstGoLiveDate":"2020-01-15T09:01:47.4393943","CreatedDate":"2020-01-15T08:59:54.0246416","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3731","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10163"}]},"ETag":"01000000-0000-001E-0000-00000004CF48","Reference":"GID-IPG10163","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Intramedullary distraction for upper limb lengthening","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-03-27T14:23:09.8393421","FirstGoLiveDate":"2020-03-27T14:23:09.8393421","CreatedDate":"2020-03-27T14:05:28.2171431","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1770","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10250"}]},"ETag":"01000000-0000-001E-0000-00000004CFAC","Reference":"GID-TA10250","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Avelumab for untreated PD-L1 positive recurrent or metastatic non-small-cell lung cancer [ID1261]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-03-27T14:50:09.8588247","FirstGoLiveDate":"2017-09-28T10:03:13.8291052","CreatedDate":"2017-09-28T10:02:11.3998593","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1261","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10634"}]},"ETag":"01000000-0000-001E-0000-00000004D685","Reference":"GID-TA10634","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Savolitinib for treating MET-driven unresectable advanced papillary renal cell carcinoma [ID1638]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-04-01T10:11:20.5505831","FirstGoLiveDate":"2020-04-01T10:11:20.5505831","CreatedDate":"2020-04-01T10:06:45.9055858","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1638","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10637"}]},"ETag":"01000000-0000-001E-0000-00000004D6A0","Reference":"GID-TA10637","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Eryaspase with chemotherapy for previously treated advanced or metastatic pancreatic cancer [ID3781]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-04-01T11:08:20.5698337","FirstGoLiveDate":"2020-04-01T11:08:20.5698337","CreatedDate":"2020-04-01T11:05:37.0512326","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3781","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10638"}]},"ETag":"01000000-0000-001E-0000-00000004D6A1","Reference":"GID-TA10638","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Naxitamab with GM-CSF for treating relapsed or refractory high-risk neuroblastoma [ID3769]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-04-01T11:08:20.6479658","FirstGoLiveDate":"2020-04-01T11:08:20.6479658","CreatedDate":"2020-04-01T11:07:04.05434","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3769","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10325"}]},"ETag":"01000000-0000-001E-0000-00000004DEA3","Reference":"GID-TA10325","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Guadecitabine for untreated acute myeloid leukaemia ID1411","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-04-06T00:02:31.8260449","FirstGoLiveDate":"2018-03-14T10:28:14.8986753","CreatedDate":"2018-03-14T10:28:10.3457754","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10134"}]},"ETag":"01000000-0000-001E-0000-00000004ED7B","Reference":"GID-TA10134","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Elotuzumab for multiple myeloma [ID966]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-04-15T00:03:05.9505939","FirstGoLiveDate":"2016-11-15T01:01:43.750093","CreatedDate":"2016-11-08T11:50:05.5020356","DevelopedAs":null,"RelevantTo":null,"IdNumber":"966","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10494"}]},"ETag":"01000000-0000-001E-0000-00000004F1CF","Reference":"GID-TA10494","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-04-17T15:24:20.3335849","FirstGoLiveDate":"2019-05-08T11:54:59.6065244","CreatedDate":"2019-05-08T11:51:42.5680199","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1597","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10343"}]},"ETag":"01000000-0000-001F-0000-000000000117","Reference":"GID-TA10343","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Abemaciclib for treating KRAS mutation-positive non-small-cell lung cancer after platinum-based chemotherapy ID1147","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-05-08T08:41:59.7180821","FirstGoLiveDate":"2018-05-08T08:41:59.7180821","CreatedDate":"2018-05-08T08:38:12.137296","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10167"}]},"ETag":"01000000-0000-001F-0000-00000000018D","Reference":"GID-NG10167","ProjectType":"NG","ProductTypeName":"Antimicrobial prescribing guideline","Process":"APG","Title":"Stye: antimicrobial prescribing","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-02-26T15:46:04.2562175","FirstGoLiveDate":"2020-02-12T09:24:33.7893206","CreatedDate":"2020-02-12T09:21:46.1807004","DevelopedAs":"APG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":["AMP"]},{"_links":{"self":[{"href":"/project/GID-NG10168"}]},"ETag":"01000000-0000-001F-0000-000000000190","Reference":"GID-NG10168","ProjectType":"NG","ProductTypeName":"Antimicrobial prescribing guideline","Process":"APG","Title":"Blepharitis: antimicrobial prescribing","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-02-26T15:46:04.271839","FirstGoLiveDate":"2020-02-12T09:25:54.1170922","CreatedDate":"2020-02-12T09:23:42.5382118","DevelopedAs":"APG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":["AMP"]},{"_links":{"self":[{"href":"/project/GID-TA10615"}]},"ETag":"01000000-0000-001F-0000-000000000324","Reference":"GID-TA10615","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Pembrolizumab with trastuzumab and chemotherapy for untreated HER2-positive advanced gastric or gastro-oesophageal junction cancer [ID3742]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-04-24T15:15:12.8257245","FirstGoLiveDate":"2020-01-29T09:58:36.0253352","CreatedDate":"2020-01-29T09:57:22.4098002","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3742","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10148"}]},"ETag":"01000000-0000-001F-0000-0000000011D1","Reference":"GID-QS10148","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Social work interventions for adults with complex needs (including learning disabilities) and mental health needs","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-05-04T15:12:51.9956633","FirstGoLiveDate":"2020-05-04T15:12:51.9956633","CreatedDate":"2020-05-04T15:08:10.5125924","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10170"}]},"ETag":"01000000-0000-001F-0000-00000000176B","Reference":"GID-IPG10170","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Removal, preservation and subsequent re-implantation of ovarian tissue to delay the menopause","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-04-16T15:56:56.3363569","FirstGoLiveDate":"2020-04-16T15:56:56.3363569","CreatedDate":"2020-04-16T15:53:32.7798667","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1804","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10375"}]},"ETag":"01000000-0000-001F-0000-0000000023FE","Reference":"GID-TA10375","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Empagliflozin for type 1 Diabetes Mellitus, adjunct to insulin ID1275","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-05-14T00:03:43.0101804","FirstGoLiveDate":"2018-08-01T11:33:52.9053439","CreatedDate":"2018-08-01T08:16:03.9935476","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10664"}]},"ETag":"01000000-0000-001F-0000-000000002FF0","Reference":"GID-TA10664","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Lacosamide for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy [ID1687]","Status":"ImpactedByCOVID19","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-05-21T13:30:53.5307456","FirstGoLiveDate":"2020-05-13T10:57:43.0083856","CreatedDate":"2020-05-13T10:54:21.0384897","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1687","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-HST10033"}]},"ETag":"01000000-0000-001F-0000-00000000303D","Reference":"GID-HST10033","ProjectType":"HST","ProductTypeName":"Highly specialised technology","Process":"HST","Title":"Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]","Status":"ImpactedByCOVID19","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-05-21T13:54:53.7597667","FirstGoLiveDate":"2020-01-10T12:07:13.1892859","CreatedDate":"2020-01-10T12:05:55.2519118","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2721","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-HST10032"}]},"ETag":"01000000-0000-001F-0000-00000000303E","Reference":"GID-HST10032","ProjectType":"HST","ProductTypeName":"Highly specialised technology","Process":"HST","Title":"Palovarotene for preventing heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID3739]","Status":"ImpactedByCOVID19","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-05-21T13:54:53.7754105","FirstGoLiveDate":"2020-01-15T08:58:47.4466244","CreatedDate":"2020-01-15T08:57:43.9866107","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3739","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10653"}]},"ETag":"01000000-0000-001F-0000-00000000305E","Reference":"GID-TA10653","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Fenfluramine hydrochloride for treating Lennox-Gastaut seizures in people aged 2 and over [ID1651]","Status":"ImpactedByCOVID19","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-05-21T13:58:15.6650704","FirstGoLiveDate":"2020-05-13T09:42:43.015061","CreatedDate":"2020-05-13T09:40:12.1736075","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1651","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-HST10020"}]},"ETag":"01000000-0000-001F-0000-000000003081","Reference":"GID-HST10020","ProjectType":"HST","ProductTypeName":"Highly specialised technology","Process":"HST","Title":"VTS-270 for treating Niemann-Pick type C1 (ID1267)","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-05-21T14:03:53.5307914","FirstGoLiveDate":"2018-07-31T06:00:51.3077052","CreatedDate":"2018-07-24T15:22:44.8721714","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1267","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10259"}]},"ETag":"01000000-0000-001F-0000-0000000031A7","Reference":"GID-TA10259","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"ADI-PEG 20 for previously treated hepatocellular carcinoma [ID1025]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-05-22T09:39:53.5317715","FirstGoLiveDate":"2017-09-29T13:30:14.3155594","CreatedDate":"2017-09-29T13:29:44.2221366","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10172"}]},"ETag":"01000000-0000-001F-0000-000000003220","Reference":"GID-IPG10172","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Botulinum toxin injection into the urethral sphincter for idiopathic chronic non-obstructive urinary retention","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-05-22T14:00:53.6002164","FirstGoLiveDate":"2020-05-22T14:00:53.6002164","CreatedDate":"2020-05-22T13:59:00.7837202","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1747","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10631"}]},"ETag":"01000000-0000-001F-0000-000000003C7C","Reference":"GID-TA10631","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Nivolumab with ipilimumab for neoadjuvant treatment of early non-small-cell lung cancer [ID3756]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-05-29T08:43:02.3984606","FirstGoLiveDate":"2020-05-29T08:43:02.3984606","CreatedDate":"2020-03-10T13:31:45.168641","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3756","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10320"}]},"ETag":"01000000-0000-001F-0000-000000003C86","Reference":"GID-TA10320","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Listeria monocytogenes vaccine for previously treated malignant pleural mesothelioma ID1353","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-05-29T08:49:02.4101429","FirstGoLiveDate":"2018-03-14T10:19:14.9524561","CreatedDate":"2018-03-14T10:17:14.2101304","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1353","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10620"}]},"ETag":"01000000-0000-001F-0000-0000000042AB","Reference":"GID-TA10620","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Tisotumab vedotin for treating recurrent or metastatic cervical cancer after systemic therapy [ID3753]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-06-02T11:07:05.8278707","FirstGoLiveDate":"2020-01-29T10:07:36.0334508","CreatedDate":"2020-01-29T10:05:50.0179861","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3753","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10173"}]},"ETag":"01000000-0000-001F-0000-000000005A1B","Reference":"GID-IPG10173","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Transanal total mesorectal excision for rectal cancer","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-06-16T13:14:11.1802579","FirstGoLiveDate":"2020-06-16T13:14:11.1802579","CreatedDate":"2020-06-16T13:11:29.2275567","DevelopedAs":null,"RelevantTo":null,"IdNumber":"11842","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10174"}]},"ETag":"01000000-0000-001F-0000-000000005A23","Reference":"GID-IPG10174","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Insertion and use of implantable pulmonary artery pressure monitors in chronic heart failure","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-06-16T13:16:23.5546655","FirstGoLiveDate":"2020-06-16T13:16:23.5546655","CreatedDate":"2020-06-16T13:14:29.5278755","DevelopedAs":null,"RelevantTo":null,"IdNumber":"972","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10175"}]},"ETag":"01000000-0000-001F-0000-000000005A28","Reference":"GID-IPG10175","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Transcutaneous electrical stimulation of the supraorbital nerve for treating and preventing migraine","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-06-16T13:17:11.1794406","FirstGoLiveDate":"2020-06-16T13:17:11.1794406","CreatedDate":"2020-06-16T13:16:12.851555","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1293","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10677"}]},"ETag":"01000000-0000-001F-0000-000000005D52","Reference":"GID-TA10677","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Eptinezumab for preventing migraine [ID3803]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-06-18T09:01:26.1980371","FirstGoLiveDate":"2020-06-18T09:01:26.1980371","CreatedDate":"2020-06-18T09:00:05.1140292","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3803","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10679"}]},"ETag":"01000000-0000-001F-0000-000000005D61","Reference":"GID-TA10679","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Remimazolam for general anaesthesia [ID3796]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-06-18T09:04:26.2289908","FirstGoLiveDate":"2020-06-18T09:04:26.2289908","CreatedDate":"2020-06-18T09:02:17.7604157","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3796","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10682"}]},"ETag":"01000000-0000-001F-0000-000000005D77","Reference":"GID-TA10682","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Valoctocogene roxaparvovec for treating severe haemophilia A [ID3806]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-06-18T09:07:26.21304","FirstGoLiveDate":"2020-06-18T09:07:26.21304","CreatedDate":"2020-06-18T09:05:51.9403995","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3806","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10684"}]},"ETag":"01000000-0000-001F-0000-000000005D89","Reference":"GID-TA10684","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Baloxavir marboxil for influenza prophylaxis in people aged 12 and over [ID3793]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-06-18T09:10:26.2441208","FirstGoLiveDate":"2020-06-18T09:10:26.2441208","CreatedDate":"2020-06-18T09:08:34.4551847","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3793","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10683"}]},"ETag":"01000000-0000-001F-0000-000000005D91","Reference":"GID-TA10683","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Baloxavir marboxil for treating influenza in people at high risk of complications [ID3794]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-06-18T09:11:17.4471686","FirstGoLiveDate":"2020-06-18T09:08:17.4474594","CreatedDate":"2020-06-18T09:07:07.541203","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3794","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10685"}]},"ETag":"01000000-0000-001F-0000-000000006498","Reference":"GID-TA10685","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Rivoceranib for treating unresectable or advanced gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3819]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-06-22T14:04:31.2994801","FirstGoLiveDate":"2020-06-22T14:04:31.2994801","CreatedDate":"2020-06-22T14:02:42.5419135","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3819","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10397"}]},"ETag":"01000000-0000-001F-0000-000000006B74","Reference":"GID-TA10397","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Pelareorep for treating metastatic or recurrent squamous cell carcinoma of the head and neck after platinum-based chemotherapy ID940","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-06-25T14:23:06.5412367","FirstGoLiveDate":"2020-06-25T14:23:06.5412367","CreatedDate":"2018-10-08T14:07:39.62863","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10686"}]},"ETag":"01000000-0000-001F-0000-000000006B75","Reference":"GID-TA10686","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Pelareorep for treating metastatic malignant melanoma after previous therapy [ID941]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-06-25T14:23:06.5881128","FirstGoLiveDate":"2020-06-25T14:23:06.5881128","CreatedDate":"2020-06-25T14:22:06.1667108","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10687"}]},"ETag":"01000000-0000-001F-0000-000000006B80","Reference":"GID-TA10687","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Pelareorep for treating relapsed or refractory multiple myeloma [ID1028]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-06-25T14:26:06.5245168","FirstGoLiveDate":"2020-06-25T14:26:06.5245168","CreatedDate":"2020-06-25T14:23:44.8534477","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1028","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10688"}]},"ETag":"01000000-0000-001F-0000-000000006B90","Reference":"GID-TA10688","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Pelareorep for treating recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer [ID1099]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-06-25T14:29:06.5398381","FirstGoLiveDate":"2020-06-25T14:29:06.5398381","CreatedDate":"2020-06-25T14:25:43.6169616","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1099","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10689"}]},"ETag":"01000000-0000-001F-0000-000000006B91","Reference":"GID-TA10689","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Pelareorep for untreated pancreatic cancer [ID1074]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-06-25T14:29:06.5710851","FirstGoLiveDate":"2020-06-25T14:29:06.5710851","CreatedDate":"2020-06-25T14:27:33.8504534","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1074","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10662"}]},"ETag":"01000000-0000-001F-0000-000000006B96","Reference":"GID-TA10662","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Sarizotan for the treatment of respiratory symptoms associated with Rett syndrome [ID1506]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-06-25T14:32:06.5551498","FirstGoLiveDate":"2020-05-13T10:51:55.6241968","CreatedDate":"2020-05-13T10:51:21.1868274","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1506","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10575"}]},"ETag":"01000000-0000-001F-0000-000000006DFF","Reference":"GID-TA10575","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Histamine dihydrochloride with interleukin-2 for maintenance treatment of acute myeloid leukaemia [ID1627]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-06-26T14:29:06.5713931","FirstGoLiveDate":"2019-12-16T10:31:03.1069718","CreatedDate":"2019-12-16T10:28:03.4603948","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1627","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10665"}]},"ETag":"01000000-0000-001F-0000-000000006E68","Reference":"GID-TA10665","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Sotagliflozin for treating type 2 diabetes [ID1657]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-06-26T16:19:37.8594239","FirstGoLiveDate":"2020-05-13T11:00:42.9812414","CreatedDate":"2020-05-13T10:58:03.1646048","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1657","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10402"}]},"ETag":"01000000-0000-001F-0000-0000000075A4","Reference":"GID-TA10402","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"PEGPH20 with nab-paclitaxel and gemcitabine for treating metastatic pancreatic cancer ID1502","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-07-01T10:04:41.1396371","FirstGoLiveDate":"2018-10-22T14:30:19.8829691","CreatedDate":"2018-10-22T14:27:36.0047005","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10694"}]},"ETag":"01000000-0000-001F-0000-000000008158","Reference":"GID-TA10694","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Selinexor for treating unresectable dedifferentiated advanced liposarcoma [ID3825]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-07-08T12:33:01.1021197","FirstGoLiveDate":"2020-07-08T12:33:01.1021197","CreatedDate":"2020-07-08T12:31:38.9874765","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3825","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10699"}]},"ETag":"01000000-0000-001F-0000-000000008172","Reference":"GID-TA10699","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Etranacogene dezaparvovec for treating haemophilia B [ID3812]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-07-08T12:58:50.4543403","FirstGoLiveDate":"2020-07-08T12:58:50.4543403","CreatedDate":"2020-07-08T12:56:48.704899","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3812","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10702"}]},"ETag":"01000000-0000-001F-0000-00000000817F","Reference":"GID-TA10702","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-07-08T13:01:50.4544066","FirstGoLiveDate":"2020-07-08T13:01:50.4544066","CreatedDate":"2020-07-08T13:00:44.8287752","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3823","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10179"}]},"ETag":"01000000-0000-001F-0000-00000000899C","Reference":"GID-IPG10179","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Stereotactic radiosurgery for trigeminal neuralgia using the gamma knife","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-07-13T12:12:18.9339732","FirstGoLiveDate":"2020-07-13T12:12:18.9339732","CreatedDate":"2020-07-13T12:05:25.0833217","DevelopedAs":null,"RelevantTo":null,"IdNumber":"173","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10180"}]},"ETag":"01000000-0000-001F-0000-0000000089A4","Reference":"GID-IPG10180","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Intramedullary distraction for lower limb lengthening","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-07-13T12:19:56.4223112","FirstGoLiveDate":"2020-07-13T12:19:56.4223112","CreatedDate":"2020-07-13T12:12:19.534589","DevelopedAs":null,"RelevantTo":null,"IdNumber":"358","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10181"}]},"ETag":"01000000-0000-001F-0000-0000000089A9","Reference":"GID-IPG10181","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Microwave ablation for treating primary lung cancer and metastases in the lung","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-07-13T12:21:18.9484907","FirstGoLiveDate":"2020-07-13T12:21:18.9484907","CreatedDate":"2020-07-13T12:19:46.1361825","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1051","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10576"}]},"ETag":"01000000-0000-001F-0000-000000008AE9","Reference":"GID-TA10576","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-07-14T11:09:15.7273988","FirstGoLiveDate":"2019-12-16T10:37:03.1609841","CreatedDate":"2019-12-16T10:36:05.4737818","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1629","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10636"}]},"ETag":"01000000-0000-001F-0000-00000000A691","Reference":"GID-TA10636","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Daratumumab with pomalidomide and dexamethasone for treating relapsed or refractory multiple myeloma [ID3775]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-07-30T15:48:57.1158663","FirstGoLiveDate":"2020-04-01T11:05:20.5544871","CreatedDate":"2020-04-01T11:03:22.1768806","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3775","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10574"}]},"ETag":"01000000-0000-001F-0000-00000000A773","Reference":"GID-TA10574","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Atezolizumab in combination for advanced epithelial ovarian, fallopian tube or primary peritoneal cancer in people who have not received any prior systemic therapy  [ID2700]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-07-31T09:57:56.9062377","FirstGoLiveDate":"2019-12-16T10:25:03.1544958","CreatedDate":"2019-12-16T10:22:51.5396432","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2700","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10707"}]},"ETag":"01000000-0000-001F-0000-00000000AC07","Reference":"GID-TA10707","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Nivolumab with ipilimumab for untreated PD-L1 positive unresectable or metastatic urothelial cancer [ID3829]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-08-03T09:02:22.8938797","FirstGoLiveDate":"2020-08-03T09:02:22.8938797","CreatedDate":"2020-08-03T09:00:40.6596971","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3829","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10715"}]},"ETag":"01000000-0000-001F-0000-00000000BE78","Reference":"GID-TA10715","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Dusquetide for treating oral mucositis during chemoradiation for head and neck cancer [ID3830]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-08-13T13:31:22.5354694","FirstGoLiveDate":"2020-08-13T13:31:22.5354694","CreatedDate":"2020-08-13T13:30:15.2271485","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3830","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10717"}]},"ETag":"01000000-0000-001F-0000-00000000BE84","Reference":"GID-TA10717","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Etrolizumab for treating moderately to severely active ulcerative colitis [ID3827]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-08-13T13:34:22.5659421","FirstGoLiveDate":"2020-08-13T13:34:22.5659421","CreatedDate":"2020-08-13T13:33:42.2423523","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3827","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10718"}]},"ETag":"01000000-0000-001F-0000-00000000BE8A","Reference":"GID-TA10718","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Abilify MyCite for treating bipolar disorder 1 or schizophrenia [ID3833]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-08-13T13:35:34.7578033","FirstGoLiveDate":"2020-08-13T13:35:34.7578033","CreatedDate":"2020-08-13T13:34:40.7891567","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3833","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10184"}]},"ETag":"01000000-0000-001F-0000-00000000C09A","Reference":"GID-IPG10184","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Endoscopic balloon dilation for subglottic or\r\ntracheal stenosis","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-08-14T16:17:52.8857563","FirstGoLiveDate":"2020-08-14T16:17:52.8857563","CreatedDate":"2020-08-14T16:14:23.8532702","DevelopedAs":null,"RelevantTo":null,"IdNumber":"938","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10187"}]},"ETag":"01000000-0000-001F-0000-00000000C0AC","Reference":"GID-IPG10187","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Endoscopic full thickness removal of gastrointestinal stromal tumours of the stomach","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-08-14T16:22:52.5093528","FirstGoLiveDate":"2020-08-14T16:22:52.5093528","CreatedDate":"2020-08-14T16:21:28.0566221","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1837","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10313"}]},"ETag":"01000000-0000-001F-0000-00000000E0CA","Reference":"GID-TA10313","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Lurbinectedin for treating advanced platinum-resistant ovarian cancer ID1340","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-09-02T15:47:08.8210554","FirstGoLiveDate":"2018-03-14T10:04:14.9467144","CreatedDate":"2018-03-14T10:01:35.8265219","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10723"}]},"ETag":"01000000-0000-001F-0000-00000000E2B6","Reference":"GID-TA10723","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Palbociclib for treating high-risk early breast cancer after neoadjuvant chemotherapy [ID3846]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-09-03T15:06:02.6903925","FirstGoLiveDate":"2020-09-03T15:06:02.6903925","CreatedDate":"2020-09-03T15:04:58.346886","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3846","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10728"}]},"ETag":"01000000-0000-001F-0000-00000000E8B2","Reference":"GID-TA10728","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"LN-145 for treating recurrent, persistent or metastatic cervical cancer [ID3844]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-09-07T13:45:06.4952281","FirstGoLiveDate":"2020-09-07T13:45:06.4952281","CreatedDate":"2020-09-07T13:42:57.261052","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3844","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10635"}]},"ETag":"01000000-0000-001F-0000-00000000F547","Reference":"GID-TA10635","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Niraparib for previously treated hormone-relapsed metastatic prostate cancer with DNA-repair anomalies [ID3782]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-09-15T10:29:35.490292","FirstGoLiveDate":"2020-04-01T11:02:20.5677699","CreatedDate":"2020-04-01T10:57:25.0848131","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3782","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10189"}]},"ETag":"01000000-0000-001F-0000-00000000F5BF","Reference":"GID-IPG10189","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Percutaneous insertion of a cystic duct stent for acute cholecystitis","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-09-15T12:23:35.5009324","FirstGoLiveDate":"2020-09-15T12:23:35.5009324","CreatedDate":"2020-09-15T12:22:18.4853957","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1560","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10190"}]},"ETag":"01000000-0000-001F-0000-00000000F5C5","Reference":"GID-IPG10190","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Liposuction for chronic lipoedema","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-09-15T12:26:35.4586604","FirstGoLiveDate":"2020-09-15T12:26:35.4586604","CreatedDate":"2020-09-15T12:24:02.8602501","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1843","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MIB10185"}]},"ETag":"01000000-0000-001F-0000-000000010281","Reference":"GID-MIB10185","ProjectType":"MIB","ProductTypeName":"Medtech innovation briefings","Process":"MIB","Title":"AI technologies for chest imaging","Status":"InProgress","ProjectGroup":"Advice","PublishedDate":"2020-12-15T00:00:00","LastModifiedDate":"2020-09-22T13:51:48.8447645","FirstGoLiveDate":null,"CreatedDate":"2019-10-23T11:45:15.2456041","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MIB10226"}]},"ETag":"01000000-0000-001F-0000-000000010283","Reference":"GID-MIB10226","ProjectType":"MIB","ProductTypeName":"Medtech innovation briefings","Process":"MIB","Title":"AI Chest Imaging","Status":"InProgress","ProjectGroup":"Advice","PublishedDate":"2020-12-29T00:00:00","LastModifiedDate":"2020-09-22T13:54:58.1482379","FirstGoLiveDate":null,"CreatedDate":"2020-09-22T13:54:58.1482379","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10747"}]},"ETag":"01000000-0000-001F-0000-00000001190E","Reference":"GID-TA10747","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pembrolizumab with chemotherapy then olaparib maintenance for treating BRCA-negative advanced epithelial ovarian, fallopian tube or peritoneal cancer [ID3853]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-05T12:27:21.5437767","FirstGoLiveDate":"2020-10-05T12:27:21.5437767","CreatedDate":"2020-10-05T12:24:17.4580027","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3853","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10748"}]},"ETag":"01000000-0000-001F-0000-00000001190F","Reference":"GID-TA10748","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Durvalumab with tremelimumab and chemotherapy for treating unresectable or advanced urothelial cancer [ID3855]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-05T12:27:21.590595","FirstGoLiveDate":"2020-10-05T12:27:21.590595","CreatedDate":"2020-10-05T12:25:57.7075724","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3855","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10750"}]},"ETag":"01000000-0000-001F-0000-00000001191B","Reference":"GID-TA10750","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Azacitidine for treating relapsed or refractory angioimmunoblastic T-cell lymphoma [ID3864]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-05T12:30:22.5903613","FirstGoLiveDate":"2020-10-05T12:30:22.5903613","CreatedDate":"2020-10-05T12:28:56.7223516","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3864","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10356"}]},"ETag":"01000000-0000-001F-0000-000000011A77","Reference":"GID-TA10356","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Enasidenib for treating IDH2-positive acute myeloid leukaemia after 2 or more therapies ID1455","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-06T08:42:25.5925481","FirstGoLiveDate":"2018-06-08T12:41:09.3506866","CreatedDate":"2018-06-08T12:40:36.0016043","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10166"}]},"ETag":"01000000-0000-001F-0000-0000000126DD","Reference":"GID-NG10166","ProjectType":"NG","ProductTypeName":"Antimicrobial prescribing guideline","Process":"APG","Title":"Conjunctivitis: antimicrobial prescribing","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-13T15:00:49.0262683","FirstGoLiveDate":"2020-02-12T09:19:54.3670584","CreatedDate":"2020-02-12T09:07:20.8390127","DevelopedAs":"APG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":["AMP"]},{"_links":{"self":[{"href":"/project/GID-QS10144"}]},"ETag":"01000000-0000-001F-0000-000000012C86","Reference":"GID-QS10144","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Adults with lifelong or very severe hearing or visual impairment: health, well-being and social care","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-16T11:45:46.5939957","FirstGoLiveDate":"2020-05-04T14:58:19.9525788","CreatedDate":"2020-05-04T14:54:05.2820967","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10145"}]},"ETag":"01000000-0000-001F-0000-000000012C9D","Reference":"GID-QS10145","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Advocacy services for adults with health and social care needs","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-16T11:48:46.5932187","FirstGoLiveDate":"2020-05-04T15:03:52.1699157","CreatedDate":"2020-05-04T15:01:26.3116696","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10146"}]},"ETag":"01000000-0000-001F-0000-000000012CA0","Reference":"GID-QS10146","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Children and young people with disabilities and severe complex needs: integrated health and social care support","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-16T11:48:46.5932187","FirstGoLiveDate":"2020-05-04T15:06:51.9994309","CreatedDate":"2020-05-04T15:04:37.7340179","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10149"}]},"ETag":"01000000-0000-001F-0000-000000012CA4","Reference":"GID-QS10149","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Supporting independent living and preventing isolation in adults of working age with social care needs","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-16T11:48:46.6244955","FirstGoLiveDate":"2020-05-04T15:15:51.966861","CreatedDate":"2020-05-04T15:13:09.995568","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10758"}]},"ETag":"01000000-0000-001F-0000-0000000130C8","Reference":"GID-TA10758","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Lurbinectedin with doxorubicin for treating advanced small-cell lung cancer after platinum-based chemotherapy [ID3872]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-19T08:57:51.2784839","FirstGoLiveDate":"2020-10-19T08:57:51.2784839","CreatedDate":"2020-10-19T08:55:47.2634566","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3872","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10191"}]},"ETag":"01000000-0000-001F-0000-0000000132FA","Reference":"GID-IPG10191","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Minimally invasive meshless and dissectionless anchoring system for pelvic organ prolapse repair","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-20T11:36:54.1279691","FirstGoLiveDate":"2020-10-20T11:36:54.1279691","CreatedDate":"2020-10-20T11:29:08.2218401","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1861","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10192"}]},"ETag":"01000000-0000-001F-0000-000000013301","Reference":"GID-IPG10192","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Superfcial vein arterialisation and selective venous embolisation for critical limb ischaemia","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-20T11:39:54.1641022","FirstGoLiveDate":"2020-10-20T11:39:54.1641022","CreatedDate":"2020-10-20T11:35:30.2842953","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1858","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10194"}]},"ETag":"01000000-0000-001F-0000-000000013311","Reference":"GID-IPG10194","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Tunnelled peritoneal drainage catheter insertion for treatment-resistant, recurrent ascites due to cirrhosis","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-20T12:30:54.1073441","FirstGoLiveDate":"2020-10-20T12:30:54.1073441","CreatedDate":"2020-10-20T12:28:08.6661913","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1840","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10195"}]},"ETag":"01000000-0000-001F-0000-000000013319","Reference":"GID-IPG10195","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Regional nerve graft to restore corneal sensation","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-20T12:33:54.122678","FirstGoLiveDate":"2020-10-20T12:33:54.122678","CreatedDate":"2020-10-20T12:30:09.6969977","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1841","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10196"}]},"ETag":"01000000-0000-001F-0000-00000001331A","Reference":"GID-IPG10196","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Supercapsular Percutaneously Assisted Total Hip replacement for osteoarthritis","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-20T12:33:54.1539291","FirstGoLiveDate":"2020-10-20T12:33:54.1539291","CreatedDate":"2020-10-20T12:32:18.5088712","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1842","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10197"}]},"ETag":"01000000-0000-001F-0000-000000013320","Reference":"GID-IPG10197","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Insertion of aortic arch remodelling graft as an adjunct to surgical repair of acute aortic dissection","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-20T12:36:54.1536806","FirstGoLiveDate":"2020-10-20T12:36:54.1536806","CreatedDate":"2020-10-20T12:34:31.9613518","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1847","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10201"}]},"ETag":"01000000-0000-001F-0000-000000013335","Reference":"GID-IPG10201","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Percutaneous thoracic duct embolization for chyle leak","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-20T12:45:54.1528666","FirstGoLiveDate":"2020-10-20T12:45:54.1528666","CreatedDate":"2020-10-20T12:42:58.4812807","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1857","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10202"}]},"ETag":"01000000-0000-001F-0000-00000001333B","Reference":"GID-IPG10202","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Focal articular prosthetic resurfacing for treating articular cartilage defects in the knee","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-20T12:48:54.128587","FirstGoLiveDate":"2020-10-20T12:48:54.128587","CreatedDate":"2020-10-20T12:46:21.7393124","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1797","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10198"}]},"ETag":"01000000-0000-001F-0000-00000001334A","Reference":"GID-IPG10198","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Transcatheter tricuspid valve reconstruction for tricuspid regurgitation","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-20T12:57:54.1674554","FirstGoLiveDate":"2020-10-20T12:39:54.1473126","CreatedDate":"2020-10-20T12:38:19.4816994","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1848","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10199"}]},"ETag":"01000000-0000-001F-0000-00000001334B","Reference":"GID-IPG10199","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Sternoclavicular joint replacement for arthritis","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-20T12:57:54.1674554","FirstGoLiveDate":"2020-10-20T12:42:54.1218614","CreatedDate":"2020-10-20T12:39:36.9034074","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1849","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10200"}]},"ETag":"01000000-0000-001F-0000-000000013350","Reference":"GID-IPG10200","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"External electrical muscle stimulation for urinary incontinence","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-20T13:00:54.1044833","FirstGoLiveDate":"2020-10-20T12:42:54.1531437","CreatedDate":"2020-10-20T12:41:26.9501099","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1856","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10539"}]},"ETag":"01000000-0000-001F-0000-00000001385D","Reference":"GID-TA10539","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Neratinib for treating HER2-positive breast cancer after 2 therapies  [ID1381]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":"2021-12-15T00:00:00","LastModifiedDate":"2020-10-23T09:04:02.2496233","FirstGoLiveDate":"2019-09-27T13:25:23.5308489","CreatedDate":"2019-09-27T13:21:32.0230857","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1381","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10716"}]},"ETag":"01000000-0000-001F-0000-0000000156C1","Reference":"GID-TA10716","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Bupivacaine–meloxicam for treating postoperative pain [ID2728]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-11-09T16:55:20.2786649","FirstGoLiveDate":"2020-08-13T13:34:22.5347156","CreatedDate":"2020-08-13T13:32:33.6757866","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2728","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10577"}]},"ETag":"01000000-0000-001F-0000-000000015B08","Reference":"GID-TA10577","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Spartalizumab with dabrafenib and trametinib for untreated BRAF V600 mutation-positive unresectable or metastatic melanoma [ID1668]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":"2021-04-21T00:00:00","LastModifiedDate":"2020-11-12T08:28:23.269094","FirstGoLiveDate":"2019-12-16T10:46:25.9635659","CreatedDate":"2019-12-16T10:43:06.277441","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1668","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10760"}]},"ETag":"01000000-0000-001F-0000-000000015CF4","Reference":"GID-TA10760","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Ruxolitinib for treating acute graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2715]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-11-13T11:40:49.0235647","FirstGoLiveDate":"2020-11-13T11:40:49.0235647","CreatedDate":"2020-11-13T11:39:56.1332138","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10761"}]},"ETag":"01000000-0000-001F-0000-000000015CFB","Reference":"GID-TA10761","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Ruxolitinib for treating chronic graft versus host disease refractory to corticosteroids in people aged 12 and over [ID2716]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-11-13T11:43:24.5505879","FirstGoLiveDate":"2020-11-13T11:43:24.5505879","CreatedDate":"2020-11-13T11:41:23.1171539","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10204"}]},"ETag":"01000000-0000-001F-0000-0000000164EA","Reference":"GID-IPG10204","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Total hip arthroplasty using the superpath approach for osteoarthritis","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-11-18T10:52:31.4832823","FirstGoLiveDate":"2020-11-18T10:52:31.4832823","CreatedDate":"2020-11-18T10:46:40.8275641","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1842","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10203"}]},"ETag":"01000000-0000-001F-0000-0000000164EB","Reference":"GID-IPG10203","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Prophylactic or therapeutic use of endoanchoring systems in endovascular aortic aneurysm repair (EVAR/TEVAR)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-11-18T10:52:31.7020288","FirstGoLiveDate":"2020-11-18T10:52:31.7020288","CreatedDate":"2020-11-18T10:35:56.266313","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1824","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10205"}]},"ETag":"01000000-0000-001F-0000-0000000164F1","Reference":"GID-IPG10205","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Biodegradable spacer insertion to reduce rectal toxicity during radiotherapy for prostate cancer","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-11-18T10:58:31.2785011","FirstGoLiveDate":"2020-11-18T10:58:31.2785011","CreatedDate":"2020-11-18T10:52:38.0770009","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1316","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10464"}]},"ETag":"01000000-0000-001F-0000-000000016900","Reference":"GID-TA10464","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Mogamulizumab for previously treated T-cell leukaemia-lymphoma [ID1390]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-11-20T11:58:34.1145505","FirstGoLiveDate":"2019-03-18T06:00:39.0057431","CreatedDate":"2019-03-11T10:56:52.058499","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10591"}]},"ETag":"01000000-0000-001F-0000-000000016912","Reference":"GID-TA10591","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Pertuzumab with trastuzumab emtansine for adjuvant treatment of early HER2-positive breast cancer [ID2711]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-11-20T13:25:34.0893744","FirstGoLiveDate":"2020-01-10T12:02:19.489242","CreatedDate":"2020-01-10T12:00:43.8803354","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2711","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10309"}]},"ETag":"01000000-0000-001F-0000-00000001699B","Reference":"GID-TA10309","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy ID1260","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-06-19T12:10:47.1004491","FirstGoLiveDate":"2018-03-14T09:46:15.0606431","CreatedDate":"2018-03-14T09:45:39.767805","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10700"}]},"ETag":"01000000-0000-001F-0000-000000016F29","Reference":"GID-TA10700","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Vosoritide for treating achondroplasia in children and young people under 18 years [ID3807]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-11-24T09:07:37.9412569","FirstGoLiveDate":"2020-07-08T12:58:50.5168059","CreatedDate":"2020-07-08T12:58:17.0638502","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3807","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10767"}]},"ETag":"01000000-0000-001F-0000-000000018184","Reference":"GID-TA10767","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Pevonedistat with azacitidine for untreated myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemia [ID3877]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-12-04T15:41:38.992912","FirstGoLiveDate":"2020-12-04T15:41:38.992912","CreatedDate":"2020-12-04T15:40:47.6961163","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3877","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10773"}]},"ETag":"01000000-0000-001F-0000-0000000181A4","Reference":"GID-TA10773","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Istradefylline with levodopa for treating motor fluctuations in Parkinson's disease  [ID3868]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-12-04T15:53:38.9982257","FirstGoLiveDate":"2020-12-04T15:53:38.9982257","CreatedDate":"2020-12-04T15:52:58.9359188","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-HST10039"}]},"ETag":"01000000-0000-001F-0000-0000000181AA","Reference":"GID-HST10039","ProjectType":"HST","ProductTypeName":"Highly specialised technology","Process":"HST","Title":"Lonafarnib for treating progeria and progeroid laminopathies [ID3867]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-12-04T15:58:50.8093579","FirstGoLiveDate":"2020-12-04T15:58:50.8093579","CreatedDate":"2020-12-04T15:57:20.512895","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3867","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10774"}]},"ETag":"01000000-0000-001F-0000-0000000181B0","Reference":"GID-TA10774","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Venetoclax with ibrutinib for treating relapsed mantle cell lymphoma [ID3879]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-12-04T16:04:50.8031769","FirstGoLiveDate":"2020-12-04T16:04:50.8031769","CreatedDate":"2020-12-04T16:03:02.1207356","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3879","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10776"}]},"ETag":"01000000-0000-001F-0000-0000000181BC","Reference":"GID-TA10776","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Plinabulin with docetaxel for previously treated advanced non-small-cell lung cancer [ID3895]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-12-04T16:10:50.7869356","FirstGoLiveDate":"2020-12-04T16:10:50.7869356","CreatedDate":"2020-12-04T16:09:01.1152986","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3895","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10778"}]},"ETag":"01000000-0000-001F-0000-0000000181C8","Reference":"GID-TA10778","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Lisocabtagene maraleucel (Liso-cel) for transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas [ID3887]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-12-04T16:16:50.833853","FirstGoLiveDate":"2020-12-04T16:16:50.833853","CreatedDate":"2020-12-04T16:15:46.2420969","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3887","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10779"}]},"ETag":"01000000-0000-001F-0000-0000000181CE","Reference":"GID-TA10779","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Ipatasertib with abiraterone and prednisone for hormone-relapsed metastatic prostate cancer [ID3889]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-12-04T16:19:50.7722023","FirstGoLiveDate":"2020-12-04T16:19:50.7722023","CreatedDate":"2020-12-04T16:17:47.2884094","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3889","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10491"}]},"ETag":"01000000-0000-001F-0000-0000000192BF","Reference":"GID-TA10491","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Isatuximab with carfilzomib and dexamethasone for treating relapsed or refractory multiple myeloma [ID1620]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-12-09T16:47:16.0338775","FirstGoLiveDate":"2019-05-08T11:33:59.216102","CreatedDate":"2019-05-08T11:30:50.4057488","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1620","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10484"}]},"ETag":"01000000-0000-001F-0000-0000000194C0","Reference":"GID-TA10484","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Relatlimab with nivolumab for treating advanced malignant melanoma after immunotherapy in people over 12 [ID1612]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-12-10T14:14:35.4060829","FirstGoLiveDate":"2019-05-02T10:08:47.8609422","CreatedDate":"2019-05-02T10:07:39.2609365","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1612","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10709"}]},"ETag":"01000000-0000-001F-0000-000000019D54","Reference":"GID-TA10709","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Rigosertib for previously treated high-risk myelodysplastic syndrome [ID805]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-12-15T15:33:02.0440417","FirstGoLiveDate":"2020-08-03T09:05:22.7685154","CreatedDate":"2020-08-03T09:04:13.6399258","DevelopedAs":null,"RelevantTo":null,"IdNumber":"805","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10416"}]},"ETag":"01000000-0000-001F-0000-00000001A00D","Reference":"GID-TA10416","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Ivosidenib for treating relapsed or refractory IDH1-positive acute myeloid leukaemia [ID1548]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-12-17T00:02:07.3878126","FirstGoLiveDate":"2018-11-07T11:33:21.476308","CreatedDate":"2018-11-07T11:31:04.0221009","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1548","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10571"}]},"ETag":"01000000-0000-001F-0000-00000001B45B","Reference":"GID-TA10571","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Durvalumab with tremelimumab for untreated unresectable hepatocellular carcinoma [ID2725]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-08-25T00:00:00","LastModifiedDate":"2020-01-24T10:55:30.3853345","FirstGoLiveDate":"2019-12-16T10:13:03.1434546","CreatedDate":"2019-12-16T10:11:11.603727","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2725","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10581"}]},"ETag":"01000000-0000-001F-0000-00000001C534","Reference":"GID-TA10581","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Nivolumab-relatlimab for untreated advanced or metastatic melanoma [ID1688]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-01-24T10:50:55.7635643","FirstGoLiveDate":"2019-12-16T11:04:03.1487491","CreatedDate":"2019-12-16T11:01:01.6521764","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1688","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10780"}]},"ETag":"01000000-0000-001F-0000-00000001C543","Reference":"GID-TA10780","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Pembrolizumab with ipilimumab for treating PD-L1-positive advanced non-small-cell lung cancer [ID3861]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-08T15:51:55.6746213","FirstGoLiveDate":"2021-01-08T15:51:55.6746213","CreatedDate":"2021-01-08T15:50:05.6465284","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3861","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10212"}]},"ETag":"01000000-0000-001F-0000-00000001D0FE","Reference":"GID-IPG10212","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Pharyngeal Electrical Stimulation for neurogenic dysphagia","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-15T14:38:40.5850887","FirstGoLiveDate":"2021-01-15T14:38:40.5850887","CreatedDate":"2021-01-15T14:27:02.9546952","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1877","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IP1046"}]},"ETag":"01000000-0000-001F-0000-00000001D553","Reference":"GID-IP1046","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Lung transplantation with ex-vivo perfusion","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-01-06T18:55:11.5548269","FirstGoLiveDate":"2016-08-30T15:11:34.3892208","CreatedDate":"2014-08-08T16:51:47","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10178"}]},"ETag":"01000000-0000-001F-0000-00000001DA66","Reference":"GID-NG10178","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Cardiovascular disease: risk assessment and reduction, including lipid modification","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2023-04-19T00:00:00","LastModifiedDate":"2020-08-24T15:26:57.080837","FirstGoLiveDate":"2020-08-12T15:05:33.6486186","CreatedDate":"2020-08-12T15:01:34.5559904","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10783"}]},"ETag":"01000000-0000-001F-0000-00000001E35A","Reference":"GID-TA10783","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Durvalumab with chemoradiation for treating unresectable locally advanced non-small-cell lung cancer [ID3906]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-26T15:25:42.1385944","FirstGoLiveDate":"2021-01-26T15:25:42.1385944","CreatedDate":"2021-01-26T15:24:13.4981425","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3906","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10784"}]},"ETag":"01000000-0000-001F-0000-00000001E360","Reference":"GID-TA10784","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907 ]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-26T15:26:55.418479","FirstGoLiveDate":"2021-01-26T15:26:55.418479","CreatedDate":"2021-01-26T15:25:52.5136095","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3907","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10785"}]},"ETag":"01000000-0000-001F-0000-00000001E366","Reference":"GID-TA10785","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Polatuzumab vedotin with R-CHP for untreated diffuse large B-cell lymphoma [ID3901 ]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-26T15:29:55.4332805","FirstGoLiveDate":"2021-01-26T15:29:55.4332805","CreatedDate":"2021-01-26T15:29:15.731953","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3901","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10786"}]},"ETag":"01000000-0000-001F-0000-00000001E36C","Reference":"GID-TA10786","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Pembrolizumab for adjuvant treatment of resected stage 2 melanoma with high risk of recurrence [ID3908 ]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-26T15:37:42.1494189","FirstGoLiveDate":"2021-01-26T15:37:42.1494189","CreatedDate":"2021-01-26T15:35:39.7594646","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3908","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10787"}]},"ETag":"01000000-0000-001F-0000-00000001E372","Reference":"GID-TA10787","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Timrepigene emparvovec for treating choroideremia [ID3916]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-26T15:41:55.4342266","FirstGoLiveDate":"2021-01-26T15:41:55.4342266","CreatedDate":"2021-01-26T15:40:23.9143063","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3916","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10788"}]},"ETag":"01000000-0000-001F-0000-00000001E378","Reference":"GID-TA10788","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Olipudase alfa for treating Niemann-Pick disease types A and B  [ID3913 ]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-26T15:43:42.1476897","FirstGoLiveDate":"2021-01-26T15:43:42.1476897","CreatedDate":"2021-01-26T15:42:00.1481803","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3913","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10789"}]},"ETag":"01000000-0000-001F-0000-00000001E37E","Reference":"GID-TA10789","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Leriglitazone for treating X-linked andrenoleukodystrophy [ID 3903]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-26T15:47:55.4276968","FirstGoLiveDate":"2021-01-26T15:47:55.4276968","CreatedDate":"2021-01-26T15:45:28.7619176","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3903","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10790"}]},"ETag":"01000000-0000-001F-0000-00000001E384","Reference":"GID-TA10790","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Pegunigalsidase alfa for treating Fabry disease [ID3904]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-26T15:49:42.1522063","FirstGoLiveDate":"2021-01-26T15:49:42.1522063","CreatedDate":"2021-01-26T15:48:27.6054503","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3904","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10791"}]},"ETag":"01000000-0000-001F-0000-00000001E506","Reference":"GID-TA10791","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Tideglusib for treating congenital myotonic dystrophy type 1 [ID3915 ]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-27T11:58:42.1552797","FirstGoLiveDate":"2021-01-27T11:58:42.1552797","CreatedDate":"2021-01-27T11:56:50.8738257","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3915","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10794"}]},"ETag":"01000000-0000-001F-0000-00000001E518","Reference":"GID-TA10794","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Brolucizumab for treating diabetic macular oedema [ID3902]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-27T12:25:42.1490868","FirstGoLiveDate":"2021-01-27T12:25:42.1490868","CreatedDate":"2021-01-27T12:20:00.4526046","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3902","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10795"}]},"ETag":"01000000-0000-001F-0000-00000001E51E","Reference":"GID-TA10795","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Mitapivat for treating pyruvate kinase deficiency [ID3914 ]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-27T12:28:42.1849146","FirstGoLiveDate":"2021-01-27T12:28:42.1849146","CreatedDate":"2021-01-27T12:25:43.3883354","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3914","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10797"}]},"ETag":"01000000-0000-001F-0000-00000001E52C","Reference":"GID-TA10797","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Omecamtiv mecarbil for treating chronic heart failure with reduced ejection fraction [ID3912 ]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-27T12:49:42.1518692","FirstGoLiveDate":"2021-01-27T12:49:42.1518692","CreatedDate":"2021-01-27T12:41:04.3401385","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3912","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10800"}]},"ETag":"01000000-0000-001F-0000-00000001E53E","Reference":"GID-TA10800","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Imetelstat for treating relapsed or refractory transfusion-dependent myelodysplastic syndromes [ID3922]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-27T13:28:42.1499253","FirstGoLiveDate":"2021-01-27T13:28:42.1499253","CreatedDate":"2021-01-27T13:28:13.3819246","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3922","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10801"}]},"ETag":"01000000-0000-001F-0000-00000001E544","Reference":"GID-TA10801","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Cemiplimab for treating recurrent or metastatic cervical cancer [ID3921]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-27T13:32:55.427686","FirstGoLiveDate":"2021-01-27T13:32:55.427686","CreatedDate":"2021-01-27T13:31:16.43096","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3921","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10802"}]},"ETag":"01000000-0000-001F-0000-00000001E8A0","Reference":"GID-TA10802","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-29T11:01:49.6802843","FirstGoLiveDate":"2021-01-29T11:01:49.6802843","CreatedDate":"2021-01-29T11:00:54.1959874","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3920","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10803"}]},"ETag":"01000000-0000-001F-0000-00000001E8AB","Reference":"GID-TA10803","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Amcenestrant for treating ER-positive, HER2-negative advanced breast cancer after hormonal therapy [ID3919]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-29T11:04:49.6643998","FirstGoLiveDate":"2021-01-29T11:04:49.6643998","CreatedDate":"2021-01-29T11:02:55.523924","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3919","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10804"}]},"ETag":"01000000-0000-001F-0000-00000001E8AC","Reference":"GID-TA10804","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after trastuzumab or a taxane [ID3909]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-29T11:04:49.6956184","FirstGoLiveDate":"2021-01-29T11:04:49.6956184","CreatedDate":"2021-01-29T11:04:34.2268878","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3909","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10088"}]},"ETag":"01000000-0000-001F-0000-00000001E8D1","Reference":"GID-TA10088","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Nelarabine for treating acute lymphoblastic leukaemia after two therapies [ID1034]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":"2017-12-27T00:00:00","LastModifiedDate":"2016-12-08T01:01:13.8381929","FirstGoLiveDate":"2016-08-05T14:10:46.6789863","CreatedDate":"2016-07-22T14:47:22.705832","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1034","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT510"}]},"ETag":"01000000-0000-001F-0000-00000001F02D","Reference":"GID-MT510","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"The Assurance Nasal Alar SpO2 Sensor (discontinued)","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-03-27T13:34:41.6652984","FirstGoLiveDate":"2017-01-25T08:01:51.9845805","CreatedDate":"2017-01-23T11:13:28.463804","DevelopedAs":null,"RelevantTo":null,"IdNumber":"310","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10186"}]},"ETag":"01000000-0000-001F-0000-0000000205B5","Reference":"GID-IPG10186","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Endovascular forearm arteriovenous fistula creation for haemodialysis access","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-02-15T14:05:20.0362597","FirstGoLiveDate":"2020-08-14T16:22:52.4780994","CreatedDate":"2020-08-14T16:20:33.6818906","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1833","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10811"}]},"ETag":"01000000-0000-001F-0000-0000000212D9","Reference":"GID-TA10811","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Lenvatinib with pembrolizumab for untreated advanced or unresectable hepatocellular carcinoma [ID3930]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-02-23T12:09:39.9773286","FirstGoLiveDate":"2021-02-23T12:09:39.9773286","CreatedDate":"2021-02-23T12:08:25.3060333","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3930","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10813"}]},"ETag":"01000000-0000-001F-0000-0000000212E2","Reference":"GID-TA10813","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Trastuzumab deruxtecan for treating HER2-negative metastatic or unresectable breast cancer after chemotherapy [ID3935]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-02-23T12:13:16.6484439","FirstGoLiveDate":"2021-02-23T12:13:16.6484439","CreatedDate":"2021-02-23T12:12:23.243232","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3935","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10814"}]},"ETag":"01000000-0000-001F-0000-0000000212E8","Reference":"GID-TA10814","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Trastuzumab deruxtecan for treating HER2-mutated unresectable or metastatic non-squamous non-small-cell lung cancer after 1 or more therapies [ID3934]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-02-23T12:15:40.0554446","FirstGoLiveDate":"2021-02-23T12:15:40.0554446","CreatedDate":"2021-02-23T12:14:44.210621","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3934","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10815"}]},"ETag":"01000000-0000-001F-0000-0000000212F7","Reference":"GID-TA10815","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic gastric or gastro-oesophageal junction cancer after 2 or more therapies [ID3933]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-02-23T12:18:40.0223307","FirstGoLiveDate":"2021-02-23T12:18:40.0223307","CreatedDate":"2021-02-23T12:16:13.4292261","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3933","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10816"}]},"ETag":"01000000-0000-001F-0000-0000000212F9","Reference":"GID-TA10816","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Mosunetuzumab for treating relapsed or refractory B-cell non-Hodgkin lymphoma [ID3931]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-02-23T12:18:40.0535711","FirstGoLiveDate":"2021-02-23T12:18:40.0535711","CreatedDate":"2021-02-23T12:17:26.8834291","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3931","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10567"}]},"ETag":"01000000-0000-001F-0000-0000000217DB","Reference":"GID-TA10567","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-09-14T00:00:00","LastModifiedDate":"2021-02-26T00:01:39.2686547","FirstGoLiveDate":"2019-12-16T08:55:03.1551786","CreatedDate":"2019-12-16T08:42:21.3676995","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1667","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10746"}]},"ETag":"01000000-0000-001F-0000-000000021932","Reference":"GID-TA10746","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Ibrutinib with venetoclax for untreated chronic lymphocytic leukaemia or small lymphocytic lymphoma [ID3860]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-02-26T14:09:49.775073","FirstGoLiveDate":"2020-10-05T12:24:21.5283735","CreatedDate":"2020-10-05T12:22:24.4973652","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3860","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10243"}]},"ETag":"01000000-0000-001F-0000-000000021945","Reference":"GID-TA10243","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Pembrolizumab for previously treated endometrial cancer [ID1205]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-02-26T14:12:49.6734419","FirstGoLiveDate":"2017-09-28T09:30:55.8105988","CreatedDate":"2017-09-28T09:28:51.3941859","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10569"}]},"ETag":"01000000-0000-001F-0000-00000002194A","Reference":"GID-TA10569","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Brigatinib for treating ALK-positive advanced non-small-cell lung cancer after alectinib or ceritinib [ID2702]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-02-26T14:13:38.618028","FirstGoLiveDate":"2019-12-16T10:07:03.2697019","CreatedDate":"2019-12-16T10:05:49.5823855","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2702","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10592"}]},"ETag":"01000000-0000-001F-0000-00000002241C","Reference":"GID-TA10592","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Pertuzumab–trastuzumab with chemotherapy for treating HER2-positive breast cancer [ID2724]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-04T08:40:06.6002782","FirstGoLiveDate":"2020-01-10T12:07:13.1580379","CreatedDate":"2020-01-10T12:03:42.5982613","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10483"}]},"ETag":"01000000-0000-001F-0000-000000022695","Reference":"GID-TA10483","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Mirvetuximab soravtansine for previously treated platinum-resistant FR-alpha positive ovarian cancer [ID1527]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-05T12:13:43.616413","FirstGoLiveDate":"2019-05-02T09:31:11.2712155","CreatedDate":"2019-05-02T08:29:21.800432","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1527","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10821"}]},"ETag":"01000000-0000-001F-0000-0000000226CB","Reference":"GID-TA10821","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Treprostinil for treating symptomatic chronic thromboembolic pulmonary hypertension [ID3926 ]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-05T14:10:43.555524","FirstGoLiveDate":"2021-03-05T14:10:43.555524","CreatedDate":"2021-03-05T13:59:08.3248105","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3926","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10823"}]},"ETag":"01000000-0000-001F-0000-0000000226D7","Reference":"GID-TA10823","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Inolimomab (Leukotac) for acute Graft versus host disease (aGvHD) after Allo-HSCT [ID3923]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-05T14:16:09.9452619","FirstGoLiveDate":"2021-03-05T14:16:09.9452619","CreatedDate":"2021-03-05T14:15:22.9297999","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3923","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10826"}]},"ETag":"01000000-0000-001F-0000-000000023839","Reference":"GID-TA10826","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Nivolumab with ipilimumab for untreated unresectable or metastatic urothelial cancer when cisplatin is unsuitable [ID3939]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-15T15:52:35.4661013","FirstGoLiveDate":"2021-03-15T15:52:35.4661013","CreatedDate":"2021-03-15T15:49:38.7995968","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3939","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10722"}]},"ETag":"01000000-0000-001F-0000-0000000239CC","Reference":"GID-TA10722","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Ibrutinib with corticosteroids for untreated chronic graft versus host disease [ID3792]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-09-22T15:11:51.4017982","FirstGoLiveDate":"2020-08-19T13:16:34.6381558","CreatedDate":"2020-08-19T13:12:51.7567254","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3792","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10818"}]},"ETag":"01000000-0000-001F-0000-0000000239D6","Reference":"GID-TA10818","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Benralizumab for previously treated severe nasal polyps [ID1659]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-16T13:58:38.5664891","FirstGoLiveDate":"2021-03-02T13:01:01.2354803","CreatedDate":"2021-03-02T12:56:17.6008864","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1659","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10474"}]},"ETag":"01000000-0000-001F-0000-000000023C3E","Reference":"GID-TA10474","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Durvalumab with tremelimumab for treating squamous cell head and neck cancer after platinum-based chemotherapy [ID1144]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-04-11T00:02:26.0729098","FirstGoLiveDate":"2019-04-11T00:02:26.0729098","CreatedDate":"2019-04-04T16:33:04.4154465","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10599"}]},"ETag":"01000000-0000-001F-0000-0000000243D2","Reference":"GID-TA10599","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Treosulfan with fludarabine before allogeneic stem cell transplant for people aged under 18 with non-malignant diseases [ID3745]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-22T10:40:53.7482718","FirstGoLiveDate":"2020-01-15T08:49:47.5022164","CreatedDate":"2020-01-15T08:48:58.6117141","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3745","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MIB10236"}]},"ETag":"01000000-0000-001F-0000-0000000246A6","Reference":"GID-MIB10236","ProjectType":"MIB","ProductTypeName":"Medtech innovation briefings","Process":"MIB","Title":"AI Bone Health","Status":"InProgress","ProjectGroup":"Advice","PublishedDate":"2021-07-13T00:00:00","LastModifiedDate":"2021-03-23T16:58:32.6376601","FirstGoLiveDate":null,"CreatedDate":"2021-01-27T17:10:39.3526845","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10777"}]},"ETag":"01000000-0000-001F-0000-00000002478D","Reference":"GID-TA10777","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Atezolizumab with chemotherapy for neoadjuvant and adjuvant treatment of resectable non-small-cell lung cancer [ID3894]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-24T10:10:54.0970408","FirstGoLiveDate":"2020-12-04T16:16:50.7870031","CreatedDate":"2020-12-04T16:14:28.9767281","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3894","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10830"}]},"ETag":"01000000-0000-001F-0000-0000000250E5","Reference":"GID-TA10830","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Cabozantinib with atezolizumab for untreated advanced hepatocellular carcinoma ID3940","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-29T14:01:57.8518042","FirstGoLiveDate":"2021-03-29T14:01:57.8518042","CreatedDate":"2021-03-29T13:59:17.0069881","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3940","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10831"}]},"ETag":"01000000-0000-001F-0000-0000000250E6","Reference":"GID-TA10831","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Loncastuximab tesirine for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies ID3943","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-29T14:01:57.8986806","FirstGoLiveDate":"2021-03-29T14:01:57.8986806","CreatedDate":"2021-03-29T14:00:28.6807193","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3943","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10832"}]},"ETag":"01000000-0000-001F-0000-0000000250EA","Reference":"GID-TA10832","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Maralixibat for treating cholestatic disease in Alagille Syndrome ID3941","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-29T14:02:17.6274204","FirstGoLiveDate":"2021-03-29T14:02:17.6274204","CreatedDate":"2021-03-29T14:01:44.7064009","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3941","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10833"}]},"ETag":"01000000-0000-001F-0000-0000000250F5","Reference":"GID-TA10833","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Mavorixafor for treating WHIM syndrome ID3946","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-29T14:04:57.8665586","FirstGoLiveDate":"2021-03-29T14:04:57.8665586","CreatedDate":"2021-03-29T14:02:36.4863377","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3946","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10834"}]},"ETag":"01000000-0000-001F-0000-0000000250F6","Reference":"GID-TA10834","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Setmelanotide for treating obesity and hyperphagia in Bardet-Biedl syndrome or Alström syndrome ID3947","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-29T14:04:57.8978211","FirstGoLiveDate":"2021-03-29T14:04:57.8978211","CreatedDate":"2021-03-29T14:03:39.8910215","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3947","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10835"}]},"ETag":"01000000-0000-001F-0000-0000000250FC","Reference":"GID-TA10835","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Tirzepatide for treating type 2 diabetes ID3938","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-29T14:07:57.8346465","FirstGoLiveDate":"2021-03-29T14:07:57.8346465","CreatedDate":"2021-03-29T14:06:49.8817819","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3938","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10752"}]},"ETag":"01000000-0000-001F-0000-000000025296","Reference":"GID-TA10752","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Lifileucel for previously treated unresectable or metastatic melanoma [ID3863]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-30T12:49:58.8020345","FirstGoLiveDate":"2020-10-05T12:36:21.4959741","CreatedDate":"2020-10-05T12:34:53.6894485","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3863","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10836"}]},"ETag":"01000000-0000-001F-0000-0000000252E7","Reference":"GID-TA10836","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Talimogene laherparepvec with pembrolizumab for treating unresectable or metastatic melanoma ID3856","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-30T15:19:58.7757689","FirstGoLiveDate":"2021-03-30T15:19:58.7757689","CreatedDate":"2021-03-30T15:16:39.6089139","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3856","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10316"}]},"ETag":"01000000-0000-001F-0000-000000025F53","Reference":"GID-TA10316","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-04-07T08:26:04.6974192","FirstGoLiveDate":"2018-03-14T10:10:14.9944047","CreatedDate":"2018-03-14T10:07:29.5911844","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10768"}]},"ETag":"01000000-0000-001F-0000-0000000262CD","Reference":"GID-TA10768","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Bintrafusp alfa for treating advanced biliary tract cancer after platinum-based chemotherapy [ID3874]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-04-09T11:14:39.7263672","FirstGoLiveDate":"2020-12-04T15:43:50.7583063","CreatedDate":"2020-12-04T15:42:36.0164047","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3874","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10214"}]},"ETag":"01000000-0000-001F-0000-000000026338","Reference":"GID-IPG10214","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Prostatic urethral temporary implant insertion for lower urinary tract symptoms caused by benign prostatic hyperplasia","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-04-09T14:08:05.4973684","FirstGoLiveDate":"2021-04-09T14:08:05.4973684","CreatedDate":"2021-04-09T13:57:18.732657","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1701","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10327"}]},"ETag":"01000000-0000-001F-0000-000000026812","Reference":"GID-TA10327","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Veliparib in combination for treating BRCA-positive, HER2-negative breast advanced cancer ID1404","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-04-06T12:11:33.8965354","FirstGoLiveDate":"2018-03-14T10:34:14.9821874","CreatedDate":"2018-03-14T10:32:29.9013839","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1404","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10442"}]},"ETag":"01000000-0000-001F-0000-000000026814","Reference":"GID-TA10442","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Veliparib for induction treatment of previously untreated advanced ovarian, fallopian tube and primary peritoneal cancer in combination with carboplatin and paclitaxel, followed by veliparib maintenance treatment as a monotherapy [ID1561]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-04-06T12:08:33.8758496","FirstGoLiveDate":"2018-12-06T15:14:19.5538135","CreatedDate":"2018-12-06T15:12:43.2733874","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1561","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-HST10010"}]},"ETag":"01000000-0000-001F-0000-000000026818","Reference":"GID-HST10010","ProjectType":"HST","ProductTypeName":"Highly specialised technology","Process":"HST","Title":"Velmanase alfa for treating alpha-mannosidosis [ID800]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-06-26T11:32:06.5566701","FirstGoLiveDate":"2017-06-14T11:02:39.0398161","CreatedDate":"2017-06-14T10:53:23.1743872","DevelopedAs":null,"RelevantTo":null,"IdNumber":"800","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10595"}]},"ETag":"01000000-0000-001F-0000-00000002681D","Reference":"GID-TA10595","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Vericiguat for treating chronic heart failure with reduced ejection fraction [ID2731]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-15T11:50:40.5880605","FirstGoLiveDate":"2020-01-15T08:43:47.4507895","CreatedDate":"2020-01-15T08:41:53.7841664","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2731","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10298"}]},"ETag":"01000000-0000-001F-0000-000000026844","Reference":"GID-TA10298","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Intravenous zanamivir for treating influenza in hospital [ID1196]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-02-06T06:00:07.0359065","FirstGoLiveDate":"2018-02-06T06:00:07.0359065","CreatedDate":"2018-02-01T14:26:36.5570095","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1196","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10110"}]},"ETag":"01000000-0000-001F-0000-00000002686E","Reference":"GID-NG10110","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Epilepsies in adults: diagnosis and management update (Please see Epilepsies in children, young people and adults)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-07-21T16:21:50.1167031","FirstGoLiveDate":"2018-05-16T14:50:45.6517048","CreatedDate":"2018-05-16T14:47:39.40172","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-SGWAVE0762"}]},"ETag":"01000000-0000-001F-0000-0000000268D9","Reference":"GID-SGWAVE0762","ProjectType":"SG","ProductTypeName":"NICE guideline","Process":"SG","Title":"Accident and emergency departments","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2015-08-04T09:54:35","FirstGoLiveDate":null,"CreatedDate":"2015-08-04T09:54:35","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10159"}]},"ETag":"01000000-0000-001F-0000-0000000268E2","Reference":"GID-IPG10159","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Magnetic resonance therapy for knee osteoarthritis","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-08-25T00:00:00","LastModifiedDate":"2021-03-25T10:16:54.7221512","FirstGoLiveDate":"2020-02-18T15:27:47.9747793","CreatedDate":"2020-02-18T15:26:19.3261342","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1800","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10152"}]},"ETag":"01000000-0000-001F-0000-0000000268E8","Reference":"GID-IPG10152","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Transapical transcatheter mitral valve-in-valve implantation for a failed surgically-implanted mitral valve bioprosthesis","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-07-28T00:00:00","LastModifiedDate":"2021-02-26T16:09:49.6811785","FirstGoLiveDate":"2019-12-16T19:01:03.1707415","CreatedDate":"2019-12-16T18:55:51.7493858","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1070","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10161"}]},"ETag":"01000000-0000-001F-0000-0000000268EC","Reference":"GID-IPG10161","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Synthetic cartilage implant insertion for first metatarsophalangeal joint osteoarthritis (hallux rigidus)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-07-28T00:00:00","LastModifiedDate":"2021-04-12T16:08:14.8785157","FirstGoLiveDate":"2020-02-18T15:30:47.9350032","CreatedDate":"2020-02-18T15:29:58.6460097","DevelopedAs":null,"RelevantTo":null,"IdNumber":"742","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-HST10030"}]},"ETag":"01000000-0000-001F-0000-000000026901","Reference":"GID-HST10030","ProjectType":"HST","ProductTypeName":"Highly specialised technology","Process":"HST","Title":"Avalglucosidase alfa for treating Pompe disease [ID3737]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-08-13T11:16:22.5703846","FirstGoLiveDate":"2020-01-15T08:41:30.7998261","CreatedDate":"2020-01-15T08:37:37.3626467","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3737","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10070"}]},"ETag":"01000000-0000-001F-0000-000000026903","Reference":"GID-QS10070","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"School-based interventions: physical and mental health and wellbeing promotion","Status":"ImpactedByCOVID19","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-05-05T11:57:52.006425","FirstGoLiveDate":"2018-04-04T11:52:06.5128761","CreatedDate":"2018-04-04T11:46:07.7041803","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10737"}]},"ETag":"01000000-0000-001F-0000-000000026910","Reference":"GID-TA10737","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA Review","Title":"Avatrombopag for treating chemotherapy-induced thrombocytopenia in non-haematological cancers [ID3837]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-02-24T00:01:21.2095233","FirstGoLiveDate":"2020-09-18T08:44:44.1931438","CreatedDate":"2020-09-18T08:43:43.0526393","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3837","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10756"}]},"ETag":"01000000-0000-001F-0000-00000002691D","Reference":"GID-TA10756","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Osimertinib for adjuvant treatment of EGFR mutation-positive non-small-cell lung cancer after complete tumour resection [ID3835]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-09-22T00:00:00","LastModifiedDate":"2021-03-01T17:40:38.0804922","FirstGoLiveDate":"2020-10-12T15:45:41.5950619","CreatedDate":"2020-10-12T15:40:32.595547","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3835","EvidenceAssessmentGroup":"ScHARR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10497"}]},"ETag":"01000000-0000-001F-0000-00000002693E","Reference":"GID-TA10497","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Ropeginterferon alfa-2b for treating polycythaemia vera without symptomatic splenomegaly ID1596","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-05-28T14:52:00.5998301","FirstGoLiveDate":"2019-05-08T13:06:59.228835","CreatedDate":"2019-05-08T13:05:22.9211452","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1596","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-PHG0"}]},"ETag":"01000000-0000-001F-0000-000000026948","Reference":"GID-PHG0","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"PHG","Title":"Personal, social, health and economic education focusing on sex and relationships and alcohol education ","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-05-18T14:14:01.3221639","FirstGoLiveDate":"2015-12-22T11:52:56.8884588","CreatedDate":"2014-07-16T13:14:34","DevelopedAs":"PH","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG387"}]},"ETag":"01000000-0000-001F-0000-00000002694C","Reference":"GID-TAG387","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Breast cancer (advanced or metastatic) - lapatinib [ID20]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10523"}]},"ETag":"01000000-0000-001F-0000-000000026966","Reference":"GID-TA10523","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours [ID1626]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-29T11:40:57.9650073","FirstGoLiveDate":"2019-08-07T06:01:06.2664959","CreatedDate":"2019-07-31T14:46:41.9500855","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1626","EvidenceAssessmentGroup":"SHTAC","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10743"}]},"ETag":"01000000-0000-001F-0000-000000026969","Reference":"GID-TA10743","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nivolumab for adjuvant treatment of oesophageal or gastro-oesophageal junction cancer [ID1676]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-11-17T00:00:00","LastModifiedDate":"2021-01-08T12:38:53.7919316","FirstGoLiveDate":"2020-10-01T14:15:15.8518365","CreatedDate":"2020-10-01T14:12:11.1089615","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1676","EvidenceAssessmentGroup":"ScHARR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10555"}]},"ETag":"01000000-0000-001F-0000-00000002698D","Reference":"GID-TA10555","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Canagliflozin for treating chronic kidney disease in people with type 2 diabetes [ID1653]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-12-23T09:38:14.7491636","FirstGoLiveDate":"2019-11-25T06:00:22.9383556","CreatedDate":"2019-11-18T14:11:14.5034996","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1653","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10552"}]},"ETag":"01000000-0000-001F-0000-000000026996","Reference":"GID-TA10552","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease [ID1672]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-04-01T11:04:59.1983893","FirstGoLiveDate":"2019-11-21T06:00:28.1584461","CreatedDate":"2019-11-14T16:34:08.2082019","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1672","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10234"}]},"ETag":"01000000-0000-001F-0000-0000000269AB","Reference":"GID-TA10234","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Nivolumab with ipilimumab for untreated non-small-cell lung cancer that has a high tumour mutational burden [ID1187]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-04-06T00:02:31.9510224","FirstGoLiveDate":"2017-09-18T06:00:04.6270658","CreatedDate":"2017-09-12T13:18:59.7923997","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1187","EvidenceAssessmentGroup":"Kleijnen Systematic Reviews","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10046"}]},"ETag":"01000000-0000-001F-0000-000000026A2C","Reference":"GID-TA10046","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Waldenstrom’s macroglobulinaemia - ibrutinib [ID884]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2017-11-22T00:00:00","LastModifiedDate":"2017-11-22T08:34:54.993937","FirstGoLiveDate":"2016-04-05T00:01:21.3656252","CreatedDate":"2016-03-29T12:14:13.9377025","DevelopedAs":null,"RelevantTo":null,"IdNumber":"884","EvidenceAssessmentGroup":"School of Health and Related Research (ScHARR), University of Sheffield","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10050"}]},"ETag":"01000000-0000-001F-0000-000000026A44","Reference":"GID-NG10050","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"PHG","Title":"Managing common infections - antimicrobial prescribing guidelines","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-10-22T09:32:19.9491448","FirstGoLiveDate":"2016-09-29T15:07:28.1306865","CreatedDate":"2016-09-29T15:06:10.6791494","DevelopedAs":"PH","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG525"}]},"ETag":"01000000-0000-001F-0000-000000026A4D","Reference":"GID-TAG525","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Third molars (impacted) - prophylactic removal  [ID898]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-09-23T11:34:19.6650352","FirstGoLiveDate":"2015-10-09T16:34:40.5917336","CreatedDate":"2015-08-11T12:20:04","DevelopedAs":null,"RelevantTo":null,"IdNumber":"898","EvidenceAssessmentGroup":"Liverpool Reviews and Implementation Group (LRIG)","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG369"}]},"ETag":"01000000-0000-001F-0000-000000026A62","Reference":"GID-TAG369","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Dementia (non-Alzheimer) - new pharmaceutical treatments [ID380]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10155"}]},"ETag":"01000000-0000-001F-0000-000000026A64","Reference":"GID-TA10155","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Peramivir for treating influenza [ID828]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-02-14T17:57:36.7079926","FirstGoLiveDate":"2017-02-01T01:01:50.7172407","CreatedDate":"2017-01-25T12:28:07.9123481","DevelopedAs":null,"RelevantTo":null,"IdNumber":"828","EvidenceAssessmentGroup":"School of Health and Related Research (ScHARR), University of Sheffield","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT539"}]},"ETag":"01000000-0000-001F-0000-000000026A88","Reference":"GID-MT539","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"MT461 Endo-SPONGE for treating low rectal anastomotic leakage","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-29T13:55:57.8387493","FirstGoLiveDate":"2019-11-12T12:06:04.8284036","CreatedDate":"2019-11-11T14:47:37.8998538","DevelopedAs":null,"RelevantTo":null,"IdNumber":"461","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10566"}]},"ETag":"01000000-0000-001F-0000-000000026A92","Reference":"GID-TA10566","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Elexacaftor, tezacaftor and ivacaftor fixed dose combination therapy for treating cystic fibrosis with the F508del mutation [ID1661]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-23T16:01:02.271107","FirstGoLiveDate":"2019-12-19T11:51:47.3933446","CreatedDate":"2019-12-12T14:51:04.5556857","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1661","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-PHG59"}]},"ETag":"01000000-0000-001F-0000-000000026AB6","Reference":"GID-PHG59","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"PHG","Title":"Workplace health - older employees","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":"2016-03-24T00:00:00","LastModifiedDate":"2017-05-18T14:14:06.6191163","FirstGoLiveDate":"2015-10-09T16:58:40.620839","CreatedDate":"2015-09-22T10:46:21","DevelopedAs":"PH","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10371"}]},"ETag":"01000000-0000-001F-0000-000000026AB9","Reference":"GID-TA10371","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Esketamine for treatment-resistant depression (ID1414)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-04-01T13:07:59.1584966","FirstGoLiveDate":"2018-08-01T06:00:52.3902212","CreatedDate":"2018-07-25T11:48:29.8307998","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1414","EvidenceAssessmentGroup":"KSR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG393"}]},"ETag":"01000000-0000-001F-0000-000000026ABB","Reference":"GID-TAG393","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10527"}]},"ETag":"01000000-0000-001F-0000-000000026AEB","Reference":"GID-TA10527","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Emapalumab for treating primary haemophagocytic lymphohistiocytosis (ID1438)","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-02-12T16:20:23.7980821","FirstGoLiveDate":"2018-07-31T06:00:51.367705","CreatedDate":"2018-07-24T16:09:13.6967544","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1438","EvidenceAssessmentGroup":"SHTAC","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG420"}]},"ETag":"01000000-0000-001F-0000-000000026AF1","Reference":"GID-TAG420","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Obesity - lorcaserin [ID337]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10112"}]},"ETag":"01000000-0000-001F-0000-000000026AF9","Reference":"GID-NG10112","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Epilepsies in children, young people and adults","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-03-09T00:00:00","LastModifiedDate":"2021-03-22T15:16:53.6316817","FirstGoLiveDate":"2018-06-19T15:22:46.2942286","CreatedDate":"2018-06-19T15:15:38.7532204","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG382"}]},"ETag":"01000000-0000-001F-0000-000000026B00","Reference":"GID-TAG382","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Pulmonary arterial hypertension (adults) - drugs [ID12]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-SGWAVE0701"}]},"ETag":"01000000-0000-001F-0000-000000026B19","Reference":"GID-SGWAVE0701","ProjectType":"SG","ProductTypeName":"NICE guideline","Process":"SG","Title":"Inpatient mental health settings","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2015-08-04T09:51:07","FirstGoLiveDate":null,"CreatedDate":"2015-08-04T09:51:07","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10531"}]},"ETag":"01000000-0000-001F-0000-000000026B74","Reference":"GID-TA10531","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Atezolizumab with chemotherapy for neoadjuvant treatment of resectable early or locally advanced invasive triple-negative breast cancer [ID1574]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-12-15T00:00:00","LastModifiedDate":"2021-02-05T10:39:07.2555103","FirstGoLiveDate":"2019-08-30T10:58:34.7499927","CreatedDate":"2019-08-30T10:57:43.5896984","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1574","EvidenceAssessmentGroup":"UL","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10431"}]},"ETag":"01000000-0000-001F-0000-000000026B8C","Reference":"GID-TA10431","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Netarsudil for treating open angle glaucoma or ocular hypertension [ID1078]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-08-05T16:25:04.6864355","FirstGoLiveDate":"2018-11-26T06:00:24.5089414","CreatedDate":"2018-11-19T11:01:49.0961762","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1078","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10598"}]},"ETag":"01000000-0000-001F-0000-000000026BA1","Reference":"GID-TA10598","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Secukinumab for treating enthesitis-related arthritis or juvenile psoriatic arthritis  [ID3738]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-07-31T15:12:56.9011124","FirstGoLiveDate":"2020-01-15T08:49:47.4553369","CreatedDate":"2020-01-15T08:47:22.2211784","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3738","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10503"}]},"ETag":"01000000-0000-001F-0000-000000026BE5","Reference":"GID-TA10503","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Midostaurin for treating advanced systemic mastocytosis ID1573","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-29T11:40:57.9025207","FirstGoLiveDate":"2019-05-24T06:00:10.9946086","CreatedDate":"2019-05-17T14:33:09.6406991","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1573","EvidenceAssessmentGroup":"UL","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10659"}]},"ETag":"01000000-0000-001F-0000-000000026C09","Reference":"GID-TA10659","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nitisinone for treating alkaptonuria [ID2691]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-02-15T12:17:20.0405614","FirstGoLiveDate":"2020-05-13T10:45:43.0477143","CreatedDate":"2020-05-13T10:44:11.8207846","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2691","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-DT14"}]},"ETag":"01000000-0000-001F-0000-000000026C23","Reference":"GID-DT14","ProjectType":"DG","ProductTypeName":"Diagnostics guidance","Process":"DT","Title":"KRAS mutation testing of tumours in adults with metastatic colorectal cancer (discontinued)","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-05-09T09:20:14.5291344","FirstGoLiveDate":"2017-04-11T09:11:13.0341121","CreatedDate":"2014-12-08T16:31:42","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG423"}]},"ETag":"01000000-0000-001F-0000-000000026C55","Reference":"GID-TAG423","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Chronic iron overload (in people with thalassaemia) - desferrioxamine, deferiprone and deferasirox [ID350]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10071"}]},"ETag":"01000000-0000-001F-0000-000000026C78","Reference":"GID-TA10071","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Osteoporosis (postmenopausal women) - abaloparatide [ID882] ","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-06-17T11:13:53.473836","FirstGoLiveDate":"2016-06-17T11:13:53.473836","CreatedDate":"2016-06-02T16:42:29.1932693","DevelopedAs":null,"RelevantTo":null,"IdNumber":"882","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-SGWAVE0761"}]},"ETag":"01000000-0000-001F-0000-000000026C7E","Reference":"GID-SGWAVE0761","ProjectType":"SG","ProductTypeName":"NICE guideline","Process":"SG","Title":"Management and organisational approaches to safe staffing","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2015-07-31T16:37:54","FirstGoLiveDate":null,"CreatedDate":"2015-07-31T16:37:54","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10508"}]},"ETag":"01000000-0000-001F-0000-000000026C92","Reference":"GID-TA10508","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Luspatercept for treating anaemia caused by myelodysplastic syndromes [ID1550]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-02-06T13:48:23.5130163","FirstGoLiveDate":"2019-06-04T06:00:30.8314291","CreatedDate":"2019-05-28T14:45:46.6531636","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1550","EvidenceAssessmentGroup":"ScHARR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10506"}]},"ETag":"01000000-0000-001F-0000-000000026C97","Reference":"GID-TA10506","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Luspatercept for treating beta-thalassaemia ID1554","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-06-16T12:28:23.5987053","FirstGoLiveDate":"2019-05-31T06:00:32.3056563","CreatedDate":"2019-05-24T13:51:36.4939845","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1554","EvidenceAssessmentGroup":"PenTAG","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG413"}]},"ETag":"01000000-0000-001F-0000-000000026CC5","Reference":"GID-TAG413","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Glioblastoma - bevacizumab [ID80]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-HST10009"}]},"ETag":"01000000-0000-001F-0000-000000026CC8","Reference":"GID-HST10009","ProjectType":"HST","ProductTypeName":"Highly specialised technology","Process":"HST","Title":"Afamelanotide for treating erythropoietic protoporphyria [ID927]","Status":"ImpactedByCOVID19","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-06-04T10:28:08.8198214","FirstGoLiveDate":"2017-05-10T10:08:15.4901393","CreatedDate":"2017-05-10T10:00:19.5457066","DevelopedAs":null,"RelevantTo":null,"IdNumber":"927","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10016"}]},"ETag":"01000000-0000-001F-0000-000000026CCA","Reference":"GID-QS10016","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Maternal health: promoting maternal health through community based strategies","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-08-05T11:54:18.2189197","FirstGoLiveDate":"2016-01-29T14:28:28.5948365","CreatedDate":"2016-01-29T14:23:49.1298497","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10070"}]},"ETag":"01000000-0000-001F-0000-000000026CD7","Reference":"GID-TA10070","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Leukaemia (acute myeloid, relapsed, refractory) - vosaroxin [ID746] ","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-04-19T13:31:31.6820844","FirstGoLiveDate":"2016-06-06T01:03:47.4329915","CreatedDate":"2016-06-02T16:25:03.7679927","DevelopedAs":null,"RelevantTo":null,"IdNumber":"746","EvidenceAssessmentGroup":"Health Economics Research Unit and Health Services Research Unit, University of Aberdeen","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT517"}]},"ETag":"01000000-0000-001F-0000-000000026CED","Reference":"GID-MT517","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"The IN.PACT drug-coated balloon for peripheral arterial disease (CANCELLED)","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-07-01T13:50:47.2423141","FirstGoLiveDate":"2017-08-21T13:21:03.4983593","CreatedDate":"2017-08-21T10:36:18.878998","DevelopedAs":null,"RelevantTo":null,"IdNumber":"336","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG437"}]},"ETag":"01000000-0000-001F-0000-000000026CEF","Reference":"GID-TAG437","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Hypercholesterolemia - mipomersen [ID524]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10179"}]},"ETag":"01000000-0000-001F-0000-000000026CF5","Reference":"GID-TA10179","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Furosemide micro-pump for treating oedema associated with heart failure (ID1061)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-07-03T08:57:28.9422832","FirstGoLiveDate":"2017-06-23T08:59:42.7831169","CreatedDate":"2017-06-23T08:31:30.4570632","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1061","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG278"}]},"ETag":"01000000-0000-001F-0000-000000026CF8","Reference":"GID-TAG278","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Lymphoma (non Hodgkin's) - bendamustine (with rituximab) [ID434]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-05-20T13:27:06.9429258","FirstGoLiveDate":"2016-05-20T13:27:06.9429258","CreatedDate":"2015-04-09T09:28:44","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10502"}]},"ETag":"01000000-0000-001F-0000-000000026CFC","Reference":"GID-TA10502","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Venetoclax with bortezomib and dexamethasone for treating relapsed or refractory multiple myeloma ID1565","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-05-29T14:05:27.2355945","FirstGoLiveDate":"2019-05-15T06:00:45.8699984","CreatedDate":"2019-05-08T15:41:41.0627532","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1565","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10089"}]},"ETag":"01000000-0000-001F-0000-000000026CFD","Reference":"GID-TA10089","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Regorafenib for treating advanced gastrointestinal stromal tumours [ID1056]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2017-11-15T00:00:00","LastModifiedDate":"2017-10-12T08:32:12.9785913","FirstGoLiveDate":"2016-08-05T14:10:46.7259008","CreatedDate":"2016-07-22T14:49:52.7276291","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1056","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10807"}]},"ETag":"01000000-0000-001F-0000-000000026D03","Reference":"GID-TA10807","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Lasmiditan for treating acute migraine [ID3759]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2023-03-29T00:00:00","LastModifiedDate":"2021-04-02T00:02:00.460353","FirstGoLiveDate":"2021-02-02T12:33:04.8057798","CreatedDate":"2021-02-02T12:29:54.6312875","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3759","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10721"}]},"ETag":"01000000-0000-001F-0000-000000026D07","Reference":"GID-TA10721","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Remdesivir for treating COVID-19 [ID3808]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-08-18T16:53:40.9403966","FirstGoLiveDate":"2020-08-18T16:53:40.9403966","CreatedDate":"2020-08-18T16:50:51.8005538","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10157"}]},"ETag":"01000000-0000-001F-0000-000000026D17","Reference":"GID-TA10157","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Masitinib for treating amyotrophic lateral sclerosis [ID967]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-05-09T17:20:45.0487376","FirstGoLiveDate":"2017-02-03T01:01:58.4868817","CreatedDate":"2017-01-27T12:26:44.3702047","DevelopedAs":null,"RelevantTo":null,"IdNumber":"967","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-PHG58"}]},"ETag":"01000000-0000-001F-0000-000000026D3B","Reference":"GID-PHG58","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"PHG","Title":"Workplace health for employees with disabilities and long-term conditions","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-06-28T14:05:03.1789818","FirstGoLiveDate":"2015-12-01T10:42:45.0090558","CreatedDate":"2015-09-14T10:00:32","DevelopedAs":"PH","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10614"}]},"ETag":"01000000-0000-001F-0000-000000026D63","Reference":"GID-TA10614","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Selpercatinib for treating advanced thyroid cancer with RET alterations [ID3744]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-29T11:49:57.8420346","FirstGoLiveDate":"2020-01-29T09:57:01.53484","CreatedDate":"2020-01-29T09:56:22.9255398","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3744","EvidenceAssessmentGroup":"KSR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT538"}]},"ETag":"01000000-0000-001F-0000-000000026D7E","Reference":"GID-MT538","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"Peezy Midstream for urine collection (MT446)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-05T15:36:21.51439","FirstGoLiveDate":"2019-10-09T09:40:52.4158468","CreatedDate":"2019-10-09T09:18:16.9311505","DevelopedAs":null,"RelevantTo":null,"IdNumber":"446","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG424"}]},"ETag":"01000000-0000-001F-0000-000000026D86","Reference":"GID-TAG424","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Lymphoma (non Hodgkin's, peripheral T-cell) - pralatrexate [ID368]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10570"}]},"ETag":"01000000-0000-001F-0000-000000026DA5","Reference":"GID-TA10570","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Atezolizumab with paclitaxel for untreated advanced triple-negative breast cancer [ID2705]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":"2021-11-17T00:00:00","LastModifiedDate":"2020-12-04T00:01:50.9348497","FirstGoLiveDate":"2019-12-16T10:10:03.1751089","CreatedDate":"2019-12-16T10:08:12.0347744","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2705","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG402"}]},"ETag":"01000000-0000-001F-0000-000000026DB0","Reference":"GID-TAG402","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Juvenile idiopathic arthritis - abatacept [ID27]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-CGWAVE0773"}]},"ETag":"01000000-0000-001F-0000-000000026DB2","Reference":"GID-CGWAVE0773","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Diagnostic services","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-07-07T13:41:23.3857883","FirstGoLiveDate":"2016-01-07T14:39:37.9652936","CreatedDate":"2015-10-05T00:00:35","DevelopedAs":"CG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10186"}]},"ETag":"01000000-0000-001F-0000-000000026DB6","Reference":"GID-NG10186","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Asthma: diagnosis, monitoring and chronic asthma management","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-03T16:26:47.2651434","FirstGoLiveDate":"2021-01-28T11:22:39.271995","CreatedDate":"2021-01-28T11:16:11.1956646","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":"0","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10133"}]},"ETag":"01000000-0000-001F-0000-000000026DBB","Reference":"GID-TA10133","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Pacritinib for treating myelofibrosis [ID880]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-02-06T16:15:21.7996333","FirstGoLiveDate":"2016-11-03T11:25:02.9084269","CreatedDate":"2016-11-03T11:19:48.8186077","DevelopedAs":null,"RelevantTo":null,"IdNumber":"880","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10198"}]},"ETag":"01000000-0000-001F-0000-000000026DC6","Reference":"GID-TA10198","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Dexamethasone intracanalicular insert for treating inflammation and pain after cataract surgery ID1154","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-08-15T12:05:52.6395804","FirstGoLiveDate":"2017-07-25T06:01:01.3242899","CreatedDate":"2017-07-20T11:54:58.3188776","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1154","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT544"}]},"ETag":"01000000-0000-001F-0000-000000026DD1","Reference":"GID-MT544","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"The MAGEC system for spinal lengthening in children with scoliosis","Status":"ImpactedByCOVID19","ProjectGroup":"Guidance","PublishedDate":"2020-09-15T00:00:00","LastModifiedDate":"2020-05-27T15:28:28.1712486","FirstGoLiveDate":"2020-01-20T11:25:29.8008402","CreatedDate":"2020-01-20T10:57:39.582964","DevelopedAs":null,"RelevantTo":null,"IdNumber":"169","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-DG10029"}]},"ETag":"01000000-0000-001F-0000-000000026DD9","Reference":"GID-DG10029","ProjectType":"DG","ProductTypeName":"Diagnostics guidance","Process":"DT","Title":"PredictSURE IBD and IBDX to guide treatment of Crohn’s disease","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-02-17T14:56:25.5328283","FirstGoLiveDate":"2019-02-25T01:02:42.8877269","CreatedDate":"2019-02-15T12:54:12.830452","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10151"}]},"ETag":"01000000-0000-001F-0000-000000026DDF","Reference":"GID-TA10151","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Nivolumab for previously treated gastric or gastro-oesophageal junction cancer [ID1118]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-11-28T15:05:34.2766614","FirstGoLiveDate":"2017-01-31T01:01:50.242417","CreatedDate":"2017-01-24T13:59:54.8053783","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1118","EvidenceAssessmentGroup":"BMJ-TAG","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737"}]},"ETag":"01000000-0000-001F-0000-000000026DE7","Reference":"GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737","ProjectType":"HST","ProductTypeName":"Highly specialised technology","Process":"HST","Title":"Lysosomal acid lipase deficiency - sebelipase alfa [ID737]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-15T10:49:35.466556","FirstGoLiveDate":"2016-02-01T11:28:34.74837","CreatedDate":"2015-09-11T00:00:00","DevelopedAs":null,"RelevantTo":null,"IdNumber":"737","EvidenceAssessmentGroup":"KSR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG360"}]},"ETag":"01000000-0000-001F-0000-000000026E03","Reference":"GID-TAG360","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Gastrointestinal stromal tumours (unresectable, metastatic) - masitinib (after progression with imatinib) ID622","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2015-02-18T18:04:03","FirstGoLiveDate":null,"CreatedDate":"2015-02-18T18:04:03","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IP1180"}]},"ETag":"01000000-0000-001F-0000-000000026E24","Reference":"GID-IP1180","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Implanting a baroreceptor stimulation device for resistant hypertension ","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2015-02-25T17:04:59","FirstGoLiveDate":null,"CreatedDate":"2015-02-25T17:04:59","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG433"}]},"ETag":"01000000-0000-001F-0000-000000026E26","Reference":"GID-TAG433","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"T-cell lymphoma (peripheral, relapsed or refractory) - romidepsin [ID504]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG507"}]},"ETag":"01000000-0000-001F-0000-000000026E2B","Reference":"GID-TAG507","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Neuroblastoma (high-risk) - dinutuximab (maintenance, after therapy) [ID799]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-08-08T09:38:13.8896046","FirstGoLiveDate":"2015-10-27T11:44:22.8215397","CreatedDate":"2015-09-04T12:56:23","DevelopedAs":null,"RelevantTo":null,"IdNumber":"799","EvidenceAssessmentGroup":"Centre for Reviews and Dissemination and Centre for Health Economics – York ","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG479"}]},"ETag":"01000000-0000-001F-0000-000000026E31","Reference":"GID-TAG479","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Melanoma (resected stage IV, high risk stage III) - ipilimumab (adjuvant) [ID721]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-01-15T11:14:45.8433839","FirstGoLiveDate":"2018-01-15T11:14:45.8433839","CreatedDate":"2015-04-09T10:39:46","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10363"}]},"ETag":"01000000-0000-001F-0000-000000026E36","Reference":"GID-TA10363","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-09-24T16:12:25.9741563","FirstGoLiveDate":"2018-07-04T06:02:35.8876595","CreatedDate":"2018-06-28T12:33:01.9140342","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1325","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10026"}]},"ETag":"01000000-0000-001F-0000-000000026E3D","Reference":"GID-TA10026","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Gastroenteropancreatic tumours (unresectable, metastatic, non-progressive) - lanreotide (subcutaneous injection) [ID961]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-11-01T13:06:50.998894","FirstGoLiveDate":"2016-01-08T11:57:40.8963703","CreatedDate":"2016-01-08T11:52:17.3557034","DevelopedAs":null,"RelevantTo":null,"IdNumber":"961","EvidenceAssessmentGroup":"Liverpool Reviews and Implementation Group, University of Liverpool","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG321"}]},"ETag":"01000000-0000-001F-0000-000000026E51","Reference":"GID-TAG321","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Lymphoma (mantle cell) - bendamustine (1st line, with rituximab) [ID609] ","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-05-19T11:27:04.2007089","FirstGoLiveDate":"2016-05-19T11:27:04.2007089","CreatedDate":"2015-04-09T09:15:52","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT267"}]},"ETag":"01000000-0000-001F-0000-000000026E5D","Reference":"GID-MT267","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"Microthane implants for breast reconstruction or breast augmentation (discontinued)","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-05-16T14:30:00.2906546","FirstGoLiveDate":"2015-10-26T15:47:19.7526395","CreatedDate":"2015-09-22T12:02:38","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG368"}]},"ETag":"01000000-0000-001F-0000-000000026E5E","Reference":"GID-TAG368","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Multiple sclerosis - sativex [ID387]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG374"}]},"ETag":"01000000-0000-001F-0000-000000026E6B","Reference":"GID-TAG374","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Thrombophilia [ID393]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG426"}]},"ETag":"01000000-0000-001F-0000-000000026E78","Reference":"GID-TAG426","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Osteoarthritis - naproxcinod [ID417]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IP1238"}]},"ETag":"01000000-0000-001F-0000-000000026E7E","Reference":"GID-IP1238","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Sacral nerve stimulation for idiopathic chronic non-obstructive urinary retention ","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2015-06-30T10:48:37","FirstGoLiveDate":null,"CreatedDate":"2015-06-30T10:48:37","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-SGWAVE0700"}]},"ETag":"01000000-0000-001F-0000-000000026E91","Reference":"GID-SGWAVE0700","ProjectType":"SG","ProductTypeName":"NICE guideline","Process":"SG","Title":"Community nursing care settings","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2015-08-04T09:55:35","FirstGoLiveDate":null,"CreatedDate":"2015-08-04T09:55:35","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10518"}]},"ETag":"01000000-0000-001F-0000-000000026E94","Reference":"GID-TA10518","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Esketamine for treating major depressive disorder in adults at imminent risk for suicide ID1604","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-09-09T00:02:22.2999251","FirstGoLiveDate":"2019-07-26T06:00:53.8926401","CreatedDate":"2019-07-19T13:19:32.585737","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1604","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10191"}]},"ETag":"01000000-0000-001F-0000-000000026E9F","Reference":"GID-NG10191","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Maternal and child nutrition","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2023-11-22T00:00:00","LastModifiedDate":"2021-04-08T10:56:04.3502318","FirstGoLiveDate":"2021-03-04T12:04:06.1878359","CreatedDate":"2021-03-04T11:33:32.4469967","DevelopedAs":"CG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG337"}]},"ETag":"01000000-0000-001F-0000-000000026EA4","Reference":"GID-TAG337","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Multiple sclerosis (relapsing-remitting) - laquinimod [ID560]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-22T09:26:14","FirstGoLiveDate":null,"CreatedDate":"2014-07-22T09:26:14","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10154"}]},"ETag":"01000000-0000-001F-0000-000000026EAA","Reference":"GID-TA10154","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Betrixaban for preventing venous thromboembolism in people hospitalised for acute medical conditions  [ID913]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-12-17T11:45:01.9337085","FirstGoLiveDate":"2017-02-01T01:01:50.6234812","CreatedDate":"2017-01-25T12:07:59.8741853","DevelopedAs":null,"RelevantTo":null,"IdNumber":"913","EvidenceAssessmentGroup":"BMJ Evidence Centre, BMJ Group","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10047"}]},"ETag":"01000000-0000-001F-0000-000000026EB2","Reference":"GID-TA10047","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Leukaemia (acute lymphoblastic) - erythrocyte encapsulated asparaginase [ID864]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-06T09:30:38.7906088","FirstGoLiveDate":"2016-04-11T00:01:35.3735072","CreatedDate":"2016-04-01T15:51:35.6922933","DevelopedAs":null,"RelevantTo":null,"IdNumber":"864","EvidenceAssessmentGroup":"Centre for Reviews and Dissemination and Centre for Health Economics, University of York","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-HST10040"}]},"ETag":"01000000-0000-001F-0000-000000026EB4","Reference":"GID-HST10040","ProjectType":"HST","ProductTypeName":"Highly specialised technology","Process":"HST","Title":"Maralixibat for treating type 2 progressive familial intrahepatic cholestasis ID3818","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-02-01T12:43:51.408991","FirstGoLiveDate":"2021-01-08T12:59:53.7802566","CreatedDate":"2021-01-08T12:52:15.9379367","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3818","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10438"}]},"ETag":"01000000-0000-001F-0000-000000026EC4","Reference":"GID-TA10438","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Semaglutide for treating type 2 diabetes (ID1450)","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-06-25T18:03:43.1889505","FirstGoLiveDate":"2018-11-29T06:00:22.9292053","CreatedDate":"2018-11-22T10:49:56.112714","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1450","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10477"}]},"ETag":"01000000-0000-001F-0000-000000026EC7","Reference":"GID-TA10477","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma [ID1444]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-09-22T00:00:00","LastModifiedDate":"2021-04-12T13:05:15.0752196","FirstGoLiveDate":"2019-05-02T00:01:11.2167975","CreatedDate":"2019-04-25T15:36:42.8610597","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1444","EvidenceAssessmentGroup":"UW","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10226"}]},"ETag":"01000000-0000-001F-0000-000000026ED3","Reference":"GID-TA10226","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"NBTXR-3 for treating soft tissue sarcoma [ID1050]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-06-25T12:31:42.09866","FirstGoLiveDate":"2017-08-11T11:56:32.4033449","CreatedDate":"2017-08-11T11:55:20.6610103","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1050","EvidenceAssessmentGroup":"Aberdeen HTA Group","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG509"}]},"ETag":"01000000-0000-001F-0000-000000026EE2","Reference":"GID-TAG509","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Melanoma (metastatic) - talimogene laherparepvec [ID508]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2016-09-28T00:00:00","LastModifiedDate":"2016-09-07T10:22:24.0444521","FirstGoLiveDate":"2016-03-16T00:03:35.2345938","CreatedDate":"2015-09-15T00:01:21","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":"Liverpool Reviews and Implementation Group (LRIG)","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG414"}]},"ETag":"01000000-0000-001F-0000-000000026F00","Reference":"GID-TAG414","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Hepatitis B (adults) - entecavir and tenofovir disoproxil fumarate [ID111]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT526"}]},"ETag":"01000000-0000-001F-0000-000000026F05","Reference":"GID-MT526","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"SpaceOAR hydrogel spacer for reducing rectal toxicity during radiotherapy for prostate cancer (Suspended – referred to technology appraisals)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-10-31T10:08:41.914996","FirstGoLiveDate":"2019-04-02T11:51:55.6713854","CreatedDate":"2019-04-02T11:00:27.7380603","DevelopedAs":null,"RelevantTo":null,"IdNumber":"451","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10706"}]},"ETag":"01000000-0000-001F-0000-000000026F0C","Reference":"GID-TA10706","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Tofacitinib for treating juvenile idiopathic arthritis [ID2718]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-10-20T00:00:00","LastModifiedDate":"2021-03-29T11:53:17.6346736","FirstGoLiveDate":"2020-07-31T15:08:18.480753","CreatedDate":"2020-07-31T13:06:55.0789446","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2718","EvidenceAssessmentGroup":"UY","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10733"}]},"ETag":"01000000-0000-001F-0000-000000026F10","Reference":"GID-TA10733","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Burosumab for treating X-linked hypophosphataemia in adults [ID3822]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-07T12:45:54.9651201","FirstGoLiveDate":"2020-09-18T08:38:44.3468605","CreatedDate":"2020-09-18T08:36:39.522288","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3822","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IP2803"}]},"ETag":"01000000-0000-001F-0000-000000026F15","Reference":"GID-IP2803","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Percutaneous electrothermal treatment of the intervertebral disc annulus for low back pain and sciatica ","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2015-08-21T16:53:21","FirstGoLiveDate":null,"CreatedDate":"2015-08-21T16:53:21","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10261"}]},"ETag":"01000000-0000-001F-0000-000000026F26","Reference":"GID-TA10261","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Ribociclib in combination with endocrine therapy and goserelin for previously untreated hormone receptor-positive, HER2-negative advanced breast cancer in premenopausal women  (ID1307)","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-18T10:17:53.9230391","FirstGoLiveDate":"2017-10-26T06:00:22.1039625","CreatedDate":"2017-10-19T12:38:06.1025501","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1307","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10332"}]},"ETag":"01000000-0000-001F-0000-000000026F37","Reference":"GID-TA10332","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Rituximab for maintenance treatment of anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1320]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-10-09T06:00:19.7687733","FirstGoLiveDate":"2018-03-27T06:01:36.9250222","CreatedDate":"2018-03-20T11:07:10.881476","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1320","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10669"}]},"ETag":"01000000-0000-001F-0000-000000026F38","Reference":"GID-TA10669","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pembrolizumab with chemotherapy for treating recurrent, persistent or metastatic cervical cancer [ID3798]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-05-04T00:00:00","LastModifiedDate":"2021-02-01T00:01:51.5253525","FirstGoLiveDate":"2020-05-28T11:16:00.6394005","CreatedDate":"2020-05-28T11:15:37.3755069","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3798","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG439"}]},"ETag":"01000000-0000-001F-0000-000000026F3C","Reference":"GID-TAG439","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Obesity - phentermine (with topiramate) [ID543]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10720"}]},"ETag":"01000000-0000-001F-0000-000000026F50","Reference":"GID-TA10720","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Remimazolam for sedation for people having diagnostic or therapeutic procedures [ID3758]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-22T15:05:49.8082662","FirstGoLiveDate":"2020-08-18T15:11:40.9155915","CreatedDate":"2020-08-18T15:07:57.8743566","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3758","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG373"}]},"ETag":"01000000-0000-001F-0000-000000026FB1","Reference":"GID-TAG373","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Systemic lupus erythematosus - prasterone [ID392]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10667"}]},"ETag":"01000000-0000-001F-0000-000000026FF7","Reference":"GID-TA10667","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Autologous chondrocyte implantation using 3D collagen matrix (novocart 3D) for treating articular cartilage defects of the knee [ID2707]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-02-08T00:02:04.1099036","FirstGoLiveDate":"2020-05-13T11:00:43.1687617","CreatedDate":"2020-05-13T11:00:21.3050548","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2707","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10239"}]},"ETag":"01000000-0000-001F-0000-000000026FFA","Reference":"GID-TA10239","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Mepolizumab for treating chronic obstructive pulmonary disease  (ID1237)","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-12-13T11:44:26.6231302","FirstGoLiveDate":"2017-09-27T06:00:13.5929961","CreatedDate":"2017-09-20T12:01:45.9793412","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1237","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10306"}]},"ETag":"01000000-0000-001F-0000-000000026FFD","Reference":"GID-TA10306","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Autologous haematopoietic stem cell transplantation for treating multiple sclerosis (ID1111)","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-10-08T09:32:21.1925806","FirstGoLiveDate":"2018-03-12T14:49:12.737181","CreatedDate":"2018-03-12T14:40:51.0186828","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1111","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10654"}]},"ETag":"01000000-0000-001F-0000-000000026FFE","Reference":"GID-TA10654","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Oleogel-S10 for treating skin wounds associated with epidermolysis bullosa  [ID1505]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-07-13T15:21:15.7557616","FirstGoLiveDate":"2020-05-13T09:42:55.6103241","CreatedDate":"2020-05-13T09:42:15.798026","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1505","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10763"}]},"ETag":"01000000-0000-001F-0000-000000026FFF","Reference":"GID-TA10763","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Epicutaneous immunotherapy for treating peanut allergy in children [ID1255]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-11-30T12:04:45.038766","FirstGoLiveDate":"2020-11-24T16:04:39.4923102","CreatedDate":"2020-11-24T15:59:17.0727873","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1255","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10345"}]},"ETag":"01000000-0000-001F-0000-000000027001","Reference":"GID-TA10345","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pegvaliase for treating phenylketonuria [ID1110]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-11-29T13:50:12.1847016","FirstGoLiveDate":"2018-05-17T06:00:26.5859018","CreatedDate":"2018-05-09T20:34:49.3645363","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1110","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10755"}]},"ETag":"01000000-0000-001F-0000-000000027002","Reference":"GID-TA10755","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA Review","Title":"Mepolizumab for treating hypereosinophilic syndrome [ID3749]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-12T12:38:19.2875604","FirstGoLiveDate":"2020-10-12T12:38:19.2875604","CreatedDate":"2020-10-12T12:32:44.303603","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3749","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-HST10019"}]},"ETag":"01000000-0000-001F-0000-000000027004","Reference":"GID-HST10019","ProjectType":"HST","ProductTypeName":"Highly specialised technology","Process":"HST","Title":"Intrathecal idursulfase for treating Mucopolysaccharidosis type II ID1223","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-05-17T06:00:26.6408971","FirstGoLiveDate":"2018-05-17T06:00:26.6408971","CreatedDate":"2018-05-14T15:48:52.0354572","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1223","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10279"}]},"ETag":"01000000-0000-001F-0000-000000027005","Reference":"GID-TA10279","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"STG320 for treating persistent allergic rhinitis caused by house dust mites (ID1278)","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-12-20T07:01:11.0069763","FirstGoLiveDate":"2017-11-30T06:01:00.9554338","CreatedDate":"2017-11-23T13:10:40.4433092","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1278","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10764"}]},"ETag":"01000000-0000-001F-0000-000000027006","Reference":"GID-TA10764","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":"2022-01-26T00:00:00","LastModifiedDate":"2021-03-15T17:22:35.4655194","FirstGoLiveDate":"2020-11-25T12:58:39.5647523","CreatedDate":"2020-11-25T12:55:40.5460807","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3768","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10439"}]},"ETag":"01000000-0000-001F-0000-000000027007","Reference":"GID-TA10439","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Dulaglutide for treating type 2 diabetes [ID1451]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-12-12T15:13:14.0161185","FirstGoLiveDate":"2018-11-29T06:00:23.1871747","CreatedDate":"2018-11-22T12:09:50.2831851","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1451","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10655"}]},"ETag":"01000000-0000-001F-0000-000000027008","Reference":"GID-TA10655","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Evinacumab for treating homozygous familial hypercholesterolaemia in people aged 12 and over [ID2704]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-12-21T00:02:10.2407541","FirstGoLiveDate":"2020-05-13T09:45:42.9835074","CreatedDate":"2020-05-13T09:43:35.6413934","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2704","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10297"}]},"ETag":"01000000-0000-001F-0000-000000027009","Reference":"GID-TA10297","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Lusutrombopag for treating thrombocytopenia in people with chronic liver disease needing elective surgery [ID1149]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-11-29T10:53:12.2818904","FirstGoLiveDate":"2018-02-02T06:00:06.0440821","CreatedDate":"2018-02-01T14:20:21.067794","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1149","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10336"}]},"ETag":"01000000-0000-001F-0000-00000002700A","Reference":"GID-TA10336","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Fingolimod for treating relapsing multiple sclerosis in children and young people [ID1378]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-09-24T10:30:02.2677408","FirstGoLiveDate":"2018-03-29T06:00:57.0374576","CreatedDate":"2018-03-23T09:40:36.5710079","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1378","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-HST10022"}]},"ETag":"01000000-0000-001F-0000-00000002700B","Reference":"GID-HST10022","ProjectType":"HST","ProductTypeName":"Highly specialised technology","Process":"HST","Title":"OTL-101 for treating adenosine deaminase deficiency–severe combined immunodeficiency [ID1152]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-08-22T10:31:32.1821469","FirstGoLiveDate":"2018-08-22T10:31:32.1821469","CreatedDate":"2018-08-22T10:25:22.1260163","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1152","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10819"}]},"ETag":"01000000-0000-001F-0000-00000002700D","Reference":"GID-TA10819","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Risankizumab for previously treated active psoriatic arthritis [ID1399]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-02T13:07:01.2178476","FirstGoLiveDate":"2021-03-02T13:07:01.2178476","CreatedDate":"2021-03-02T13:03:51.0111348","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1399","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10519"}]},"ETag":"01000000-0000-001F-0000-00000002700E","Reference":"GID-TA10519","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Perampanel for adjunctive treatment of partial onset or generalised tonic-clonic seizures in children aged below 12 years with epilepsy ID1587","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-02-11T15:18:15.0896123","FirstGoLiveDate":"2019-07-26T06:00:54.0020187","CreatedDate":"2019-07-19T14:22:08.2789517","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1587","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10741"}]},"ETag":"01000000-0000-001F-0000-000000027013","Reference":"GID-TA10741","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Netarsudil-latanoprost for previously treated open-angle glaucoma or ocular hypertension [ID1363]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-09-28T13:54:05.7598477","FirstGoLiveDate":"2020-09-28T13:54:05.7598477","CreatedDate":"2020-09-28T13:48:40.5259664","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1363","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10536"}]},"ETag":"01000000-0000-001F-0000-000000027014","Reference":"GID-TA10536","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Eflornithine with sulindac for treating familial adenomatous polyposis [ID1543]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-08-20T16:22:43.8347397","FirstGoLiveDate":"2019-09-26T06:01:20.5792378","CreatedDate":"2019-09-19T16:20:24.6987458","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1543","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-HST10038"}]},"ETag":"01000000-0000-001F-0000-000000027015","Reference":"GID-HST10038","ProjectType":"HST","ProductTypeName":"Highly specialised technology","Process":"HST","Title":"Lenti-D for treating cerebral adrenoleukodystrophy [ID1284]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-11-30T12:02:27.1643544","FirstGoLiveDate":"2020-11-24T15:31:37.9636888","CreatedDate":"2020-11-24T15:27:32.9003559","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1284","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10346"}]},"ETag":"01000000-0000-001F-0000-000000027016","Reference":"GID-TA10346","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Tocilizumab for treating systemic sclerosis (ID1396)","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-06-28T09:47:45.6562182","FirstGoLiveDate":"2018-05-22T06:00:40.8801129","CreatedDate":"2018-05-15T15:59:46.2241271","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1396","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10393"}]},"ETag":"01000000-0000-001F-0000-000000027017","Reference":"GID-TA10393","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Rivaroxaban for treating chronic heart failure [ID1462]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-12-13T13:50:26.6216255","FirstGoLiveDate":"2018-10-04T06:00:13.8328157","CreatedDate":"2018-09-27T16:55:34.0079642","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1462","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10605"}]},"ETag":"01000000-0000-001F-0000-000000027018","Reference":"GID-TA10605","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Fostemsavir for treating adults with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2726]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-22T15:07:27.0736471","FirstGoLiveDate":"2020-01-15T09:01:48.4862728","CreatedDate":"2020-01-15T09:01:17.2273725","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2726","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10453"}]},"ETag":"01000000-0000-001F-0000-00000002701A","Reference":"GID-TA10453","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Treosulfan with fludarabine for non-malignant disease before allogeneic stem cell transplant [ID1540]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-12-09T15:52:08.5223035","FirstGoLiveDate":"2019-01-31T06:00:27.3321436","CreatedDate":"2019-01-24T11:53:14.8833182","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1540","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10657"}]},"ETag":"01000000-0000-001F-0000-00000002701D","Reference":"GID-TA10657","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Ibalizumab for treating adults infected with multidrug resistant HIV-1 for whom it is not possible to construct a suppressive anti-viral regimen [ID2720]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-01T11:31:38.004526","FirstGoLiveDate":"2020-05-13T10:36:43.0103156","CreatedDate":"2020-05-13T10:35:37.2917122","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2720","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10338"}]},"ETag":"01000000-0000-001F-0000-00000002701E","Reference":"GID-TA10338","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Atezolizumab plus bevacizumab for untreated locally advanced or metastatic renal cell carcinoma [ID1365]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-11-23T10:06:21.8728474","FirstGoLiveDate":"2018-04-10T06:00:08.7015585","CreatedDate":"2018-04-03T16:15:24.5703305","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1365","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG363"}]},"ETag":"01000000-0000-001F-0000-00000002701F","Reference":"GID-TAG363","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Pancreatic cancer (metastatic) - nimotuzumab (1st line) [ID513]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-09-25T13:22:38","FirstGoLiveDate":null,"CreatedDate":"2014-09-25T13:22:38","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG482"}]},"ETag":"01000000-0000-001F-0000-000000027020","Reference":"GID-TAG482","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Leukaemia (chronic lymphocytic, relapsed) - ofatumumab (maintenance) [ID732] ","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-02-10T01:01:52.9598647","FirstGoLiveDate":"2015-11-02T00:02:35.243806","CreatedDate":"2015-04-08T17:00:11","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10413"}]},"ETag":"01000000-0000-001F-0000-000000027021","Reference":"GID-TA10413","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pembrolizumab with etoposide and a platinum-based compound for untreated extensive-stage small-cell lung cancer ID1509","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-07-15T00:01:59.2256253","FirstGoLiveDate":"2018-11-07T10:55:50.3044797","CreatedDate":"2018-11-07T10:54:22.6878089","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1509","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG526"}]},"ETag":"01000000-0000-001F-0000-000000027023","Reference":"GID-TAG526","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":" Axitinib, everolimus, sorafenib and sunitinib for treated advanced or metastatic renal cell carcinoma [ID897] ","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-04-05T15:37:24.1486822","FirstGoLiveDate":"2016-01-19T00:01:03.3477116","CreatedDate":"2015-10-06T16:50:41","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":"BMJ","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10267"}]},"ETag":"01000000-0000-001F-0000-000000027024","Reference":"GID-TA10267","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Enzalutamide for the treatment of hormone refractory prostate cancer  TA316","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-01-19T11:29:58.1616659","FirstGoLiveDate":"2017-11-15T09:01:13.3057102","CreatedDate":"2017-11-13T09:06:40.312872","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10072"}]},"ETag":"01000000-0000-001F-0000-000000027025","Reference":"GID-TA10072","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Non-bisphosphonates for treating osteoporosis [ID901]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-22T18:52:53.6249742","FirstGoLiveDate":"2016-06-17T11:10:53.5392215","CreatedDate":"2016-06-17T11:01:47.2829981","DevelopedAs":null,"RelevantTo":null,"IdNumber":"901","EvidenceAssessmentGroup":"School of Health and Related Research, University of Sheffield","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-HST10004"}]},"ETag":"01000000-0000-001F-0000-000000027026","Reference":"GID-HST10004","ProjectType":"HST","ProductTypeName":"Highly specialised technology","Process":"HST","Title":"Drisapersen for the first-line treatment of Duchenne’s muscular dystrophy [ID911]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-06-30T11:14:02.386787","FirstGoLiveDate":"2016-06-30T11:14:02.386787","CreatedDate":"2016-06-28T12:06:26.4260256","DevelopedAs":null,"RelevantTo":null,"IdNumber":"911","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG494"}]},"ETag":"01000000-0000-001F-0000-00000002702A","Reference":"GID-TAG494","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Pancreatic cancer (metastatic, untreated) - liposomal cisplatin (with gemcitabine) [ID658]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2015-04-09T11:07:59","FirstGoLiveDate":null,"CreatedDate":"2015-04-09T11:07:59","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10452"}]},"ETag":"01000000-0000-001F-0000-00000002702B","Reference":"GID-TA10452","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"L-glutamine for preventing painful crises in sickle cell disease in people aged 5 years and over [ID1523]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-06-26T00:01:59.4658714","FirstGoLiveDate":"2019-01-30T06:00:15.2414245","CreatedDate":"2019-01-23T16:58:10.257906","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1523","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10395"}]},"ETag":"01000000-0000-001F-0000-00000002702C","Reference":"GID-TA10395","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer ID1495","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-01-29T00:01:36.2794085","FirstGoLiveDate":"2018-10-09T06:00:19.6927967","CreatedDate":"2018-10-02T15:26:10.8474951","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1495","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10196"}]},"ETag":"01000000-0000-001F-0000-000000027031","Reference":"GID-TA10196","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Lifitegrast for treating dry eye disease [ID1229]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-07-16T00:02:01.8764708","FirstGoLiveDate":"2017-07-24T06:00:54.4079315","CreatedDate":"2017-07-20T10:42:58.3290815","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1229","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10697"}]},"ETag":"01000000-0000-001F-0000-000000027033","Reference":"GID-TA10697","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pembrolizumab with lenvatinib for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3809]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-19T00:01:51.5861691","FirstGoLiveDate":"2021-02-09T10:47:06.6023096","CreatedDate":"2020-07-08T12:39:26.1471634","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3809","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10099"}]},"ETag":"01000000-0000-001F-0000-000000027034","Reference":"GID-TA10099","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Biotin for treating primary and secondary progressive multiple sclerosis [ID919]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-02-16T18:57:17.9530365","FirstGoLiveDate":"2016-09-08T00:01:24.0530402","CreatedDate":"2016-09-01T10:31:23.2145802","DevelopedAs":null,"RelevantTo":null,"IdNumber":"919","EvidenceAssessmentGroup":"Warwick Evidence, Warwick Medical School, University of Warwick","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10563"}]},"ETag":"01000000-0000-001F-0000-000000027035","Reference":"GID-TA10563","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Liraglutide for managing obesity in people aged 12 to 17 [ID1630]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-05-12T11:15:42.3955278","FirstGoLiveDate":"2019-11-28T06:00:25.9351686","CreatedDate":"2019-11-20T13:59:16.1464963","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1630","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10766"}]},"ETag":"01000000-0000-001F-0000-000000027036","Reference":"GID-TA10766","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pembrolizumab with pemetrexed and platinum-based chemotherapy for previously TKI-treated EGFR-positive metastatic non-squamous non-small-cell lung cancer [ID3873]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-05T12:16:09.8671807","FirstGoLiveDate":"2020-12-04T15:40:50.8211372","CreatedDate":"2020-12-04T15:38:37.3995036","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3873","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10489"}]},"ETag":"01000000-0000-001F-0000-000000027038","Reference":"GID-TA10489","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"ERC1671 for treating progressed or recurrent grade IV glioma (glioblastoma or gliosarcoma) [ID1623]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-05-06T13:33:33.2536056","FirstGoLiveDate":"2019-05-08T11:27:59.2584127","CreatedDate":"2019-05-08T11:23:54.7391319","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1623","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10264"}]},"ETag":"01000000-0000-001F-0000-000000027039","Reference":"GID-TA10264","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Abemaciclib monotherapy for treating advanced hormone-receptor positive, HER2-negative breast cancer after endocrine therapy and chemotherapy ID1347","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-09-28T10:56:06.332593","FirstGoLiveDate":"2017-10-26T06:00:24.1989011","CreatedDate":"2017-10-23T13:39:38.9744796","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1347","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10467"}]},"ETag":"01000000-0000-001F-0000-00000002703A","Reference":"GID-TA10467","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Rivogenlecleucel for treating haematological cancers in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1601]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-02-12T11:53:23.9474662","FirstGoLiveDate":"2019-03-27T06:00:41.2307492","CreatedDate":"2019-03-20T14:45:26.4187269","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1601","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10405"}]},"ETag":"01000000-0000-001F-0000-00000002703C","Reference":"GID-TA10405","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Rivogenlecleucel for treating haematological non-malignant diseases in children and young people undergoing haploidentical haematopoietic stem cell transplant [ID1496]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-02-05T00:01:55.6781515","FirstGoLiveDate":"2018-10-22T14:36:19.6433881","CreatedDate":"2018-10-22T14:34:37.1802912","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1496","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10543"}]},"ETag":"01000000-0000-001F-0000-00000002703D","Reference":"GID-TA10543","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Atezolizumab with cobimetinib and vemurafenib for treating unresectable or metastatic BRAF V600 mutation-positive melanoma [ID1674]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-02-03T00:01:43.8145297","FirstGoLiveDate":"2019-10-09T06:01:52.3162353","CreatedDate":"2019-10-02T12:10:08.3733633","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1674","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG300"}]},"ETag":"01000000-0000-001F-0000-00000002703E","Reference":"GID-TAG300","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Bone metastases (hormone refractory prostate cancer) - denosumab [ID405]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10310"}]},"ETag":"01000000-0000-001F-0000-00000002703F","Reference":"GID-TA10310","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Idebenone for treating Duchenne muscular dystrophy ID1092","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-27T00:07:06.4819799","FirstGoLiveDate":"2018-03-14T09:52:14.8443638","CreatedDate":"2018-03-14T09:48:56.3368573","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1092","EvidenceAssessmentGroup":"KSR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10212"}]},"ETag":"01000000-0000-001F-0000-000000027041","Reference":"GID-TA10212","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Rovalpituzumab tesirine for treating small-cell lung cancer after 2 therapies ID1288","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-03-18T06:00:38.8177485","FirstGoLiveDate":"2017-08-03T09:14:55.0193146","CreatedDate":"2017-08-03T09:14:06.3983486","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1288","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10390"}]},"ETag":"01000000-0000-001F-0000-000000027042","Reference":"GID-TA10390","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-10-07T13:35:21.2831809","FirstGoLiveDate":"2018-10-02T06:00:19.3099342","CreatedDate":"2018-09-25T16:00:12.0965322","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1486","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG493"}]},"ETag":"01000000-0000-001F-0000-000000027043","Reference":"GID-TAG493","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Atherothrombotic events - vorapaxar [ID616] ","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2015-01-07T12:22:46","FirstGoLiveDate":null,"CreatedDate":"2015-01-07T12:22:46","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG422"}]},"ETag":"01000000-0000-001F-0000-000000027047","Reference":"GID-TAG422","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Lung cancer (non-small cell) - afatinib [ID357]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10244"}]},"ETag":"01000000-0000-001F-0000-000000027048","Reference":"GID-TA10244","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pembrolizumab for gastric or gastroesophageal junction adenocarcinoma ID1305","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-12-24T00:02:17.9351049","FirstGoLiveDate":"2017-09-28T09:42:13.491621","CreatedDate":"2017-09-28T09:39:48.2645258","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1305","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10672"}]},"ETag":"01000000-0000-001F-0000-000000027049","Reference":"GID-TA10672","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Idecabtagene vicleucel for treating relapsed and refractory multiple myeloma in people who have received at least 3 prior therapies  [ID1442]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-07T00:02:30.2969234","FirstGoLiveDate":"2020-07-17T10:50:03.1053786","CreatedDate":"2020-06-08T10:23:28.6402252","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1442","EvidenceAssessmentGroup":"BMJ","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10511"}]},"ETag":"01000000-0000-001F-0000-00000002704A","Reference":"GID-TA10511","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Abicipar pegol for treating wet age-related macular degeneration ID1533","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-08-04T00:01:00.3913726","FirstGoLiveDate":"2019-06-05T06:01:41.9169008","CreatedDate":"2019-05-29T18:02:06.0077273","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1533","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG496"}]},"ETag":"01000000-0000-001F-0000-00000002704C","Reference":"GID-TAG496","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Lung cancer (non-small cell, advanced, inoperable) - liposomal cisplatin (with chemotherapy) [ID657] ","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2015-01-27T14:29:59","FirstGoLiveDate":null,"CreatedDate":"2015-01-27T14:29:59","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10158"}]},"ETag":"01000000-0000-001F-0000-00000002704D","Reference":"GID-TA10158","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-09-23T09:01:19.994332","FirstGoLiveDate":"2017-02-17T01:01:18.8948446","CreatedDate":"2017-02-13T10:45:11.5483377","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1126","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10380"}]},"ETag":"01000000-0000-001F-0000-00000002704E","Reference":"GID-TA10380","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-04-17T09:12:19.2901386","FirstGoLiveDate":"2018-08-22T06:01:31.3793712","CreatedDate":"2018-08-15T16:41:31.1387978","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1458","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG395"}]},"ETag":"01000000-0000-001F-0000-00000002704F","Reference":"GID-TAG395","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Lung cancer (non-small-cell) - cetuximab [ID9]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10318"}]},"ETag":"01000000-0000-001F-0000-000000027050","Reference":"GID-TA10318","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Durvalumab for untreated EGFR-negative, ALK-negative non-small-cell lung cancer ID1331","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-10-24T09:02:26.6904665","FirstGoLiveDate":"2018-03-14T10:13:15.1947227","CreatedDate":"2018-03-14T10:13:02.7966576","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1331","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10109"}]},"ETag":"01000000-0000-001F-0000-000000027051","Reference":"GID-TA10109","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Idelalisib with bendamustine and rituximab for previously treated chronic lymphocytic leukaemia [ID839]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-05-10T14:48:07.6602285","FirstGoLiveDate":"2016-09-20T23:02:50.5821518","CreatedDate":"2016-09-14T11:31:44.0420813","DevelopedAs":null,"RelevantTo":null,"IdNumber":"839","EvidenceAssessmentGroup":"BMJ Evidence Centre, BMJ Group","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10159"}]},"ETag":"01000000-0000-001F-0000-000000027052","Reference":"GID-TA10159","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Pertuzumab for untreated metastatic HER2-positive gastric or gastro-oesophageal junction cancer [ID1096]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-10-08T08:50:18.8894464","FirstGoLiveDate":"2017-02-20T01:01:46.8647905","CreatedDate":"2017-02-13T11:11:56.9813296","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1096","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10740"}]},"ETag":"01000000-0000-001F-0000-000000027053","Reference":"GID-TA10740","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis [ID1581]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-07-13T00:00:00","LastModifiedDate":"2021-02-26T00:01:39.1436504","FirstGoLiveDate":"2020-09-23T14:44:56.6049663","CreatedDate":"2020-09-23T14:38:53.9361765","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1581","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10110"}]},"ETag":"01000000-0000-001F-0000-000000027054","Reference":"GID-TA10110","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Pembrolizumab for previously treated metastatic colorectal cancer that has high microsatellite instability or mismatch repair deficiency [ID1071]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-12-20T13:41:21.4700412","FirstGoLiveDate":"2016-09-21T23:01:36.2480308","CreatedDate":"2016-09-15T12:48:13.8832878","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1071","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10324"}]},"ETag":"01000000-0000-001F-0000-000000027056","Reference":"GID-TA10324","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-07-07T00:01:48.8092359","FirstGoLiveDate":"2018-03-14T10:28:14.8696767","CreatedDate":"2018-03-14T10:26:11.212014","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1169","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10199"}]},"ETag":"01000000-0000-001F-0000-000000027058","Reference":"GID-TA10199","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Avacopan for treating anti-neutrophil cytoplasmic antibody-associated vasculitis ID1178","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-03-16T00:01:48.3202114","FirstGoLiveDate":"2017-07-25T06:01:01.4632895","CreatedDate":"2017-07-20T12:07:12.4878677","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1178","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10295"}]},"ETag":"01000000-0000-001F-0000-000000027059","Reference":"GID-TA10295","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-07-15T00:02:16.9599635","FirstGoLiveDate":"2018-02-07T06:00:28.132177","CreatedDate":"2018-01-31T12:13:04.6542057","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1246","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10645"}]},"ETag":"01000000-0000-001F-0000-00000002705A","Reference":"GID-TA10645","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma [ID3795]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-08-10T00:00:00","LastModifiedDate":"2021-01-12T00:01:04.3276916","FirstGoLiveDate":"2020-05-04T11:03:30.8289433","CreatedDate":"2020-05-04T11:00:26.5863887","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3795","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-HST10007"}]},"ETag":"01000000-0000-001F-0000-00000002705C","Reference":"GID-HST10007","ProjectType":"HST","ProductTypeName":"Highly specialised technology","Process":"HST","Title":"Eteplirsen for treating Duchenne muscular dystrophy [ID1003] ","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-04T11:32:35.8563276","FirstGoLiveDate":"2017-04-10T15:05:51.5827958","CreatedDate":"2017-04-10T15:02:19.1408387","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1003","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10504"}]},"ETag":"01000000-0000-001F-0000-00000002705D","Reference":"GID-TA10504","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after initial platinum-based chemotherapy [ID1518]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-09-16T00:01:03.8406045","FirstGoLiveDate":"2019-05-28T06:00:13.5646529","CreatedDate":"2019-05-21T13:49:17.1133856","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1518","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10193"}]},"ETag":"01000000-0000-001F-0000-00000002705E","Reference":"GID-TA10193","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Pembrolizumab for previously treated multiple myeloma (ID1139)","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-08-03T09:01:48.5205708","FirstGoLiveDate":"2017-07-19T11:32:50.7801354","CreatedDate":"2017-07-18T09:50:40.9619844","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1139","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10482"}]},"ETag":"01000000-0000-001F-0000-00000002705F","Reference":"GID-TA10482","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Tagraxofusp for treating blastic plasmacytoid dendritic cell neoplasm [ID1556]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-10T10:01:22.075335","FirstGoLiveDate":"2019-05-01T15:15:46.6687746","CreatedDate":"2019-05-01T15:06:06.2099492","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1556","EvidenceAssessmentGroup":"KSR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10045"}]},"ETag":"01000000-0000-001F-0000-000000027061","Reference":"GID-TA10045","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Lung cancer (non-small-cell, EGFR T790M-positive, metastatic, treated) - rociletinib  [ID883]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-05-13T11:47:50.0747703","FirstGoLiveDate":"2016-03-28T00:01:03.5623578","CreatedDate":"2016-03-22T14:37:41.6403104","DevelopedAs":null,"RelevantTo":null,"IdNumber":"883","EvidenceAssessmentGroup":"Liverpool Reviews and Implementation Group, University of Liverpool","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10609"}]},"ETag":"01000000-0000-001F-0000-000000027062","Reference":"GID-TA10609","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-09T00:03:31.5682171","FirstGoLiveDate":"2020-01-28T06:01:34.3045571","CreatedDate":"2020-01-21T15:25:08.2858505","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1682","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10712"}]},"ETag":"01000000-0000-001F-0000-000000027063","Reference":"GID-TA10712","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"CDF Review","Title":"Olaparib for maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy (CDF review of TA620) [ID3788]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-31T10:19:58.798729","FirstGoLiveDate":"2020-08-10T00:01:13.8001814","CreatedDate":"2020-08-03T15:34:10.8756464","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3788","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10322"}]},"ETag":"01000000-0000-001F-0000-000000027064","Reference":"GID-TA10322","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pembrolizumab for previously treated oesophageal or gastro-oesophageal junction cancer ID1357","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-12-29T11:39:32.569711","FirstGoLiveDate":"2018-03-14T10:25:14.8540656","CreatedDate":"2018-03-14T10:22:57.094669","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1357","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10522"}]},"ETag":"01000000-0000-001F-0000-000000027065","Reference":"GID-TA10522","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-04-10T00:01:38.4381393","FirstGoLiveDate":"2019-07-25T06:00:58.0901951","CreatedDate":"2019-07-23T10:18:50.575413","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1529","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10366"}]},"ETag":"01000000-0000-001F-0000-000000027066","Reference":"GID-TA10366","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Talazoparib for treating BRCA 1 or 2 mutated advanced breast cancer after prior chemotherapy (ID1342)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-12-16T00:01:22.2691009","FirstGoLiveDate":"2018-07-12T06:00:04.1526383","CreatedDate":"2018-07-05T10:46:10.1568748","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1342","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10171"}]},"ETag":"01000000-0000-001F-0000-000000027068","Reference":"GID-TA10171","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Plitidepsin in combination with dexamethasone for treating relapsed or refractory multiple myeloma [ID1081]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-04-20T11:50:19.5330965","FirstGoLiveDate":"2017-06-09T17:08:40.3822444","CreatedDate":"2017-06-09T15:39:15.3890322","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1081","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10186"}]},"ETag":"01000000-0000-001F-0000-000000027069","Reference":"GID-TA10186","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Durvalumab with tremelimumab for untreated non-small-cell lung cancer with no EGFR- or ALK-positive mutations [ID1143]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-01-03T12:28:06.9403629","FirstGoLiveDate":"2017-06-26T09:22:23.9019577","CreatedDate":"2017-06-26T09:17:44.0128942","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1143","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10556"}]},"ETag":"01000000-0000-001F-0000-00000002706B","Reference":"GID-TA10556","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Ponesimod for treating relapsing multiple sclerosis [ID1393]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-11-17T00:00:00","LastModifiedDate":"2021-03-31T10:13:58.8079062","FirstGoLiveDate":"2019-11-26T06:00:22.7184826","CreatedDate":"2019-11-19T11:45:47.4500203","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1393","EvidenceAssessmentGroup":"PenTAG","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10315"}]},"ETag":"01000000-0000-001F-0000-00000002706C","Reference":"GID-TA10315","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer ID1335","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-07-07T00:01:48.8248624","FirstGoLiveDate":"2018-03-14T10:07:14.9044139","CreatedDate":"2018-03-14T10:05:22.7152157","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1335","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10254"}]},"ETag":"01000000-0000-001F-0000-00000002706D","Reference":"GID-TA10254","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Ixazomib with lenalidomide and dexamethasone for untreated multiple myeloma [ID1170]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-06-19T00:01:26.2516813","FirstGoLiveDate":"2018-05-02T06:02:31.8608185","CreatedDate":"2017-09-28T10:21:56.8057049","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1170","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG380"}]},"ETag":"01000000-0000-001F-0000-00000002706E","Reference":"GID-TAG380","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Colon cancer (adjuvant) - irinotecan [ID379]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2015-07-31T10:59:50","FirstGoLiveDate":null,"CreatedDate":"2015-07-31T10:59:50","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10065"}]},"ETag":"01000000-0000-001F-0000-000000027071","Reference":"GID-TA10065","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Colorectal cancer (metastatic) - MABp1 (after previous treatment) [ID917] ","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-03-27T17:19:51.9660819","FirstGoLiveDate":"2016-05-20T13:21:06.9309142","CreatedDate":"2016-05-20T12:27:18.4349791","DevelopedAs":null,"RelevantTo":null,"IdNumber":"917","EvidenceAssessmentGroup":"Kleijnen Systematic Reviews Ltd","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG379"}]},"ETag":"01000000-0000-001F-0000-000000027072","Reference":"GID-TAG379","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Prostate cancer (hormone refractory) - atrasentan [ID390]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10221"}]},"ETag":"01000000-0000-001F-0000-000000027073","Reference":"GID-TA10221","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-02-12T00:02:12.963947","FirstGoLiveDate":"2017-08-11T11:17:32.3638961","CreatedDate":"2017-08-11T11:16:02.8625774","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1248","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10544"}]},"ETag":"01000000-0000-001F-0000-000000027074","Reference":"GID-TA10544","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Satralizumab for preventing relapses in neuromyelitis optica spectrum disorders [ID1319]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-24T13:31:54.736818","FirstGoLiveDate":"2019-10-10T06:01:54.52138","CreatedDate":"2019-10-03T11:08:35.4231452","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1319","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG409"}]},"ETag":"01000000-0000-001F-0000-000000027075","Reference":"GID-TAG409","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Prostate cancer (prevention) - dutasteride [ID75]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG425"}]},"ETag":"01000000-0000-001F-0000-000000027077","Reference":"GID-TAG425","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Lymphoma (follicular non Hodgkin's - advanced) - bortezomib [ID407]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10404"}]},"ETag":"01000000-0000-001F-0000-000000027078","Reference":"GID-TA10404","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Avelumab for previously treated platinum-resistant ovarian cancer ID1497","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-01-04T10:51:28.131528","FirstGoLiveDate":"2018-10-22T14:30:32.2561937","CreatedDate":"2018-10-22T14:30:04.7807573","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10277"}]},"ETag":"01000000-0000-001F-0000-000000027079","Reference":"GID-TA10277","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Tezacaftor and ivacaftor combination therapy for treating cystic fibrosis with the F508del mutation [ID1303]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-11-12T13:18:04.8407325","FirstGoLiveDate":"2017-11-30T06:01:00.6314406","CreatedDate":"2017-11-23T09:16:30.1631726","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1303","EvidenceAssessmentGroup":"Kleijnen Systematic Reviews","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10233"}]},"ETag":"01000000-0000-001F-0000-00000002707B","Reference":"GID-TA10233","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Nivolumab in combination with platinum-doublet chemotherapy for untreated non-small-cell lung cancer   (ID1135)","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-08-13T00:01:13.7470112","FirstGoLiveDate":"2017-09-18T06:00:04.4690843","CreatedDate":"2017-09-12T12:41:59.4673295","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1135","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG508"}]},"ETag":"01000000-0000-001F-0000-00000002707D","Reference":"GID-TAG508","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Lymphoma (mantle cell, relapsed, refractory) - lenalidomide [ID739]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2015-11-06T15:14:45.2792608","FirstGoLiveDate":"2015-11-06T15:14:45.2792608","CreatedDate":"2015-09-16T16:32:04","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10341"}]},"ETag":"01000000-0000-001F-0000-00000002707F","Reference":"GID-TA10341","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Avelumab for treating non-small-cell lung cancer after platinum-based chemotherapy [ID1146]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-01-24T00:01:30.5581286","FirstGoLiveDate":"2018-04-25T14:56:02.9178991","CreatedDate":"2018-04-25T14:55:07.2424252","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1146","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10429"}]},"ETag":"01000000-0000-001F-0000-000000027081","Reference":"GID-TA10429","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-09-26T09:01:23.5591935","FirstGoLiveDate":"2018-11-23T06:00:21.8699163","CreatedDate":"2018-11-16T12:26:38.956078","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1514","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10353"}]},"ETag":"01000000-0000-001F-0000-000000027082","Reference":"GID-TA10353","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Elotuzumab with pomalidomide and dexamethasone for treating multiple myeloma after 2 therapies ID1467","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-09-28T08:33:11.7950409","FirstGoLiveDate":"2018-06-08T12:34:29.2747148","CreatedDate":"2018-06-08T12:33:35.8083894","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1467","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10632"}]},"ETag":"01000000-0000-001F-0000-000000027084","Reference":"GID-TA10632","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nivolumab with chemotherapy for neoadjuvant treatment of early non-small-cell lung cancer [ID3757]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-25T08:37:54.9186811","FirstGoLiveDate":"2020-03-10T13:34:32.9484608","CreatedDate":"2020-03-10T13:33:09.2926448","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3757","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10424"}]},"ETag":"01000000-0000-001F-0000-000000027085","Reference":"GID-TA10424","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"KTE-X19 for previously treated B-precursor acute lymphoblastic leukaemia ID1494","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-04-08T08:26:39.7624783","FirstGoLiveDate":"2018-11-12T10:58:04.5045879","CreatedDate":"2018-11-12T10:55:48.8204787","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1494","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG320"}]},"ETag":"01000000-0000-001F-0000-000000027086","Reference":"GID-TAG320","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Multiple myeloma - bortezomib (consolidation therapy) [ID529]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-11-07T09:18:52","FirstGoLiveDate":null,"CreatedDate":"2014-11-07T09:18:52","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10066"}]},"ETag":"01000000-0000-001F-0000-000000027087","Reference":"GID-TA10066","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Breast cancer (brain metastases) - etirinotecan pegol [ID881] ","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-04-29T00:03:24.242571","FirstGoLiveDate":"2016-06-21T14:52:23.1266408","CreatedDate":"2016-06-02T15:39:58.9883179","DevelopedAs":null,"RelevantTo":null,"IdNumber":"881","EvidenceAssessmentGroup":"BMJ Group ","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10177"}]},"ETag":"01000000-0000-001F-0000-000000027088","Reference":"GID-TA10177","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Empagliflozin for reducing the risk of cardiovascular events in type 2 diabetes [ID1037]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-08-01T14:45:52.1480042","FirstGoLiveDate":"2017-06-22T12:05:41.0111084","CreatedDate":"2017-06-22T11:58:32.0639704","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1037","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG435"}]},"ETag":"01000000-0000-001F-0000-000000027089","Reference":"GID-TAG435","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Multiple myeloma (one prior therapy) - vorinostat (with bortezomib) [ID501]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG436"}]},"ETag":"01000000-0000-001F-0000-00000002708B","Reference":"GID-TAG436","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Breast cancer (ErbB2 HER2, metastatic) - lapatinib (with paclitaxel, 1st line) [ID517]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10028"}]},"ETag":"01000000-0000-001F-0000-00000002708C","Reference":"GID-TA10028","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA Review","Title":"Breast cancer (HER2 negative, HR positive) - everolimus (with exemestane, after endocrine therapy) [ID965]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-06-23T15:55:06.8685279","FirstGoLiveDate":"2016-02-03T11:22:40.4849199","CreatedDate":"2016-02-03T11:04:03.4448816","DevelopedAs":null,"RelevantTo":null,"IdNumber":"965","EvidenceAssessmentGroup":"tbc","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG432"}]},"ETag":"01000000-0000-001F-0000-00000002708D","Reference":"GID-TAG432","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Breast cancer (HER2 negative, metastatic) - bevacizumab (2nd line) [ID488]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10425"}]},"ETag":"01000000-0000-001F-0000-00000002708F","Reference":"GID-TA10425","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Galcanezumab for preventing cluster headache [ID1212]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":"2021-02-24T00:00:00","LastModifiedDate":"2020-04-24T00:03:13.0301719","FirstGoLiveDate":"2018-11-20T06:00:21.6979479","CreatedDate":"2018-11-13T11:16:54.318649","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1212","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG403"}]},"ETag":"01000000-0000-001F-0000-000000027090","Reference":"GID-TAG403","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Breast cancer (locally advanced or metastatic) - ixabepilone [ID377]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10271"}]},"ETag":"01000000-0000-001F-0000-000000027091","Reference":"GID-TA10271","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Pembrolizumab for untreated PD-L1 positive non-small-cell lung cancer with at least 1% tumour proportion score [ID1247]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-06-30T00:02:25.8005109","FirstGoLiveDate":"2017-11-24T06:01:34.0006742","CreatedDate":"2017-11-17T11:33:16.3369075","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1247","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10033"}]},"ETag":"01000000-0000-001F-0000-000000027092","Reference":"GID-TA10033","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Gastroenteropancreatic neuroendocrine tumours (somatostatin, non-progressive) - lutetium-177 DOTATATE [ID857] ","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-10-26T11:51:21.6348595","FirstGoLiveDate":"2016-02-04T16:01:43.277122","CreatedDate":"2016-02-04T10:20:27.3631649","DevelopedAs":null,"RelevantTo":null,"IdNumber":"857","EvidenceAssessmentGroup":"Liverpool Reviews and Implementation Group, University of Liverpool","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG417"}]},"ETag":"01000000-0000-001F-0000-000000027093","Reference":"GID-TAG417","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Breast cancer (metastatic) -trastuzumab (as monotherapy and in combination with a taxane) [ID345]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-10-17T14:27:33.0844251","FirstGoLiveDate":"2017-10-17T14:27:33.0844251","CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10308"}]},"ETag":"01000000-0000-001F-0000-000000027097","Reference":"GID-TA10308","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Lenalidomide for untreated follicular lymphoma ID1245","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-08-13T12:46:22.649013","FirstGoLiveDate":"2018-03-14T09:46:14.9926446","CreatedDate":"2018-03-14T09:42:13.5666843","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1245","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG444"}]},"ETag":"01000000-0000-001F-0000-000000027098","Reference":"GID-TAG444","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Ovarian (epithelial), fallopian and peritoneal cancer - pazopanib (maintenance) [ID545]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG332"}]},"ETag":"01000000-0000-001F-0000-000000027099","Reference":"GID-TAG332","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Ovarian cancer - vintafolide (with pegylated liposomal doxorubicin) [ID564]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-22T11:11:45","FirstGoLiveDate":null,"CreatedDate":"2014-07-22T11:11:45","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10168"}]},"ETag":"01000000-0000-001F-0000-00000002709C","Reference":"GID-TA10168","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Ovarian, fallopian tube and peritoneal cancer - rucaparib [ID1184]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-11-24T10:38:54.4237613","FirstGoLiveDate":"2017-05-11T13:41:14.9195575","CreatedDate":"2017-05-11T13:38:30.8864991","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1184","EvidenceAssessmentGroup":"Kleijnen Systematics Reviews","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG421"}]},"ETag":"01000000-0000-001F-0000-00000002709F","Reference":"GID-TAG421","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Generalised anxiety disorder - quetiapine [ID347]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10499"}]},"ETag":"01000000-0000-001F-0000-0000000270A0","Reference":"GID-TA10499","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nivolumab with ipilimumab for adjuvant treatment of completely resected stage III or IV melanoma ID1610","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-12-17T00:02:07.4347236","FirstGoLiveDate":"2019-05-08T13:57:59.2259901","CreatedDate":"2019-05-08T13:57:03.758517","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1610","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10418"}]},"ETag":"01000000-0000-001F-0000-0000000270A4","Reference":"GID-TA10418","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-07-13T00:01:56.4627763","FirstGoLiveDate":"2018-11-07T11:36:21.485663","CreatedDate":"2018-11-07T11:34:59.9884534","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1545","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG381"}]},"ETag":"01000000-0000-001F-0000-0000000270A5","Reference":"GID-TAG381","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Glaucoma - lerdelimumab (CAT-152) [ID383]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10321"}]},"ETag":"01000000-0000-001F-0000-0000000270A7","Reference":"GID-TA10321","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nivolumab with ipilimumab for treating squamous cell carcinoma of the head and neck  ID1355","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-05-23T00:01:34.9406368","FirstGoLiveDate":"2018-03-14T10:22:15.0397881","CreatedDate":"2018-03-14T10:20:50.5201701","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1355","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10024"}]},"ETag":"01000000-0000-001F-0000-0000000270A8","Reference":"GID-TA10024","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Neuroendocrine tumours (metastatic, unresectable, progressive) - everolimus and sunitinib  [ID858]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2017-06-28T00:00:00","LastModifiedDate":"2017-06-20T13:35:41.9584988","FirstGoLiveDate":"2016-01-06T11:45:51.107995","CreatedDate":"2016-01-06T11:36:09.5500027","DevelopedAs":null,"RelevantTo":null,"IdNumber":"858","EvidenceAssessmentGroup":"Peninsula Technology Assessment Group (PenTAG), University of Exeter","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG280"}]},"ETag":"01000000-0000-001F-0000-0000000270AB","Reference":"GID-TAG280","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Macular oedema (diabetic) - pegaptanib sodium [ID452]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG418"}]},"ETag":"01000000-0000-001F-0000-0000000270AD","Reference":"GID-TAG418","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Rheumatoid arthritis (after the failure of conventional DMARDs) -rituximab [ID333]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10019"}]},"ETag":"01000000-0000-001F-0000-0000000270B0","Reference":"GID-TA10019","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Mastocytosis (systemic) - masitinib [ID781] ","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-09-19T10:48:07.8586357","FirstGoLiveDate":"2015-11-27T15:03:36.2949847","CreatedDate":"2015-11-27T14:57:31.7444183","DevelopedAs":null,"RelevantTo":null,"IdNumber":"781","EvidenceAssessmentGroup":"Kleijnen Systematic Reviews Ltd","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10143"}]},"ETag":"01000000-0000-001F-0000-0000000270B1","Reference":"GID-TA10143","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"DCVax-L for treating newly diagnosed glioblastoma multiforme [ID836]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-09-20T10:25:58.9640058","FirstGoLiveDate":"2016-12-29T01:01:46.9046705","CreatedDate":"2016-12-22T13:15:19.689063","DevelopedAs":null,"RelevantTo":null,"IdNumber":"836","EvidenceAssessmentGroup":"Southampton Health Technology Assessments Centre ","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG440"}]},"ETag":"01000000-0000-001F-0000-0000000270B2","Reference":"GID-TAG440","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Melanoma (metastatic) - paclitaxel albumin-bound nanoparticles (1st line) [ID570]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-17T10:13:25","FirstGoLiveDate":null,"CreatedDate":"2014-07-17T10:13:25","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10498"}]},"ETag":"01000000-0000-001F-0000-0000000270B3","Reference":"GID-TA10498","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nivolumab with ipilimumab for untreated unresectable malignant pleural mesothelioma [ID1609]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-10-13T00:00:00","LastModifiedDate":"2021-01-21T15:47:48.0962057","FirstGoLiveDate":"2019-05-08T13:57:59.1920104","CreatedDate":"2019-05-08T13:55:01.7223925","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1609","EvidenceAssessmentGroup":"KSR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10337"}]},"ETag":"01000000-0000-001F-0000-0000000270B4","Reference":"GID-TA10337","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein (ID1362)","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":"2020-02-19T00:00:00","LastModifiedDate":"2019-01-28T06:00:27.3043029","FirstGoLiveDate":"2018-04-10T06:00:08.6355613","CreatedDate":"2018-04-03T12:10:11.1773725","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1362","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10427"}]},"ETag":"01000000-0000-001F-0000-0000000270B7","Reference":"GID-TA10427","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nintedanib for treating interstitial lung disease caused by systemic sclerosis [ID1420]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-01T09:00:15.3825284","FirstGoLiveDate":"2018-11-22T06:00:29.3898769","CreatedDate":"2018-11-15T13:48:06.0280185","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1420","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10242"}]},"ETag":"01000000-0000-001F-0000-0000000270B8","Reference":"GID-TA10242","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Depatuxizumab mafodotin for treating recurrent EGFR-amplified glioblastoma [ID1244]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-01-29T10:00:06.5108007","FirstGoLiveDate":"2017-10-02T06:00:14.9111392","CreatedDate":"2017-09-25T11:58:46.7753332","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1244","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10180"}]},"ETag":"01000000-0000-001F-0000-0000000270B9","Reference":"GID-TA10180","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-10-30T00:02:30.2966409","FirstGoLiveDate":"2017-06-23T09:17:42.6784879","CreatedDate":"2017-06-23T09:02:22.0866992","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1002","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10572"}]},"ETag":"01000000-0000-001F-0000-0000000270BB","Reference":"GID-TA10572","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nivolumab with platinum-based chemotherapy for advanced unresectable, recurrent or metastatic previously untreated oesophageal cancer [ID2712]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-09-30T14:36:10.3634758","FirstGoLiveDate":"2019-12-16T10:16:03.1821028","CreatedDate":"2019-12-16T10:14:35.3231482","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2712","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG407"}]},"ETag":"01000000-0000-001F-0000-0000000270BC","Reference":"GID-TAG407","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Head and neck cancer - contusugene ladenovec [ID76]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG244"}]},"ETag":"01000000-0000-001F-0000-0000000270BD","Reference":"GID-TAG244","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Diabetes - buccal insulin [ID311]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2015-04-08T16:48:24","FirstGoLiveDate":null,"CreatedDate":"2015-04-08T16:48:24","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10443"}]},"ETag":"01000000-0000-001F-0000-0000000270BE","Reference":"GID-TA10443","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nivolumab with radiation therapy for untreated glioblastoma ID1562","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-07-19T17:46:59.4933437","FirstGoLiveDate":"2018-12-06T15:15:22.7092944","CreatedDate":"2018-12-06T15:13:58.1927631","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1562","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10611"}]},"ETag":"01000000-0000-001F-0000-0000000270BF","Reference":"GID-TA10611","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Sodium thiosulfate for preventing hearing loss in people with cancer who are under 18 and having cisplatin chemotherapy [ID1001]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-01-29T00:01:49.7283762","FirstGoLiveDate":"2020-01-30T06:00:04.8494639","CreatedDate":"2020-01-23T14:22:50.2039363","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1001","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG454"}]},"ETag":"01000000-0000-001F-0000-0000000270C0","Reference":"GID-TAG454","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Heart failure (acute) - serelaxin [ID673]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG330"}]},"ETag":"01000000-0000-001F-0000-0000000270C1","Reference":"GID-TAG330","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Pancreatic cancer (locally advanced, metastatic) - masitinib [ID566]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T15:05:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T15:05:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10359"}]},"ETag":"01000000-0000-001F-0000-0000000270C2","Reference":"GID-TA10359","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nintedanib for untreated malignant pleural mesothelioma (ID1424)","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-07-27T00:02:18.1432686","FirstGoLiveDate":"2018-06-18T06:00:19.7489094","CreatedDate":"2018-06-12T15:34:05.5982841","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1424","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10495"}]},"ETag":"01000000-0000-001F-0000-0000000270C3","Reference":"GID-TA10495","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nivolumab with temozolomide and radiotherapy for newly diagnosed glioblastoma with MGMT methylation  [ID1582]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":"2021-08-18T00:00:00","LastModifiedDate":"2021-02-19T00:01:10.5847272","FirstGoLiveDate":"2019-05-08T11:57:59.1899069","CreatedDate":"2019-05-08T11:55:37.4817884","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1582","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG431"}]},"ETag":"01000000-0000-001F-0000-0000000270C4","Reference":"GID-TAG431","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Soft tissue or bone sarcoma (metastatic) - ridaforolimus (maintenance) [ID415]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG456"}]},"ETag":"01000000-0000-001F-0000-0000000270C5","Reference":"GID-TAG456","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Hepatitis C (genotype 1, chronic) - faldaprevir [ID670] ","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2015-02-26T13:49:26","FirstGoLiveDate":null,"CreatedDate":"2015-02-26T13:49:26","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10018"}]},"ETag":"01000000-0000-001F-0000-0000000270C8","Reference":"GID-TA10018","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Cediranib for treating relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer [ID790]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-09-14T15:39:52.2049578","FirstGoLiveDate":"2015-11-27T14:48:36.3339992","CreatedDate":"2015-11-27T14:43:53.2606193","DevelopedAs":null,"RelevantTo":null,"IdNumber":"790","EvidenceAssessmentGroup":"BMJ Evidence Centre, BMJ Group","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10105"}]},"ETag":"01000000-0000-001F-0000-0000000270CA","Reference":"GID-TA10105","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Anamorelin for treating anorexia and cachexia associated with non-small cell lung cancer [ID821]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-06-21T11:00:58.9353547","FirstGoLiveDate":"2016-09-19T23:01:27.0293377","CreatedDate":"2016-09-13T15:47:06.0176114","DevelopedAs":null,"RelevantTo":null,"IdNumber":"821","EvidenceAssessmentGroup":"Southampton Health Technology Assessment Centre (SHTAC)","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG419"}]},"ETag":"01000000-0000-001F-0000-0000000270CB","Reference":"GID-TAG419","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Venous thromboembolism - apixaban (acute medical illness) [ID310]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG427"}]},"ETag":"01000000-0000-001F-0000-0000000270CC","Reference":"GID-TAG427","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Venous thromboembolism (prevention) - rivaroxaban [ID463]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10365"}]},"ETag":"01000000-0000-001F-0000-0000000270CD","Reference":"GID-TA10365","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy ID1264","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-09-23T09:01:19.9787213","FirstGoLiveDate":"2018-07-04T15:22:18.9494156","CreatedDate":"2018-07-04T15:18:31.2812395","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1264","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10164"}]},"ETag":"01000000-0000-001F-0000-0000000270CE","Reference":"GID-TA10164","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Nivolumab for previously treated advanced hepatocellular carcinoma [ID1141]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-09-15T15:44:43.1868399","FirstGoLiveDate":"2017-04-13T17:02:07.420219","CreatedDate":"2017-04-13T16:56:56.056342","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1141","EvidenceAssessmentGroup":"Warwick Evidence","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10213"}]},"ETag":"01000000-0000-001F-0000-0000000270CF","Reference":"GID-TA10213","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Vemurafenib for treating resected BRAF V600 mutation-positive melanoma ID1250","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-10-18T13:24:26.7500195","FirstGoLiveDate":"2017-08-11T09:02:32.4551145","CreatedDate":"2017-08-04T12:45:42.9209393","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1250","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10382"}]},"ETag":"01000000-0000-001F-0000-0000000270D1","Reference":"GID-TA10382","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Ibrutinib combination therapy for untreated diffuse large B-cell lymphoma ID997","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-11-23T09:00:21.8854385","FirstGoLiveDate":"2018-09-24T06:00:02.3388203","CreatedDate":"2018-09-18T09:59:02.3520523","DevelopedAs":null,"RelevantTo":null,"IdNumber":"997","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10165"}]},"ETag":"01000000-0000-001F-0000-0000000270D2","Reference":"GID-TA10165","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Nivolumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1136]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-02-13T13:00:17.3136372","FirstGoLiveDate":"2017-04-13T17:05:07.4876879","CreatedDate":"2017-04-13T17:02:20.4754259","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1136","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10507"}]},"ETag":"01000000-0000-001F-0000-0000000270D3","Reference":"GID-TA10507","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Angiotensin II for treating vasopressor-resistant hypotension caused by distributive shock ID1588","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-09-18T09:36:43.2973511","FirstGoLiveDate":"2019-05-31T06:00:32.4546226","CreatedDate":"2019-05-24T16:44:05.0178858","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1588","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10377"}]},"ETag":"01000000-0000-001F-0000-0000000270D4","Reference":"GID-TA10377","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Apalutamide for treating non-metastatic, hormone-relapsed prostate cancer [ID1174]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-05-07T10:18:37.394561","FirstGoLiveDate":"2018-08-15T06:01:25.3385061","CreatedDate":"2018-08-08T15:04:24.8762042","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1174","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG499"}]},"ETag":"01000000-0000-001F-0000-0000000270D5","Reference":"GID-TAG499","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Spasticity (after stroke) - botulinum toxin type A [ID768]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-10-18T10:01:32.5572738","FirstGoLiveDate":"2016-10-18T10:01:32.5572738","CreatedDate":"2015-06-24T13:49:57","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10228"}]},"ETag":"01000000-0000-001F-0000-0000000270D7","Reference":"GID-TA10228","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Atezolizumab for treating metastatic colorectal cancer after 2 therapies [1298]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-03T09:06:37.2452408","FirstGoLiveDate":"2017-08-11T12:08:56.857682","CreatedDate":"2017-08-11T12:08:26.3927609","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1298","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10202"}]},"ETag":"01000000-0000-001F-0000-0000000270D8","Reference":"GID-TA10202","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Atezolizumab in combination with platinum-based chemotherapy for untreated locally advanced or metastatic urothelial cancer [ID1206]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-11-16T00:01:54.1736897","FirstGoLiveDate":"2017-07-27T14:41:52.9068075","CreatedDate":"2017-07-27T14:41:05.6581719","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1206","EvidenceAssessmentGroup":"SHTAC","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG511"}]},"ETag":"01000000-0000-001F-0000-000000027113","Reference":"GID-TAG511","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Multiple myeloma - carfilzomib (with lenalidomide and dexamethasone, after prior therapy) [ID677]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-04-08T16:28:31.7303178","FirstGoLiveDate":"2015-10-09T16:31:40.6086246","CreatedDate":"2015-05-21T09:15:32","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG372"}]},"ETag":"01000000-0000-001F-0000-00000002712B","Reference":"GID-TAG372","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Osteoarthritis and rheumatoid arthritis - cox-II inhibitors (review) [ID388]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT516"}]},"ETag":"01000000-0000-001F-0000-000000027130","Reference":"GID-MT516","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"SeQuent Please Neo balloon catheter for in-stent coronary restenosis - update of MTG1 (discontinued)","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-10T14:39:00.9468538","FirstGoLiveDate":"2017-08-10T08:00:01.2605662","CreatedDate":"2017-08-04T13:25:52.60042","DevelopedAs":null,"RelevantTo":null,"IdNumber":"302","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10185"}]},"ETag":"01000000-0000-001F-0000-000000027140","Reference":"GID-IPG10185","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Laparoscopic morcellation of uterine fibroids","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-08-25T00:00:00","LastModifiedDate":"2021-04-13T10:29:55.8844553","FirstGoLiveDate":"2020-08-14T16:20:52.9005228","CreatedDate":"2020-08-14T16:19:40.9477469","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1816","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10165"}]},"ETag":"01000000-0000-001F-0000-00000002714C","Reference":"GID-IPG10165","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Hysteroscopic removal of uterine fibroids with power morcellation","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-08-25T00:00:00","LastModifiedDate":"2021-04-13T10:32:07.0090325","FirstGoLiveDate":"2020-03-27T14:26:09.8390283","CreatedDate":"2020-03-27T14:12:20.8256655","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG239"}]},"ETag":"01000000-0000-001F-0000-000000027153","Reference":"GID-TAG239","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Kidney transplantation (rejection) - belatacept [ID87]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-11-01T15:12:43.7303885","FirstGoLiveDate":"2016-02-26T10:11:53.8107242","CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG399"}]},"ETag":"01000000-0000-001F-0000-00000002715B","Reference":"GID-TAG399","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Leukaemia (acute lymphoblastic) - dasatinib [ID386]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG396"}]},"ETag":"01000000-0000-001F-0000-0000000271DD","Reference":"GID-TAG396","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Prostate cancer - intensity modulated radiotherapy [ID17]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10059"}]},"ETag":"01000000-0000-001F-0000-0000000271E5","Reference":"GID-NG10059","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Reducing the mortality and morbidity for healthcare associated infections","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2017-06-23T14:23:42.8221775","FirstGoLiveDate":"2017-02-23T08:19:46.9594834","CreatedDate":"2017-01-26T13:56:35.6227847","DevelopedAs":"CG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT531"}]},"ETag":"01000000-0000-001F-0000-0000000271F3","Reference":"GID-MT531","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"DHT001 (DHT pilot) myCOPD for self-management of chronic obstructive pulmonary disease (COPD)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-03-31T00:00:00","LastModifiedDate":"2021-04-13T13:26:07.0281828","FirstGoLiveDate":"2019-08-13T12:45:26.166743","CreatedDate":"2019-08-13T12:34:28.6871185","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IP1041"}]},"ETag":"01000000-0000-001F-0000-00000002730A","Reference":"GID-IP1041","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Electrochemotherapy for the treatment of malignant melanoma ","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2016-08-30T15:02:34.3532153","FirstGoLiveDate":"2016-08-30T15:02:34.3532153","CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10142"}]},"ETag":"01000000-0000-001F-0000-000000027311","Reference":"GID-IPG10142","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"High tibial osteotomy with adjustable magnetic nail insertion for symptomatic medial knee osteoarthritis","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-10T11:58:22.0906033","FirstGoLiveDate":"2019-09-25T13:40:20.5429144","CreatedDate":"2019-09-25T13:38:11.06225","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1762","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG390"}]},"ETag":"01000000-0000-001F-0000-000000027318","Reference":"GID-TAG390","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Breast cancer - intensity modulated radiotherapy [ID16]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG378"}]},"ETag":"01000000-0000-001F-0000-0000000274C8","Reference":"GID-TAG378","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Venous thromboembolism (VTE) - ximelagatran [ID396]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10053"}]},"ETag":"01000000-0000-001F-0000-000000027557","Reference":"GID-NG10053","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"PHG","Title":"Housing: planning to improve health and wellbeing","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-02-12T16:06:17.1359271","FirstGoLiveDate":"2016-10-31T13:06:46.4265085","CreatedDate":"2016-10-31T13:05:01.7410873","DevelopedAs":"PH","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-CGWAVE0771"}]},"ETag":"01000000-0000-001F-0000-0000000275C4","Reference":"GID-CGWAVE0771","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Hernia","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-02-21T11:47:22.7625137","FirstGoLiveDate":"2018-02-21T11:47:22.7625137","CreatedDate":"2015-06-16T14:36:18","DevelopedAs":"CG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG397"}]},"ETag":"01000000-0000-001F-0000-0000000276A1","Reference":"GID-TAG397","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Head and neck cancer - intensity modulated radiotherapy [ID15]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT536"}]},"ETag":"01000000-0000-001F-0000-00000002771E","Reference":"GID-MT536","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"DHT pilot: DECODE decision support system for the identification of dementia (Discontinued)","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-05-13T14:42:42.9543042","FirstGoLiveDate":"2019-08-20T11:16:24.3525836","CreatedDate":"2019-08-20T11:14:51.1422606","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10236"}]},"ETag":"01000000-0000-001F-0000-00000002777D","Reference":"GID-TA10236","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Dapagliflozin, empagliflozin and sotagliflozin for treating type 1 diabetes [ID1217]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-09-28T11:56:06.1579338","FirstGoLiveDate":"2017-09-26T06:00:11.8590189","CreatedDate":"2017-09-19T12:16:55.8522176","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1217","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG375"}]},"ETag":"01000000-0000-001F-0000-000000027850","Reference":"GID-TAG375","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Falls - faller's clinics [ID103]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IP2806"}]},"ETag":"01000000-0000-001F-0000-0000000278AE","Reference":"GID-IP2806","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Epiduroscopic lumbar discectomy via the sacral hiatus for sciatica ","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-03-27T20:35:11.8546127","FirstGoLiveDate":"2016-02-04T16:58:43.2530429","CreatedDate":"2015-04-14T15:12:52","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-DG10036"}]},"ETag":"01000000-0000-001F-0000-0000000278C3","Reference":"GID-DG10036","ProjectType":"DG","ProductTypeName":"Diagnostics guidance","Process":"DT","Title":"Quantitative faecal immunochemical tests to guide colorectal cancer pathway referral for people with a change in bowel habit or abdominal pain","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-11-17T13:55:31.3122256","FirstGoLiveDate":"2020-02-14T01:02:03.7330747","CreatedDate":"2020-02-07T15:17:29.8807484","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10184"}]},"ETag":"01000000-0000-001F-0000-0000000278C8","Reference":"GID-NG10184","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"NG","Title":"SACT","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-02-12T01:02:12.9208089","FirstGoLiveDate":"2021-02-12T01:02:12.9208089","CreatedDate":"2021-01-11T14:40:18.6149903","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG398"}]},"ETag":"01000000-0000-001F-0000-0000000278C9","Reference":"GID-TAG398","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Renal cell carcinoma (second line metastatic) - pazopanib [ID70]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":"2011-01-01T00:00:00","LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG371"}]},"ETag":"01000000-0000-001F-0000-0000000278CB","Reference":"GID-TAG371","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Diabetic foot ulcers - new treatments [ID381]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG370"}]},"ETag":"01000000-0000-001F-0000-0000000278CC","Reference":"GID-TAG370","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Venous leg ulcers - new treatments [ID394]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG404"}]},"ETag":"01000000-0000-001F-0000-0000000278CE","Reference":"GID-TAG404","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Breast cancer (advanced or metastatic) hormone-sensitive - lapatinib [ID115]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG411"}]},"ETag":"01000000-0000-001F-0000-0000000278D1","Reference":"GID-TAG411","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Bone loss (therapy-induced) in non-metastatic breast cancer - denosumab [ID83]","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2014-07-16T13:14:34","FirstGoLiveDate":null,"CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10841"}]},"ETag":"01000000-0000-001F-0000-000000027C22","Reference":"GID-TA10841","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma ID1629","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-04-19T11:00:09.2990664","FirstGoLiveDate":"2021-04-19T11:00:09.2990664","CreatedDate":"2021-04-16T09:49:52.6131252","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1629","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MIB10246"}]},"ETag":"01000000-0000-001F-0000-000000027D48","Reference":"GID-MIB10246","ProjectType":"MIB","ProductTypeName":"Medtech innovation briefings","Process":"MIB","Title":"Trublood-prostate for triaging and diagnosing people with symptoms of prostate cancer","Status":"InProgress","ProjectGroup":"Advice","PublishedDate":"0001-01-01T00:00:00","LastModifiedDate":"2021-04-19T16:20:28.1034089","FirstGoLiveDate":null,"CreatedDate":"2021-04-19T16:20:28.1034089","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT556"}]},"ETag":"01000000-0000-001F-0000-000000027E23","Reference":"GID-MT556","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"MT582 AnaConDa-S for sedation with volatile anaesthetics in intensive care","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-02-23T00:00:00","LastModifiedDate":"2021-04-20T09:21:09.2112968","FirstGoLiveDate":"2020-12-07T14:49:53.954559","CreatedDate":"2020-12-07T14:43:22.2541512","DevelopedAs":null,"RelevantTo":null,"IdNumber":"582","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10799"}]},"ETag":"01000000-0000-001F-0000-000000027F17","Reference":"GID-TA10799","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Faricimab for treating wet age-related macular degeneration [ID3898 ]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-04-20T13:35:14.2728142","FirstGoLiveDate":"2021-01-27T12:59:55.4206944","CreatedDate":"2021-01-27T12:58:31.339715","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3898","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10828"}]},"ETag":"01000000-0000-001F-0000-000000027F3E","Reference":"GID-TA10828","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Romosozumab for treating severe osteoporosis [ID3936]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-04-20T14:45:15.7276709","FirstGoLiveDate":"2021-03-23T08:25:54.2598424","CreatedDate":"2021-03-23T08:21:40.0940301","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3936","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10643"}]},"ETag":"01000000-0000-001F-0000-0000000280C6","Reference":"GID-TA10643","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nivolumab with cabozantinib for untreated advanced or metastatic renal cell carcinoma [ID1625]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-04-21T10:29:12.1063747","FirstGoLiveDate":"2020-04-23T16:18:12.8751906","CreatedDate":"2020-04-23T15:10:58.1541211","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1625","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10839"}]},"ETag":"01000000-0000-001F-0000-000000028141","Reference":"GID-TA10839","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Rimegepant for treating or preventing migraine [ID1539]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-04-21T14:29:12.1353217","FirstGoLiveDate":"2021-04-19T11:00:09.2521781","CreatedDate":"2021-04-15T15:34:53.6159075","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1539","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10798"}]},"ETag":"01000000-0000-001F-0000-000000028160","Reference":"GID-TA10798","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Faricimab for treating diabetic macular oedema [ID3899]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-04-21T14:47:12.1906828","FirstGoLiveDate":"2021-01-27T12:52:42.7297086","CreatedDate":"2021-01-27T12:50:43.8597849","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3899","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10216"}]},"ETag":"01000000-0000-001F-0000-0000000281D0","Reference":"GID-IPG10216","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Beating heart off-pump chordal repair for mitral valve incompetence","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-04-09T14:11:05.5752017","FirstGoLiveDate":"2021-04-09T14:11:05.5752017","CreatedDate":"2021-04-09T14:09:08.7631184","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1889","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10215"}]},"ETag":"01000000-0000-001F-0000-0000000281D1","Reference":"GID-IPG10215","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Middle Meningeal Embolisation for Chronic Subdural Haematomas (CSDH)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-04-09T14:08:44.3558607","FirstGoLiveDate":"2021-04-09T14:08:44.3558607","CreatedDate":"2021-04-09T14:06:59.4669211","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1887","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10158"}]},"ETag":"01000000-0000-001F-0000-00000002824F","Reference":"GID-IPG10158","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Radiofrequency ablation for palliation of painful spinal metastases","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-04-22T01:02:12.1275751","FirstGoLiveDate":"2020-02-18T15:24:47.9200856","CreatedDate":"2020-02-18T15:24:07.9201648","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1783","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT562"}]},"ETag":"01000000-0000-001F-0000-0000000282E4","Reference":"GID-MT562","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"GID-MT562 FibroScan for assessing liver fibrosis and cirrhosis in primary care","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-04-22T11:12:16.3674702","FirstGoLiveDate":"2021-03-01T14:40:38.0082209","CreatedDate":"2021-03-01T14:36:51.1588721","DevelopedAs":null,"RelevantTo":null,"IdNumber":"562","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10154"}]},"ETag":"01000000-0000-001F-0000-00000002833C","Reference":"GID-IPG10154","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Transcatheter Mitral Valve In Ring (TMVIR) for treating a failing mitral valve repair","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-07-28T00:00:00","LastModifiedDate":"2021-02-26T16:09:49.6968017","FirstGoLiveDate":"2020-01-22T17:35:45.3280057","CreatedDate":"2020-01-22T17:34:15.8530597","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1791","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10796"}]},"ETag":"01000000-0000-001F-0000-000000028462","Reference":"GID-TA10796","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Tezepelumab for treating severe asthma [ID3910]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-04-22T16:20:13.4128765","FirstGoLiveDate":"2021-01-27T12:37:42.1615023","CreatedDate":"2021-01-27T12:30:48.4659882","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3910","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10462"}]},"ETag":"01000000-0000-001F-0000-00000002851B","Reference":"GID-TA10462","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"LJ TEST","Status":"Discontinued","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2019-03-05T08:39:13.8968662","FirstGoLiveDate":"2019-02-20T11:39:28.9997898","CreatedDate":"2019-02-20T11:22:16.6350194","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10734"}]},"ETag":"01000000-0000-001F-0000-000000028576","Reference":"GID-TA10734","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Relugolix with oestradiol and norethindrone acetate for treating uterine fibroids [ID3842]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-03-09T00:00:00","LastModifiedDate":"2021-04-23T09:41:13.4178274","FirstGoLiveDate":"2020-09-18T08:38:44.7374812","CreatedDate":"2020-09-18T08:38:24.2095872","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3842","EvidenceAssessmentGroup":"KSR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10725"}]},"ETag":"01000000-0000-001F-0000-00000002857A","Reference":"GID-TA10725","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":" Cemiplimab for untreated PD-L1-postive advanced or metastatic non-small-cell lung cancer [ID3839]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-03-09T00:00:00","LastModifiedDate":"2021-04-23T10:17:13.5532751","FirstGoLiveDate":"2020-09-03T15:09:02.5176644","CreatedDate":"2020-09-03T15:08:15.575126","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3839","EvidenceAssessmentGroup":"UL","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10822"}]},"ETag":"01000000-0000-001F-0000-00000002857B","Reference":"GID-TA10822","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-05T14:16:09.9140111","FirstGoLiveDate":"2021-03-05T14:16:09.9140111","CreatedDate":"2021-03-05T14:14:10.1954013","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3924","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10505"}]},"ETag":"01000000-0000-001F-0000-00000002860D","Reference":"GID-TA10505","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Voxelotor for treating sickle cell disease [ID1403]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":"2022-08-10T00:00:00","LastModifiedDate":"2021-04-23T15:29:13.4166704","FirstGoLiveDate":"2019-05-30T06:01:15.6419286","CreatedDate":"2019-05-23T13:58:03.3835577","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1403","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10106"}]},"ETag":"01000000-0000-001F-0000-000000028B6B","Reference":"GID-QS10106","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Safe prescribing and withdrawal management of prescribed drugs associated with dependence and withdrawal","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2018-07-24T16:27:32.7760946","FirstGoLiveDate":"2018-07-24T16:27:32.7760946","CreatedDate":"2018-07-24T16:21:56.1574224","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10141"}]},"ETag":"01000000-0000-001F-0000-000000028B74","Reference":"GID-NG10141","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Medicines associated with dependence or withdrawal symptoms: safe prescribing and withdrawal management for adults","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-04-20T00:00:00","LastModifiedDate":"2021-04-26T16:41:14.9384428","FirstGoLiveDate":"2019-02-15T15:49:32.4553696","CreatedDate":"2019-02-15T15:47:22.8718556","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10188"}]},"ETag":"01000000-0000-001F-0000-000000028CFF","Reference":"GID-IPG10188","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Lateral elbow resurfacing for arthritis","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-04-27T12:22:31.0233417","FirstGoLiveDate":"2020-09-15T12:23:35.4540621","CreatedDate":"2020-09-15T12:17:38.8204775","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1788","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10793"}]},"ETag":"01000000-0000-001F-0000-000000028EDE","Reference":"GID-TA10793","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Difelikefalin for treating pruritus in people having haemodialysis [ID3890 ]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-04-22T09:20:12.1493094","FirstGoLiveDate":"2021-01-27T12:13:42.1553751","CreatedDate":"2021-01-27T12:13:01.5460707","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3890","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10209"}]},"ETag":"01000000-0000-001F-0000-0000000290BE","Reference":"GID-TA10209","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Duvelisib for treating relapsed follicular lymphoma after 2 systemic therapies [ID1090]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-04-29T13:44:18.9400307","FirstGoLiveDate":"2017-08-02T15:07:42.0923774","CreatedDate":"2017-08-02T15:06:30.9898052","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1090","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10352"}]},"ETag":"01000000-0000-001F-0000-0000000290D6","Reference":"GID-TA10352","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nivolumab in combination with chemotherapy for untreated advanced gastric or gastro-oesophageal junction cancer [ID1465]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-10-13T00:00:00","LastModifiedDate":"2021-04-29T15:29:18.9837736","FirstGoLiveDate":"2018-06-08T12:34:29.2266781","CreatedDate":"2018-06-08T12:32:10.7404887","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1465","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10432"}]},"ETag":"01000000-0000-001F-0000-0000000291D8","Reference":"GID-TA10432","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Mexiletine for treating myotonia in adults with non-dystrophic myotonic disorders ID1488","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-11-17T00:00:00","LastModifiedDate":"2021-04-30T00:02:17.8694332","FirstGoLiveDate":"2018-11-26T06:00:24.8059154","CreatedDate":"2018-11-19T12:35:57.9972452","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1488","EvidenceAssessmentGroup":"KSR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10538"}]},"ETag":"01000000-0000-001F-0000-0000000291DB","Reference":"GID-TA10538","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"CDF Review","Title":"Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy (CDF Review TA490) [ID1585]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-08-25T00:00:00","LastModifiedDate":"2021-04-30T00:02:17.9788127","FirstGoLiveDate":"2019-09-26T13:37:23.6337809","CreatedDate":"2019-09-26T13:35:32.9620825","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1585","EvidenceAssessmentGroup":"KSR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT561"}]},"ETag":"01000000-0000-001F-0000-000000029236","Reference":"GID-MT561","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"GID-MT561 ClearGuard HD Antimicrobial Barrier Cap for preventing haemodialysis catheter-related bloodstream infections","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-02-02T00:00:00","LastModifiedDate":"2021-04-30T09:38:17.828483","FirstGoLiveDate":"2021-02-15T15:12:21.7574472","CreatedDate":"2021-02-15T15:11:08.3882226","DevelopedAs":null,"RelevantTo":null,"IdNumber":"561","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10194"}]},"ETag":"01000000-0000-001F-0000-00000002925A","Reference":"GID-NG10194","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Prostate cancer (update)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-04-30T10:24:51.5500188","FirstGoLiveDate":"2021-04-19T11:36:09.2122718","CreatedDate":"2021-04-19T11:33:16.4806236","DevelopedAs":"CG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10742"}]},"ETag":"01000000-0000-001F-0000-000000029881","Reference":"GID-TA10742","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nivolumab for treating resected high-risk invasive urothelial cancer [ID2694]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-01-05T00:00:00","LastModifiedDate":"2021-05-04T10:10:18.0492473","FirstGoLiveDate":"2020-10-01T13:12:15.2347988","CreatedDate":"2020-10-01T13:08:47.9545092","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2694","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10681"}]},"ETag":"01000000-0000-001F-0000-000000029986","Reference":"GID-TA10681","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Liposomal bupivacaine for treating postoperative pain  [ID3799]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-04T16:10:59.402761","FirstGoLiveDate":"2020-06-18T09:05:17.4476319","CreatedDate":"2020-06-18T09:04:29.5814224","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3799","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10260"}]},"ETag":"01000000-0000-001F-0000-0000000299E2","Reference":"GID-TA10260","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Duvelisib for treating relapsed or refractory chronic lymphocytic leukaemia [ID1083]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-05T00:00:52.5425834","FirstGoLiveDate":"2017-09-29T13:30:56.8377227","CreatedDate":"2017-09-29T13:30:40.0539083","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1083","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10619"}]},"ETag":"01000000-0000-001F-0000-000000029AAE","Reference":"GID-TA10619","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pemigatinib for treating relapsed or refractory advanced cholangiocarcinoma with FGFR2 alterations [ID3740]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-08-25T00:00:00","LastModifiedDate":"2021-05-05T15:20:34.4229633","FirstGoLiveDate":"2020-01-29T10:06:01.60136","CreatedDate":"2020-01-29T10:04:48.8360551","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3740","EvidenceAssessmentGroup":"KSR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10417"}]},"ETag":"01000000-0000-001F-0000-000000029B36","Reference":"GID-TA10417","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pembrolizumab in combination for untreated, locally recurrent inoperable or metastatic, triple negative breast cancer [ID1546]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-05T16:45:52.4226471","FirstGoLiveDate":"2018-11-07T11:34:50.3069679","CreatedDate":"2018-11-07T11:33:44.5564815","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1546","EvidenceAssessmentGroup":"ScHARR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10772"}]},"ETag":"01000000-0000-001F-0000-000000029DC2","Reference":"GID-TA10772","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Foslevodopa-foscarbidopa for treating Parkinson’s disease with motor fluctuations [ID3876]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-07T00:00:58.8840413","FirstGoLiveDate":"2020-12-04T15:52:50.8200821","CreatedDate":"2020-12-04T15:51:47.2799605","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3876","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TAG367"}]},"ETag":"01000000-0000-001F-0000-000000029EA6","Reference":"GID-TAG367","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Constipation (opioid induced) - lubiprostone [ID646]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-07T14:11:22.9186743","FirstGoLiveDate":"2021-01-29T09:41:58.2506251","CreatedDate":"2014-07-16T13:14:34","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10843"}]},"ETag":"01000000-0000-001F-0000-000000029F19","Reference":"GID-TA10843","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Ixazomib citrate for maintenance treatment of untreated multiple myeloma after autologous stem cell transplant [ID1517]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-07T15:47:22.8690338","FirstGoLiveDate":"2021-05-07T15:47:22.8690338","CreatedDate":"2021-05-07T15:46:31.9400424","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10714"}]},"ETag":"01000000-0000-001F-0000-000000029F22","Reference":"GID-TA10714","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Diroximel fumarate for treating relapsing-remitting multiple sclerosis [ID1673]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-07T16:34:00.0672956","FirstGoLiveDate":"2020-08-07T13:07:35.2084185","CreatedDate":"2020-08-07T13:05:15.7552881","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1673","EvidenceAssessmentGroup":"UW","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10805"}]},"ETag":"01000000-0000-001F-0000-000000029F36","Reference":"GID-TA10805","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Cabozantinib for previously treated advanced hepatocellular carcinoma [ID3917]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-07T17:14:22.8936732","FirstGoLiveDate":"2021-02-01T12:46:51.428931","CreatedDate":"2021-02-01T12:45:51.0227424","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3917","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-HST10034"}]},"ETag":"01000000-0000-001F-0000-00000002A33C","Reference":"GID-HST10034","ProjectType":"HST","ProductTypeName":"Highly specialised technology","Process":"HST","Title":"Setmelanotide for treating obesity caused by LEPR or POMC deficiency [ID3764]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-03-23T00:00:00","LastModifiedDate":"2021-05-10T13:43:05.7310596","FirstGoLiveDate":"2020-05-13T10:48:43.0000107","CreatedDate":"2020-05-13T10:46:07.9695211","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3764","EvidenceAssessmentGroup":"PenTAG","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10666"}]},"ETag":"01000000-0000-001F-0000-00000002A3F3","Reference":"GID-TA10666","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Upadacitinib for treating active psoriatic arthritis after inadequate response to DMARDs [ID2690]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-10T15:47:24.0868891","FirstGoLiveDate":"2020-05-21T13:36:53.5338101","CreatedDate":"2020-05-13T10:59:19.2270482","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2690","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10663"}]},"ETag":"01000000-0000-001F-0000-00000002A537","Reference":"GID-TA10663","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Ticagrelor for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic attack [ID2689]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":"2022-06-01T00:00:00","LastModifiedDate":"2021-05-11T14:38:24.8057896","FirstGoLiveDate":"2020-05-13T10:54:42.9827875","CreatedDate":"2020-05-13T10:52:34.1708989","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2689","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10770"}]},"ETag":"01000000-0000-001F-0000-00000002A59B","Reference":"GID-TA10770","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pralsetinib for treating RET-positive advanced non-small-cell lung cancer after platinum-based chemotherapy [ID3875]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-11T15:32:24.0830727","FirstGoLiveDate":"2020-12-04T15:44:38.9846022","CreatedDate":"2020-12-04T15:44:20.9301205","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3875","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10753"}]},"ETag":"01000000-0000-001F-0000-00000002A5B2","Reference":"GID-TA10753","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Slow-release potassium bicarbonate and potassium citrate for treating distal renal tubular acidosis [ID3787]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":"2022-03-23T00:00:00","LastModifiedDate":"2021-05-11T15:55:08.2663834","FirstGoLiveDate":"2020-10-05T13:27:21.4911203","CreatedDate":"2020-10-05T13:25:23.6126437","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3787","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MIB10247"}]},"ETag":"01000000-0000-001F-0000-00000002A6DB","Reference":"GID-MIB10247","ProjectType":"MIB","ProductTypeName":"Medtech innovation briefings","Process":"MIB","Title":"Imbio Lung texture analysis for measurement of interstitial lung disease","Status":"InProgress","ProjectGroup":"Advice","PublishedDate":"2021-08-10T00:00:00","LastModifiedDate":"2021-05-12T13:18:59.0803385","FirstGoLiveDate":null,"CreatedDate":"2021-04-19T16:23:31.3839591","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MIB10251"}]},"ETag":"01000000-0000-001F-0000-00000002A6E2","Reference":"GID-MIB10251","ProjectType":"MIB","ProductTypeName":"Medtech innovation briefings","Process":"MIB","Title":"clonoSEQ Assay for detecting and monitoring minimal residue disease (MRD)","Status":"InProgress","ProjectGroup":"Advice","PublishedDate":"2021-08-10T00:00:00","LastModifiedDate":"2021-05-12T13:26:50.1617305","FirstGoLiveDate":null,"CreatedDate":"2021-05-12T13:26:50.1617305","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MIB10252"}]},"ETag":"01000000-0000-001F-0000-00000002A6E9","Reference":"GID-MIB10252","ProjectType":"MIB","ProductTypeName":"Medtech innovation briefings","Process":"MIB","Title":"The Patient Status Engine (PSE)","Status":"InProgress","ProjectGroup":"Advice","PublishedDate":"2021-08-10T00:00:00","LastModifiedDate":"2021-05-12T13:29:57.5163241","FirstGoLiveDate":null,"CreatedDate":"2021-05-12T13:29:57.5163241","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-HST10017"}]},"ETag":"01000000-0000-001F-0000-00000002A832","Reference":"GID-HST10017","ProjectType":"HST","ProductTypeName":"Highly specialised technology","Process":"HST","Title":"Human alpha1-proteinase inhibitor for treating emphysema ID856","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-13T09:56:27.4747671","FirstGoLiveDate":"2018-02-21T11:45:47.6545068","CreatedDate":"2018-02-21T11:44:16.210386","DevelopedAs":null,"RelevantTo":null,"IdNumber":"856","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10387"}]},"ETag":"01000000-0000-001F-0000-00000002A838","Reference":"GID-TA10387","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Fostamatinib for treating persistent or chronic immune thrombocytopenia [ID1087]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-24T10:46:54.7475953","FirstGoLiveDate":"2018-09-28T06:00:11.977664","CreatedDate":"2018-09-21T13:26:27.5041774","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1087","EvidenceAssessmentGroup":"UA","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10144"}]},"ETag":"01000000-0000-001F-0000-00000002A8B1","Reference":"GID-NG10144","ProjectType":"NG","ProductTypeName":"Antimicrobial prescribing guideline","Process":"APG","Title":"Clostridioides difficile infection: antimicrobial prescribing","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-07-23T00:00:00","LastModifiedDate":"2021-05-13T11:49:17.6664763","FirstGoLiveDate":"2019-04-18T14:18:59.3947099","CreatedDate":"2019-04-18T14:16:58.306589","DevelopedAs":"APG","RelevantTo":"APG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":["AMP"]},{"_links":{"self":[{"href":"/project/GID-TA10732"}]},"ETag":"01000000-0000-001F-0000-00000002A8D4","Reference":"GID-TA10732","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Ozanimod for treating moderately to severely active ulcerative colitis [ID3841]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-13T13:46:17.6716332","FirstGoLiveDate":"2020-09-18T08:36:43.475388","CreatedDate":"2020-09-18T08:35:18.0353065","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3841","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10678"}]},"ETag":"01000000-0000-001F-0000-00000002A8D5","Reference":"GID-TA10678","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Gefapixant for treating refractory or unexplained chronic cough [ID3789]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-13T13:46:17.6872347","FirstGoLiveDate":"2020-06-18T09:02:17.5977361","CreatedDate":"2020-06-18T09:01:05.8637337","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3789","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10512"}]},"ETag":"01000000-0000-001F-0000-00000002A8DC","Reference":"GID-TA10512","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nivolumab with ipilimumab for untreated recurrent or metastatic squamous cell cancer of the head and neck cancer ID1429","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-06-22T00:00:00","LastModifiedDate":"2021-05-13T13:47:27.4362488","FirstGoLiveDate":"2019-06-14T06:01:30.871554","CreatedDate":"2019-06-07T11:07:03.0477592","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1429","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10751"}]},"ETag":"01000000-0000-001F-0000-00000002A8E3","Reference":"GID-TA10751","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Atezolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3852 ]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-13T13:53:27.4173892","FirstGoLiveDate":"2020-10-05T12:33:21.5275397","CreatedDate":"2020-10-05T12:30:49.393691","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3852","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT560"}]},"ETag":"01000000-0000-001F-0000-00000002AA43","Reference":"GID-MT560","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"MT476 UroShield for preventing catheter-associated urinary tract infections","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-03-15T00:00:00","LastModifiedDate":"2021-05-14T09:01:17.6889675","FirstGoLiveDate":"2021-02-03T11:01:52.7905735","CreatedDate":"2021-02-03T10:48:13.6882933","DevelopedAs":null,"RelevantTo":null,"IdNumber":"476","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-HST10037"}]},"ETag":"01000000-0000-001F-0000-00000002AF1A","Reference":"GID-HST10037","ProjectType":"HST","ProductTypeName":"Highly specialised technology","Process":"HST","Title":"Arimoclomol for treating Niemann-Pick disease Type C [ID1312]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-17T12:34:24.7080915","FirstGoLiveDate":"2020-08-19T16:13:34.654045","CreatedDate":"2020-08-19T16:09:10.1269434","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1312","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10759"}]},"ETag":"01000000-0000-001F-0000-00000002AF89","Reference":"GID-TA10759","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Upadacitinib for previously treated moderate active rheumatoid arthritis [ID3878]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-17T16:10:25.435595","FirstGoLiveDate":"2020-10-30T16:58:08.8065989","CreatedDate":"2020-10-30T16:21:26.3942315","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3878","EvidenceAssessmentGroup":"PenTAG","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10765"}]},"ETag":"01000000-0000-001F-0000-00000002B084","Reference":"GID-TA10765","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Semaglutide for managing overweight and obesity [ID3850]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-03-30T00:00:00","LastModifiedDate":"2021-05-18T08:47:12.7552205","FirstGoLiveDate":"2020-11-25T14:46:39.8799675","CreatedDate":"2020-11-25T14:43:57.9117873","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3850","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10629"}]},"ETag":"01000000-0000-001F-0000-00000002B09C","Reference":"GID-TA10629","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Lenvatinib with everolimus or pembrolizumab for untreated advanced renal cell carcinoma [ID3760]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2023-01-19T00:00:00","LastModifiedDate":"2021-05-18T10:56:12.7159139","FirstGoLiveDate":"2020-03-10T13:31:32.9811593","CreatedDate":"2020-03-10T13:29:36.0126907","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3760","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10176"}]},"ETag":"01000000-0000-001F-0000-00000002B276","Reference":"GID-NG10176","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Pernicious anaemia","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2023-11-01T00:00:00","LastModifiedDate":"2021-05-19T08:59:12.7542199","FirstGoLiveDate":"2020-06-15T15:40:23.0047076","CreatedDate":"2020-06-15T15:36:29.7782803","DevelopedAs":"CG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10465"}]},"ETag":"01000000-0000-001F-0000-00000002B27E","Reference":"GID-TA10465","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Apalutamide with abiraterone acetate and prednisone for treating metastatic hormone-relapsed prostate cancer [ID1480]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-19T10:01:31.9260144","FirstGoLiveDate":"2019-03-18T06:00:39.2277102","CreatedDate":"2019-03-11T11:11:44.6444732","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MIB10248"}]},"ETag":"01000000-0000-001F-0000-00000002B451","Reference":"GID-MIB10248","ProjectType":"MIB","ProductTypeName":"Medtech innovation briefings","Process":"MIB","Title":"MMprofiler for prognostic risk classification in multiple myeloma","Status":"InProgress","ProjectGroup":"Advice","PublishedDate":"2021-08-03T00:00:00","LastModifiedDate":"2021-05-20T10:20:44.1362026","FirstGoLiveDate":null,"CreatedDate":"2021-04-19T16:25:03.1337097","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MIB10250"}]},"ETag":"01000000-0000-001F-0000-00000002B452","Reference":"GID-MIB10250","ProjectType":"MIB","ProductTypeName":"Medtech innovation briefings","Process":"MIB","Title":"PLASMA button electrode","Status":"InProgress","ProjectGroup":"Advice","PublishedDate":"2021-08-31T00:00:00","LastModifiedDate":"2021-05-20T10:26:19.2214584","FirstGoLiveDate":null,"CreatedDate":"2021-04-19T17:04:16.9774302","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MIB10244"}]},"ETag":"01000000-0000-001F-0000-00000002B453","Reference":"GID-MIB10244","ProjectType":"MIB","ProductTypeName":"Medtech innovation briefings","Process":"MIB","Title":"Colli-pee void urine collection device","Status":"InProgress","ProjectGroup":"Advice","PublishedDate":"2021-08-31T00:00:00","LastModifiedDate":"2021-05-20T10:35:52.8160027","FirstGoLiveDate":null,"CreatedDate":"2021-04-19T16:10:29.2298982","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10652"}]},"ETag":"01000000-0000-001F-0000-00000002B46A","Reference":"GID-TA10652","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Bulevirtide for treating chronic hepatitis D [ID3732]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":"2022-07-28T00:00:00","LastModifiedDate":"2021-05-20T11:10:31.9355354","FirstGoLiveDate":"2020-05-13T09:39:42.9549994","CreatedDate":"2020-05-13T09:38:32.908427","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3732","EvidenceAssessmentGroup":"BMJ","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10092"}]},"ETag":"01000000-0000-001F-0000-00000002B612","Reference":"GID-QS10092","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Brain tumours (primary) and brain metastases in adults","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-12-07T00:00:00","LastModifiedDate":"2021-05-21T10:59:29.8783409","FirstGoLiveDate":"2018-07-24T15:06:32.3718554","CreatedDate":"2018-07-24T15:03:59.8276091","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10749"}]},"ETag":"01000000-0000-001F-0000-00000002B635","Reference":"GID-TA10749","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer [ID3857]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-21T11:13:35.9377543","FirstGoLiveDate":"2020-10-05T12:30:21.5122496","CreatedDate":"2020-10-05T12:27:29.5040153","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3857","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-HST10044"}]},"ETag":"01000000-0000-001F-0000-00000002B6DF","Reference":"GID-HST10044","ProjectType":"HST","ProductTypeName":"Highly specialised technology","Process":"HST","Title":"Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (review of HST3) ID1642","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-21T13:13:35.8813621","FirstGoLiveDate":"2020-04-06T12:53:56.517777","CreatedDate":"2020-04-06T12:51:54.2677849","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1642","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10478"}]},"ETag":"01000000-0000-001F-0000-00000002B74F","Reference":"GID-TA10478","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable [ID1564]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-11-24T00:00:00","LastModifiedDate":"2021-05-21T16:31:35.8925876","FirstGoLiveDate":"2019-05-02T06:00:46.8002193","CreatedDate":"2019-04-25T17:15:42.9060398","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1564","EvidenceAssessmentGroup":"UA","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10825"}]},"ETag":"01000000-0000-001F-0000-00000002BAD9","Reference":"GID-TA10825","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Alpelisib in combination with fulvestrant for treating advanced hormone-receptor positive, HER2-negative, PIK3CA-mutated breast cancer [ID3929]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-03-30T00:00:00","LastModifiedDate":"2021-05-24T09:41:32.3792504","FirstGoLiveDate":"2021-03-15T14:37:35.5054089","CreatedDate":"2021-03-15T14:34:18.4079049","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3929","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10096"}]},"ETag":"01000000-0000-001F-0000-00000002BAE0","Reference":"GID-NG10096","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Antenatal care","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-08-19T00:00:00","LastModifiedDate":"2021-05-24T09:44:32.3435557","FirstGoLiveDate":"2017-11-02T11:54:54.6302775","CreatedDate":"2017-11-02T11:53:49.9169713","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10472"}]},"ETag":"01000000-0000-001F-0000-00000002BCA8","Reference":"GID-TA10472","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nivolumab with ipilimumab and chemotherapy for untreated metastatic non-small-cell lung cancer [ID1566]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-18T12:26:12.7655672","FirstGoLiveDate":"2019-04-08T00:02:22.0749817","CreatedDate":"2019-04-01T16:15:09.489017","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1566","EvidenceAssessmentGroup":"UY","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT551"}]},"ETag":"01000000-0000-001F-0000-00000002BCB1","Reference":"GID-MT551","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"GID-MT551 Prontosan for acute and chronic wounds","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-10-05T00:00:00","LastModifiedDate":"2021-05-25T09:47:34.4513512","FirstGoLiveDate":"2020-09-30T08:54:10.3517631","CreatedDate":"2020-09-30T08:51:30.0558807","DevelopedAs":null,"RelevantTo":null,"IdNumber":"551","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10713"}]},"ETag":"01000000-0000-001F-0000-00000002BE00","Reference":"GID-TA10713","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Palforzia for treating peanut allergy [ID1282]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-01-26T00:00:00","LastModifiedDate":"2021-05-25T19:49:47.8163297","FirstGoLiveDate":"2020-08-06T14:40:04.6973172","CreatedDate":"2020-08-06T14:29:29.8982049","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1282","EvidenceAssessmentGroup":"UA","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10596"}]},"ETag":"01000000-0000-001F-0000-00000002BE10","Reference":"GID-TA10596","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-12-15T00:00:00","LastModifiedDate":"2021-05-25T20:19:47.8215242","FirstGoLiveDate":"2020-01-15T08:44:30.893307","CreatedDate":"2020-01-15T08:44:07.1382014","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3734","EvidenceAssessmentGroup":"BMJ","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10661"}]},"ETag":"01000000-0000-001F-0000-00000002BF35","Reference":"GID-TA10661","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Cenobamate for focal onset seizures in epilepsy [ID1553]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-10-13T00:00:00","LastModifiedDate":"2021-05-26T13:32:33.6384959","FirstGoLiveDate":"2020-05-13T10:51:43.195032","CreatedDate":"2020-05-13T10:50:06.4684519","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1553","EvidenceAssessmentGroup":"UY","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10656"}]},"ETag":"01000000-0000-001F-0000-00000002BFD4","Reference":"GID-TA10656","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Daratumumab in combination for untreated systemic amyloid light-chain amyloidosis [ID3748]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-03-02T00:00:00","LastModifiedDate":"2021-05-26T17:02:33.6192374","FirstGoLiveDate":"2020-05-13T09:48:43.0144575","CreatedDate":"2020-05-13T09:45:19.0148108","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3748","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10806"}]},"ETag":"01000000-0000-001F-0000-00000002BFE6","Reference":"GID-TA10806","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Ciltacabtagene autoleucel for treating relapsed or refractory multiple myeloma [ID3816]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-02-02T00:00:00","LastModifiedDate":"2021-05-26T17:13:51.0864279","FirstGoLiveDate":"2021-02-01T15:31:50.2243371","CreatedDate":"2021-02-01T15:27:33.6468549","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3816","EvidenceAssessmentGroup":"UY","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10485"}]},"ETag":"01000000-0000-001F-0000-00000002BFED","Reference":"GID-TA10485","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 1 prior therapy [ID1557]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-26T18:25:51.0853761","FirstGoLiveDate":"2019-05-02T10:17:47.9181073","CreatedDate":"2019-05-02T10:12:11.1911242","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1557","EvidenceAssessmentGroup":"PenTAG","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10449"}]},"ETag":"01000000-0000-001F-0000-00000002C04A","Reference":"GID-TA10449","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Daratumumab in combination for untreated multiple myeloma when stem cell transplant is suitable [ID1510]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-27T00:01:51.118343","FirstGoLiveDate":"2019-01-16T06:00:28.0359203","CreatedDate":"2019-01-09T14:38:23.6796732","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1510","EvidenceAssessmentGroup":"SHTAC","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10166"}]},"ETag":"01000000-0000-001F-0000-00000002C04F","Reference":"GID-IPG10166","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Laparoscopic renal denervation for loin pain haematuria syndrome ","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-27T01:01:51.0913381","FirstGoLiveDate":"2020-03-27T14:26:09.8702703","CreatedDate":"2020-03-27T14:13:18.8725078","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1795","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10171"}]},"ETag":"01000000-0000-001F-0000-00000002C050","Reference":"GID-IPG10171","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Geniculate artery embolisation for pain from knee osteoarthritis","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-27T01:01:51.1694498","FirstGoLiveDate":"2020-05-22T14:00:53.5221211","CreatedDate":"2020-05-22T13:56:51.0701346","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1745","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10193"}]},"ETag":"01000000-0000-001F-0000-00000002C0B7","Reference":"GID-IPG10193","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Percutaneous endovascular forearm-arteriovenous fistula creation for haemodialysis access","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-27T08:58:51.0894912","FirstGoLiveDate":"2020-10-20T12:27:54.200816","CreatedDate":"2020-10-20T12:26:08.0730262","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1833","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10373"}]},"ETag":"01000000-0000-001F-0000-00000002C1CC","Reference":"GID-TA10373","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Fenfluramine for treating seizures associated with Dravet syndrome [ID1109]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-27T16:10:51.0656226","FirstGoLiveDate":"2018-08-02T06:00:06.1956225","CreatedDate":"2018-07-26T16:30:06.6592954","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1109","EvidenceAssessmentGroup":"KSR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10147"}]},"ETag":"01000000-0000-001F-0000-00000002C28F","Reference":"GID-QS10147","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Safeguarding adults in care homes","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-16T11:48:46.60884","FirstGoLiveDate":"2020-05-04T15:09:51.9991881","CreatedDate":"2020-05-04T15:06:39.1400451","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10430"}]},"ETag":"01000000-0000-001F-0000-00000002C2FC","Reference":"GID-TA10430","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Solriamfetol for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1499]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-28T13:43:59.0760612","FirstGoLiveDate":"2018-11-23T06:00:21.9748762","CreatedDate":"2018-11-16T15:24:57.1531485","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1499","EvidenceAssessmentGroup":"SHTAC","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT557"}]},"ETag":"01000000-0000-001F-0000-00000002C309","Reference":"GID-MT557","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"GID-MT557 Novii Wireless Patch System for maternal and fetal monitoring (MT509)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-03-31T00:00:00","LastModifiedDate":"2021-05-28T13:55:59.0752678","FirstGoLiveDate":"2020-12-15T13:12:02.0356946","CreatedDate":"2020-12-15T13:10:30.6224604","DevelopedAs":null,"RelevantTo":null,"IdNumber":"509","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10139"}]},"ETag":"01000000-0000-001F-0000-00000002C32E","Reference":"GID-QS10139","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Fetal alcohol spectrum disorder","Status":"ImpactedByCOVID19","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-05-28T15:19:59.0565889","FirstGoLiveDate":"2019-05-13T13:42:15.1872764","CreatedDate":"2019-05-13T13:39:51.420358","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10082"}]},"ETag":"01000000-0000-001F-0000-00000002C864","Reference":"GID-NG10082","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Inducing labour (update)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-10-14T00:00:00","LastModifiedDate":"2021-06-01T09:53:03.8632645","FirstGoLiveDate":"2017-07-26T14:05:54.7874073","CreatedDate":"2017-07-07T14:09:58.7146384","DevelopedAs":"CG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10220"}]},"ETag":"01000000-0000-001F-0000-00000002C993","Reference":"GID-NG10220","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Glaucoma: diagnosis and management","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-01T16:35:36.9995495","FirstGoLiveDate":"2021-06-01T16:05:03.8650117","CreatedDate":"2021-06-01T15:51:59.9026051","DevelopedAs":"CG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10127"}]},"ETag":"01000000-0000-001F-0000-00000002CA95","Reference":"GID-NG10127","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Osteoarthritis: care and management (update)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-10-19T00:00:00","LastModifiedDate":"2021-06-02T11:17:07.3632684","FirstGoLiveDate":"2018-11-29T11:40:01.4448486","CreatedDate":"2018-11-29T11:35:18.275405","DevelopedAs":"CG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-DG10038"}]},"ETag":"01000000-0000-001F-0000-00000002CAFC","Reference":"GID-DG10038","ProjectType":"DG","ProductTypeName":"Diagnostics guidance","Process":"DT","Title":"Exploratory economic modelling of SARS-CoV-2 viral detection point of care tests and serology tests","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-02T11:56:07.3891548","FirstGoLiveDate":"2020-06-10T14:43:16.7535312","CreatedDate":"2020-06-09T12:09:47.3958408","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10612"}]},"ETag":"01000000-0000-001F-0000-00000002CB07","Reference":"GID-TA10612","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Risdiplam for treating spinal muscular atrophy in children and adults [ID1631]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-02T00:02:07.3811897","FirstGoLiveDate":"2020-02-03T06:00:13.297904","CreatedDate":"2020-01-27T14:56:41.9707392","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1631","EvidenceAssessmentGroup":"ScHARR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10385"}]},"ETag":"01000000-0000-001F-0000-00000002CBDC","Reference":"GID-TA10385","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pitolisant hydrochloride for treating excessive daytime sleepiness caused by obstructive sleep apnoea [ID1065]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-03T00:02:12.0998515","FirstGoLiveDate":"2018-09-27T06:00:05.2662868","CreatedDate":"2018-09-20T11:08:43.303971","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1065","EvidenceAssessmentGroup":"KSR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10729"}]},"ETag":"01000000-0000-001F-0000-00000002CD59","Reference":"GID-TA10729","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Amivantamab for treating EGFR Exon 20 insertion-positive non-small-cell lung cancer after platinum-based chemotherapy  [ID3836]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-10-12T00:00:00","LastModifiedDate":"2021-06-04T00:02:12.1243087","FirstGoLiveDate":"2020-09-07T13:47:19.6668721","CreatedDate":"2020-09-07T13:45:42.5997632","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3836","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10691"}]},"ETag":"01000000-0000-001F-0000-00000002CDC8","Reference":"GID-TA10691","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitors [ID3813]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-04T10:53:14.0586522","FirstGoLiveDate":"2020-07-08T12:25:50.4568117","CreatedDate":"2020-07-08T12:24:43.9414523","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3813","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MIB10253"}]},"ETag":"01000000-0000-001F-0000-00000002CE36","Reference":"GID-MIB10253","ProjectType":"MIB","ProductTypeName":"Medtech innovation briefings","Process":"MIB","Title":"BPMpathway remote patient assessment platform","Status":"InProgress","ProjectGroup":"Advice","PublishedDate":"2021-08-31T00:00:00","LastModifiedDate":"2021-06-04T14:27:30.7153439","FirstGoLiveDate":null,"CreatedDate":"2021-06-04T14:27:30.7153439","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MIB10254"}]},"ETag":"01000000-0000-001F-0000-00000002CE3A","Reference":"GID-MIB10254","ProjectType":"MIB","ProductTypeName":"Medtech innovation briefings","Process":"MIB","Title":"Bardy Carnation Ambulatory Monitor","Status":"InProgress","ProjectGroup":"Advice","PublishedDate":"2021-09-14T00:00:00","LastModifiedDate":"2021-06-04T14:32:45.7455265","FirstGoLiveDate":null,"CreatedDate":"2021-06-04T14:32:45.7455265","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10578"}]},"ETag":"01000000-0000-001F-0000-00000002D24A","Reference":"GID-TA10578","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Axicabtagene ciloleucel for treating relapsed or refractory low-grade non-Hodgkin’s lymphoma [ID1685]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-07T10:02:31.6598232","FirstGoLiveDate":"2019-12-16T10:52:03.1704","CreatedDate":"2019-12-16T10:49:44.103539","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1685","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10524"}]},"ETag":"01000000-0000-001F-0000-00000002D36C","Reference":"GID-TA10524","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Solriamfetol for treating excessive daytime sleepiness caused by narcolepsy [ID1602]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-07T16:11:40.727417","FirstGoLiveDate":"2019-08-07T11:26:42.5776468","CreatedDate":"2019-08-07T11:23:48.7033709","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1602","EvidenceAssessmentGroup":"SHTAC","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10829"}]},"ETag":"01000000-0000-001F-0000-00000002D468","Reference":"GID-TA10829","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Sacituzumab govitecan for treating metastatic or unresectable triple-negative breast cancer after 2 or more therapies ID3942","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-06-29T00:00:00","LastModifiedDate":"2021-06-08T09:29:23.5748933","FirstGoLiveDate":"2021-03-29T13:58:57.9293462","CreatedDate":"2021-03-29T13:57:50.9935642","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3942","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT552"}]},"ETag":"01000000-0000-001F-0000-00000002D4CC","Reference":"GID-MT552","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"MT443 Sleepio for adults with difficulty sleeping  ","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-03-14T00:00:00","LastModifiedDate":"2021-06-08T13:50:23.5743488","FirstGoLiveDate":"2020-10-19T14:00:54.1615808","CreatedDate":"2020-10-19T13:53:01.8186504","DevelopedAs":null,"RelevantTo":null,"IdNumber":"443","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-DG10043"}]},"ETag":"01000000-0000-001F-0000-00000002D541","Reference":"GID-DG10043","ProjectType":"DG","ProductTypeName":"Diagnostics guidance","Process":"DT","Title":"Transperineal biopsy in people with suspected prostate cancer","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-06-22T00:00:00","LastModifiedDate":"2021-06-08T16:17:23.6987405","FirstGoLiveDate":"2021-02-22T01:01:16.2930103","CreatedDate":"2021-02-17T09:14:18.0989573","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-HST10027"}]},"ETag":"01000000-0000-001F-0000-00000002D603","Reference":"GID-HST10027","ProjectType":"HST","ProductTypeName":"Highly specialised technology","Process":"HST","Title":"Elosulfase alfa for treating mucopolysaccharidosis type IVa (review of HST2) [ID1643]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-09T09:32:31.8811314","FirstGoLiveDate":"2019-10-31T09:38:42.0823682","CreatedDate":"2019-10-31T08:54:39.2772059","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1643","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10113"}]},"ETag":"01000000-0000-001F-0000-00000002D697","Reference":"GID-QS10113","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Indoor air quality at home","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-02-15T00:00:00","LastModifiedDate":"2021-06-09T14:47:31.9157794","FirstGoLiveDate":"2018-07-24T16:42:32.3369808","CreatedDate":"2018-07-24T16:40:49.76414","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT564"}]},"ETag":"01000000-0000-001F-0000-00000002D7C7","Reference":"GID-MT564","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"GID-MT564  GreenLight XPS for treating benign prostatic hyperplasia","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-03-08T12:19:20.8794117","FirstGoLiveDate":"2021-03-08T12:13:45.6929366","CreatedDate":"2021-03-08T12:13:15.5918148","DevelopedAs":null,"RelevantTo":null,"IdNumber":"564","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10817"}]},"ETag":"01000000-0000-001F-0000-00000002D7D5","Reference":"GID-TA10817","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Belzutifan for treating clear-cell renal carcinoma caused by von Hippel-Lindau disease [ID3932]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-08-17T00:00:00","LastModifiedDate":"2021-06-10T10:47:31.1350456","FirstGoLiveDate":"2021-02-23T12:18:40.1160645","CreatedDate":"2021-02-23T12:18:22.2723708","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3932","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10676"}]},"ETag":"01000000-0000-001F-0000-00000002D82F","Reference":"GID-TA10676","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Anifrolumab for treating active autoantibody-positive systemic lupus erythematosus [ID3804]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-04-27T00:00:00","LastModifiedDate":"2021-06-10T12:02:31.1315845","FirstGoLiveDate":"2020-06-18T08:59:17.604501","CreatedDate":"2020-06-18T08:58:37.2397395","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3804","EvidenceAssessmentGroup":"KSR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10216"}]},"ETag":"01000000-0000-001F-0000-00000002D836","Reference":"GID-NG10216","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"NG","Title":"Osteoporosis: assessing the risk of fragility fracture","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2024-02-21T00:00:00","LastModifiedDate":"2021-06-10T13:35:31.1182218","FirstGoLiveDate":"2021-05-26T09:52:47.8074013","CreatedDate":"2021-05-26T09:46:49.4571383","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10827"}]},"ETag":"01000000-0000-001F-0000-00000002D84A","Reference":"GID-TA10827","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA Review","Title":"Ibrutinib for treating Waldenstrom’s macroglobulinaemia (CDF Review of TA491) [ID3778]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-12-14T00:00:00","LastModifiedDate":"2021-06-10T15:02:34.0251306","FirstGoLiveDate":"2021-03-26T00:02:02.3675335","CreatedDate":"2021-03-19T13:49:10.8622412","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3778","EvidenceAssessmentGroup":"ScHARR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10311"}]},"ETag":"01000000-0000-001F-0000-00000002D8A6","Reference":"GID-TA10311","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Dasatinib for treating Philadelphia-chromosome-positive acute lymphoblastic leukaemia in children and adults ID1297","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-10T15:47:31.1545729","FirstGoLiveDate":"2018-03-14T09:58:14.9470005","CreatedDate":"2018-03-14T09:55:11.4980528","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-HST10035"}]},"ETag":"01000000-0000-001F-0000-00000002D919","Reference":"GID-HST10035","ProjectType":"HST","ProductTypeName":"Highly specialised technology","Process":"HST","Title":"Givosiran for treating acute hepatic porphyria [ID1549]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-11T00:02:31.1269848","FirstGoLiveDate":"2020-05-13T10:51:42.9918852","CreatedDate":"2020-05-13T10:48:38.2265942","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1549","EvidenceAssessmentGroup":"PenTAG","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10660"}]},"ETag":"01000000-0000-001F-0000-00000002D91A","Reference":"GID-TA10660","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Lumasiran for treating primary hyperoxaluria type 1 [ID3765]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-11T00:02:31.1426401","FirstGoLiveDate":"2020-05-13T10:48:43.0781365","CreatedDate":"2020-05-13T10:47:38.7972315","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3765","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10305"}]},"ETag":"01000000-0000-001F-0000-00000002D97B","Reference":"GID-TA10305","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Mogamulizumab for previously treated mycosis fungoides and Sézary syndrome [ID1405]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-11T08:02:31.1677162","FirstGoLiveDate":"2018-03-19T06:01:25.3445041","CreatedDate":"2018-03-12T11:23:12.2285681","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1405","EvidenceAssessmentGroup":"KSR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10423"}]},"ETag":"01000000-0000-001F-0000-00000002DA72","Reference":"GID-TA10423","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Apalutamide for treating prostate cancer [ID1534]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-11T16:41:33.8083767","FirstGoLiveDate":"2018-11-12T10:46:04.6638406","CreatedDate":"2018-11-12T10:44:27.5556812","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1534","EvidenceAssessmentGroup":"SHTAC","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10272"}]},"ETag":"01000000-0000-001F-0000-00000002DD86","Reference":"GID-TA10272","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nivolumab with ipilimumab for previously treated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency [ID1332]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-07-21T00:00:00","LastModifiedDate":"2021-06-14T00:02:41.1015799","FirstGoLiveDate":"2017-11-27T06:00:56.500479","CreatedDate":"2017-11-20T10:14:29.8854429","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1332","EvidenceAssessmentGroup":"UL","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10701"}]},"ETag":"01000000-0000-001F-0000-00000002DD87","Reference":"GID-TA10701","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Mepolizumab for previously treated severe chronic rhinosinusitis with nasal polyps [ID3817]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-07-20T00:00:00","LastModifiedDate":"2021-06-14T00:02:41.2266419","FirstGoLiveDate":"2020-07-08T13:00:01.1102457","CreatedDate":"2020-07-08T12:59:30.4853618","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3817","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10845"}]},"ETag":"01000000-0000-001F-0000-00000002DE7E","Reference":"GID-TA10845","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Hybrid closed loop systems for managing blood glucose levels in type 1 diabetes","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-04-13T00:00:00","LastModifiedDate":"2021-06-14T11:49:04.0210559","FirstGoLiveDate":"2021-06-14T11:49:04.0210559","CreatedDate":"2021-06-07T08:58:26.8804766","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3957","EvidenceAssessmentGroup":"UW","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10745"}]},"ETag":"01000000-0000-001F-0000-00000002DF27","Reference":"GID-TA10745","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nivolumab for adjuvant treatment of high-risk hepatocellular carcinoma after liver resection or ablation [ID3858]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-10-05T12:21:21.5443939","FirstGoLiveDate":"2020-10-05T12:21:21.5443939","CreatedDate":"2020-10-05T12:18:58.2477882","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3858","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10626"}]},"ETag":"01000000-0000-001F-0000-00000002DF28","Reference":"GID-TA10626","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Belimumab for the treatment of active autoantibody-positive systemic lupus erythematosus  (Review of TA397) [ID1591]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-04T00:02:12.0618098","FirstGoLiveDate":"2020-02-27T12:23:10.656357","CreatedDate":"2020-02-27T12:20:55.2505833","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1591","EvidenceAssessmentGroup":"KSR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10842"}]},"ETag":"01000000-0000-001F-0000-00000002DFF1","Reference":"GID-TA10842","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Teduglutide for treating short bowel syndrome [ID3937]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-15T09:01:08.2773472","FirstGoLiveDate":"2021-04-19T12:05:11.0750663","CreatedDate":"2021-04-19T11:33:15.334029","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10155"}]},"ETag":"01000000-0000-001F-0000-00000002E05B","Reference":"GID-NG10155","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Melanoma: assessment and management","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-07-06T00:00:00","LastModifiedDate":"2021-06-15T11:37:44.8105117","FirstGoLiveDate":"2019-09-16T17:13:02.7922558","CreatedDate":"2019-09-16T17:05:33.9865977","DevelopedAs":"CG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MIB10243"}]},"ETag":"01000000-0000-001F-0000-00000002E092","Reference":"GID-MIB10243","ProjectType":"MIB","ProductTypeName":"Medtech innovation briefings","Process":"MIB","Title":"OrganOx metra normothermic organ perfusion device","Status":"InProgress","ProjectGroup":"Advice","PublishedDate":"2021-09-14T00:00:00","LastModifiedDate":"2021-06-15T12:42:59.7134668","FirstGoLiveDate":null,"CreatedDate":"2021-04-19T16:01:39.2013377","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10428"}]},"ETag":"01000000-0000-001F-0000-00000002E095","Reference":"GID-TA10428","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Tebentafusp for treating advanced uveal melanoma ID1441","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-07-20T00:00:00","LastModifiedDate":"2021-06-15T12:43:08.2757369","FirstGoLiveDate":"2018-11-22T06:00:29.4198748","CreatedDate":"2018-11-15T14:50:13.7900736","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1441","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-HST10045"}]},"ETag":"01000000-0000-001F-0000-00000002E0CC","Reference":"GID-HST10045","ProjectType":"HST","ProductTypeName":"Highly specialised technology","Process":"HST","Title":"Selumetinib for treating symptomatic and inoperable plexiform neurofibromas associated with type 1 neurofibromatosis in children aged 3 years and over [ID1590]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-05-05T00:00:00","LastModifiedDate":"2021-06-15T14:55:44.841577","FirstGoLiveDate":"2019-09-26T06:01:20.5479881","CreatedDate":"2019-09-19T12:47:48.8821022","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1590","EvidenceAssessmentGroup":"KSR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10848"}]},"ETag":"01000000-0000-001F-0000-00000002E201","Reference":"GID-TA10848","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Pembrolizumab with lenvatinib for untreated advanced melanoma [ID3948]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-16T09:14:48.2655053","FirstGoLiveDate":"2021-06-15T16:25:44.7873214","CreatedDate":"2021-06-15T16:12:02.5105671","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3948","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10849"}]},"ETag":"01000000-0000-001F-0000-00000002E206","Reference":"GID-TA10849","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies [ID3950]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-16T09:17:48.2765707","FirstGoLiveDate":"2021-06-15T16:34:08.2572173","CreatedDate":"2021-06-15T16:32:52.745261","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3950","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10744"}]},"ETag":"01000000-0000-001F-0000-00000002E2A4","Reference":"GID-TA10744","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Melphalan flufenamide with dexamethasone for treating relapsed or refractory multiple myeloma  [ID3862]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-06-22T00:00:00","LastModifiedDate":"2021-06-16T13:38:48.252476","FirstGoLiveDate":"2020-10-05T12:18:21.5061208","CreatedDate":"2020-10-05T12:17:07.4666842","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3862","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10579"}]},"ETag":"01000000-0000-001F-0000-00000002E2A5","Reference":"GID-TA10579","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Carfilzomib with daratumumab and dexamethasone for treating relapsed or refractory multiple myeloma [ID2709]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-10-19T00:00:00","LastModifiedDate":"2021-06-16T13:38:48.2680986","FirstGoLiveDate":"2019-12-16T10:55:03.1810553","CreatedDate":"2019-12-16T10:53:13.9312581","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2709","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10646"}]},"ETag":"01000000-0000-001F-0000-00000002E2A9","Reference":"GID-TA10646","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Selinexor with bortezomib and low-dose dexamethasone for treating relapsed refractory multiple myeloma [ID3797]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-16T13:38:50.6662327","FirstGoLiveDate":"2020-05-04T11:24:30.7933425","CreatedDate":"2020-05-04T11:22:42.8645249","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3797","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10616"}]},"ETag":"01000000-0000-001F-0000-00000002E2B1","Reference":"GID-TA10616","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Durvalumab with chemotherapy for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations [ID3751]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-16T13:47:48.2463796","FirstGoLiveDate":"2020-01-29T10:00:01.571846","CreatedDate":"2020-01-29T09:58:33.4878335","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3751","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10633"}]},"ETag":"01000000-0000-001F-0000-00000002E2C3","Reference":"GID-TA10633","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Durvalumab for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID3762]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-16T13:50:48.2886987","FirstGoLiveDate":"2020-03-10T13:35:25.0732085","CreatedDate":"2020-03-10T13:34:12.3089844","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3762","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10422"}]},"ETag":"01000000-0000-001F-0000-00000002E2C4","Reference":"GID-TA10422","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Durvalumab (Imfinzi) + Tremelimumab + standard chemotherapy for non-small cell lung cancer (NSCLC) lacking activating EGFR mutations and ALK fusions ID1538","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-16T13:50:48.2886987","FirstGoLiveDate":"2018-11-12T10:43:04.6971632","CreatedDate":"2018-11-12T10:42:33.1458916","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10726"}]},"ETag":"01000000-0000-001F-0000-00000002E2D0","Reference":"GID-TA10726","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Daratumumab in combination for untreated multiple myeloma when high-dose chemotherapy with stem cell transplant is unsuitable [ID3843]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-16T14:05:50.6838992","FirstGoLiveDate":"2020-09-03T15:15:02.5115726","CreatedDate":"2020-09-03T15:09:35.8456516","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3843","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10441"}]},"ETag":"01000000-0000-001F-0000-00000002E2D9","Reference":"GID-TA10441","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Daratumumab in combination for untreated multiple myeloma when stem cell transplant is unsuitable [ID1492]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-16T14:11:48.2584738","FirstGoLiveDate":"2018-12-03T09:23:16.357624","CreatedDate":"2018-12-03T09:22:01.1949285","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1492","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10696"}]},"ETag":"01000000-0000-001F-0000-00000002E2EF","Reference":"GID-TA10696","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Pembrolizumab with olaparib for treating hormone-relapsed metastatic prostate cancer after chemotherapy and abiraterone or enzalutamide [ID3814]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-16T14:20:48.3056962","FirstGoLiveDate":"2021-06-16T14:20:48.3056962","CreatedDate":"2020-07-08T12:38:41.4398727","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3814","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10668"}]},"ETag":"01000000-0000-001F-0000-00000002E2F0","Reference":"GID-TA10668","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Pembrolizumab with docetaxel for treating hormone-relapsed metastatic prostate cancer untreated with chemotherapy [ID3801]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-16T14:20:48.4150558","FirstGoLiveDate":"2020-05-28T11:16:00.5769008","CreatedDate":"2020-05-28T11:14:54.4225974","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3801","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10175"}]},"ETag":"01000000-0000-001F-0000-00000002E322","Reference":"GID-NG10175","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Stroke rehabilitation in adults","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-12-14T00:00:00","LastModifiedDate":"2021-06-16T15:23:48.2743694","FirstGoLiveDate":"2020-06-15T10:52:22.257565","CreatedDate":"2020-06-15T10:47:14.4992578","DevelopedAs":"CG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10399"}]},"ETag":"01000000-0000-001F-0000-00000002E3E2","Reference":"GID-TA10399","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer [ID1500]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-17T00:02:48.3341369","FirstGoLiveDate":"2018-10-22T06:00:21.0507433","CreatedDate":"2018-10-15T14:49:43.2816849","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1500","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10693"}]},"ETag":"01000000-0000-001F-0000-00000002E3E5","Reference":"GID-TA10693","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pembrolizumab for adjuvant treatment of renal cell carcinoma [ID3810]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-17T00:02:48.365387","FirstGoLiveDate":"2020-07-08T12:30:01.1342082","CreatedDate":"2020-07-08T12:28:46.86928","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3810","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10735"}]},"ETag":"01000000-0000-001F-0000-00000002E3EB","Reference":"GID-TA10735","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Upadacitinib for treating active ankylosing spondylitis [ID3848]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-17T00:02:48.4278515","FirstGoLiveDate":"2020-09-18T08:41:44.240511","CreatedDate":"2020-09-18T08:39:41.2407107","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3848","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10771"}]},"ETag":"01000000-0000-001F-0000-00000002E3EE","Reference":"GID-TA10771","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Tofacitinib for treating active ankylosing spondylitis [ID3865]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-17T00:02:48.4591006","FirstGoLiveDate":"2020-12-04T15:52:50.7888298","CreatedDate":"2020-12-04T15:50:44.6952781","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3865","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10458"}]},"ETag":"01000000-0000-001F-0000-00000002E3F1","Reference":"GID-TA10458","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Ixekizumab for treating axial spondyloarthritis after NSAIDs [ID1532]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-07-21T00:00:00","LastModifiedDate":"2021-06-17T00:02:48.5215683","FirstGoLiveDate":"2019-02-07T06:00:29.0318584","CreatedDate":"2019-01-31T15:05:50.716148","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1532","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10457"}]},"ETag":"01000000-0000-001F-0000-00000002E3F2","Reference":"GID-TA10457","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Secukinumab for treating non-radiographic axial spondyloarthritis [ID1419]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-07-21T00:00:00","LastModifiedDate":"2021-06-17T00:02:48.5528561","FirstGoLiveDate":"2019-02-07T06:00:28.9138768","CreatedDate":"2019-01-31T13:37:04.3673027","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1419","EvidenceAssessmentGroup":"UY","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT550"}]},"ETag":"01000000-0000-001F-0000-00000002E4C5","Reference":"GID-MT550","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"GID-MT550 DyeVert Systems for reducing the risk of acute kidney injury in coronary and peripheral angiography","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-10-04T00:00:00","LastModifiedDate":"2021-06-14T10:28:04.0022427","FirstGoLiveDate":"2020-09-30T08:48:34.4155012","CreatedDate":"2020-09-30T08:47:40.5249473","DevelopedAs":null,"RelevantTo":null,"IdNumber":"550","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10708"}]},"ETag":"01000000-0000-001F-0000-00000002E538","Reference":"GID-TA10708","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-12-22T00:00:00","LastModifiedDate":"2021-06-17T18:35:47.9943806","FirstGoLiveDate":"2020-08-03T09:04:00.4993503","CreatedDate":"2020-08-03T09:02:31.3157466","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3828","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10670"}]},"ETag":"01000000-0000-001F-0000-00000002E540","Reference":"GID-TA10670","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Dostarlimab for previously treated advanced or recurrent endometrial cancer with high microsatellite instability or mismatch repair deficiency [ID3802]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-01-26T00:00:00","LastModifiedDate":"2021-06-17T18:38:47.9927782","FirstGoLiveDate":"2020-05-28T11:19:00.6078064","CreatedDate":"2020-05-28T11:17:00.6392836","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3802","EvidenceAssessmentGroup":"UW","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10597"}]},"ETag":"01000000-0000-001F-0000-00000002E547","Reference":"GID-TA10597","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-10-27T00:00:00","LastModifiedDate":"2021-06-17T18:59:48.2382495","FirstGoLiveDate":"2020-01-15T08:46:47.4187262","CreatedDate":"2020-01-15T08:45:40.3619718","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3733","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10692"}]},"ETag":"01000000-0000-001F-0000-00000002E5A6","Reference":"GID-TA10692","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"MTA","Title":"Lenvatinib with pembrolizumab for previously treated advanced, metastatic or recurrent endometrial cancer\r\n [ID3811]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2023-02-15T00:00:00","LastModifiedDate":"2021-06-18T00:02:48.0534547","FirstGoLiveDate":"2020-07-08T12:28:50.462992","CreatedDate":"2020-07-08T12:26:02.9881066","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3811","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10580"}]},"ETag":"01000000-0000-001F-0000-00000002E5A9","Reference":"GID-TA10580","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 1 systemic therapy [ID1684]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-18T00:02:48.1159551","FirstGoLiveDate":"2019-12-16T10:58:25.9773736","CreatedDate":"2019-12-16T10:57:39.4031194","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1684","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10757"}]},"ETag":"01000000-0000-001F-0000-00000002E5AA","Reference":"GID-TA10757","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Lisocabtagene maraleucel for treating relapsed or refractory aggressive B-cell non-Hodgkin lymphoma after 1 systemic treatment [ID3869]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-18T00:02:48.1784577","FirstGoLiveDate":"2020-10-19T08:54:51.3418321","CreatedDate":"2020-10-19T08:53:18.5141932","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3869","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT553"}]},"ETag":"01000000-0000-001F-0000-00000002E614","Reference":"GID-MT553","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"GID-MT553 Synergo for non-muscle-invasive bladder cancer","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-11-30T00:00:00","LastModifiedDate":"2021-06-18T09:02:48.4146255","FirstGoLiveDate":"2020-10-29T10:10:10.2961328","CreatedDate":"2020-10-29T10:09:51.7492815","DevelopedAs":null,"RelevantTo":null,"IdNumber":"533","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10624"}]},"ETag":"01000000-0000-001F-0000-00000002E68D","Reference":"GID-TA10624","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapy [ID3735]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-08-25T00:00:00","LastModifiedDate":"2021-06-18T13:32:48.3863542","FirstGoLiveDate":"2020-02-06T14:51:23.5105231","CreatedDate":"2020-02-06T14:50:50.6010663","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3735","EvidenceAssessmentGroup":"UA","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-DG10041"}]},"ETag":"01000000-0000-001F-0000-00000002E696","Reference":"GID-DG10041","ProjectType":"DG","ProductTypeName":"Diagnostics guidance","Process":"DT","Title":"EarlyCDT Lung for lung cancer risk classification of solid pulmonary nodules","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-02-23T00:00:00","LastModifiedDate":"2021-06-18T15:11:48.9111601","FirstGoLiveDate":"2020-11-16T01:01:53.9641452","CreatedDate":"2020-11-10T09:08:48.4157363","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10142"}]},"ETag":"01000000-0000-001F-0000-00000002E6FC","Reference":"GID-QS10142","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Venous thromboembolism in adults (QS update)","Status":"ImpactedByCOVID19","ProjectGroup":"Guidance","PublishedDate":"2021-08-19T00:00:00","LastModifiedDate":"2021-06-18T15:59:48.369911","FirstGoLiveDate":"2020-02-07T16:51:23.5402502","CreatedDate":"2020-02-07T15:55:05.963364","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/TA560"}]},"ETag":"01000000-0000-001F-0000-00000002E7C4","Reference":"TA560","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Bevacizumab in combination with carboplatin, gemcitabine and paclitaxel for treating the first recurrence of platinum-sensitive advanced ovarian cancer [ID1145]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2019-02-20T00:00:00","LastModifiedDate":"2021-06-18T17:44:48.3359024","FirstGoLiveDate":"2017-09-28T09:51:13.4974499","CreatedDate":"2017-09-28T09:49:30.162575","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10342"}]},"ETag":"01000000-0000-001F-0000-00000002EBB8","Reference":"GID-TA10342","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Olaparib for treating BRCA 1 or 2 mutated metastatic breast cancer after prior chemotherapy [ID1382]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-21T12:35:49.377074","FirstGoLiveDate":"2018-05-02T06:02:31.9958235","CreatedDate":"2018-04-25T16:00:34.6670626","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1382","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10391"}]},"ETag":"01000000-0000-001F-0000-00000002EBBD","Reference":"GID-TA10391","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Lenadogene nolparvovec for treating Leber hereditary optic neuropathy caused by the G11778A ND4 mitochondrial mutation [ID1410]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-21T12:38:49.3726302","FirstGoLiveDate":"2018-10-02T06:00:19.4409337","CreatedDate":"2018-09-25T16:43:17.4681761","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1410","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-APA10016"}]},"ETag":"01000000-0000-001F-0000-00000002EBC2","Reference":"GID-APA10016","ProjectType":"APA","ProductTypeName":"Antimicrobial prescribing evidence summary","Process":"APA","Title":"Antimicrobial prescribing: delafloxacin for community acquired pneumonia","Status":"InProgress","ProjectGroup":"Advice","PublishedDate":"2021-08-10T00:00:00","LastModifiedDate":"2021-06-21T12:52:33.5543687","FirstGoLiveDate":null,"CreatedDate":"2021-06-09T13:51:54.6809061","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":["AMP"]},{"_links":{"self":[{"href":"/project/GID-ES10021"}]},"ETag":"01000000-0000-001F-0000-00000002EBC7","Reference":"GID-ES10021","ProjectType":"ES","ProductTypeName":"Evidence summary","Process":"ES","Title":"Melatonin for treating insomnia in adults with visual disorders","Status":"InProgress","ProjectGroup":"Advice","PublishedDate":"2021-08-18T00:00:00","LastModifiedDate":"2021-06-21T12:54:10.7410102","FirstGoLiveDate":null,"CreatedDate":"2021-06-21T12:54:10.7410102","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10613"}]},"ETag":"01000000-0000-001F-0000-00000002EC4E","Reference":"GID-TA10613","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pembrolizumab with platinum-based chemotherapy for untreated advanced oesophageal cancer [ID3741]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-10-13T00:00:00","LastModifiedDate":"2021-06-21T15:32:49.4061801","FirstGoLiveDate":"2020-01-29T09:55:36.0193301","CreatedDate":"2020-01-29T09:54:54.7850479","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3741","EvidenceAssessmentGroup":"PenTAG","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10125"}]},"ETag":"01000000-0000-001F-0000-00000002EE19","Reference":"GID-NG10125","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"PHG","Title":"Social, emotional and mental wellbeing in primary and secondary education","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-07-06T00:00:00","LastModifiedDate":"2021-06-22T17:38:51.3129345","FirstGoLiveDate":"2018-11-20T10:26:52.0751344","CreatedDate":"2018-11-20T10:19:53.7379886","DevelopedAs":"PH","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT563"}]},"ETag":"01000000-0000-001F-0000-00000002EF00","Reference":"GID-MT563","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"GID-MT563 NPi-200 for pupillary light reflex in critical care patients","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-08-08T00:00:00","LastModifiedDate":"2021-06-23T10:32:51.1851837","FirstGoLiveDate":"2021-03-02T14:16:01.1966601","CreatedDate":"2021-03-02T14:14:22.8730426","DevelopedAs":null,"RelevantTo":null,"IdNumber":"563","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT565"}]},"ETag":"01000000-0000-001F-0000-00000002EF11","Reference":"GID-MT565","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"GID-MT565  Optilume for anterior urethral strictures","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-08-30T00:00:00","LastModifiedDate":"2021-06-23T10:38:51.1607403","FirstGoLiveDate":"2021-06-16T11:38:48.3159117","CreatedDate":"2021-06-08T15:59:57.8344753","DevelopedAs":null,"RelevantTo":null,"IdNumber":"565","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT566"}]},"ETag":"01000000-0000-001F-0000-00000002EF16","Reference":"GID-MT566","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"GID-MT566 Faecal microbiota transplant for recurrent or refractory Clostridioides difficile infection","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-08-30T00:00:00","LastModifiedDate":"2021-06-23T10:41:51.2030733","FirstGoLiveDate":"2021-06-16T15:32:48.2726024","CreatedDate":"2021-06-08T16:02:54.3769153","DevelopedAs":null,"RelevantTo":null,"IdNumber":"566","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MIB10255"}]},"ETag":"01000000-0000-001F-0000-00000002EFA6","Reference":"GID-MIB10255","ProjectType":"MIB","ProductTypeName":"Medtech innovation briefings","Process":"MIB","Title":"24/7 EEG SubQ for people with epilepsy","Status":"InProgress","ProjectGroup":"Advice","PublishedDate":"2021-10-05T00:00:00","LastModifiedDate":"2021-06-23T13:27:36.6706079","FirstGoLiveDate":null,"CreatedDate":"2021-06-23T13:27:36.6706079","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10276"}]},"ETag":"01000000-0000-001F-0000-00000002F0F3","Reference":"GID-TA10276","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Dupilumab for treating severe asthma [ID1213]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-24T11:20:51.8216883","FirstGoLiveDate":"2017-11-29T06:01:44.6143745","CreatedDate":"2017-11-22T14:17:13.9707877","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1213","EvidenceAssessmentGroup":"SHTAC","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10705"}]},"ETag":"01000000-0000-001F-0000-00000002F1DB","Reference":"GID-TA10705","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-24T16:35:51.6956473","FirstGoLiveDate":"2020-07-23T14:21:35.4604665","CreatedDate":"2020-07-23T14:18:37.7543072","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1427","EvidenceAssessmentGroup":"KSR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10600"}]},"ETag":"01000000-0000-001F-0000-00000002F23F","Reference":"GID-TA10600","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Filgotinib for treating moderately to severely active ulcerative colitis  [ID3736]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-24T19:59:51.7294393","FirstGoLiveDate":"2020-01-15T08:52:47.4638713","CreatedDate":"2020-01-15T08:51:10.4708423","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3736","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10086"}]},"ETag":"01000000-0000-001F-0000-00000002F2AC","Reference":"GID-NG10086","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"PHG","Title":"Tobacco: preventing uptake, promoting quitting and treating dependence (update)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-11-30T00:00:00","LastModifiedDate":"2021-06-25T07:50:51.7072287","FirstGoLiveDate":"2017-09-10T00:36:06.8620062","CreatedDate":"2017-09-10T00:32:26.6914801","DevelopedAs":"PH","RelevantTo":"PH","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10711"}]},"ETag":"01000000-0000-001F-0000-00000002F2C2","Reference":"GID-TA10711","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Tanezumab for treating moderate to severe chronic pain caused by osteoarthritis [ID1603]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-25T09:00:23.2950281","FirstGoLiveDate":"2020-08-03T14:55:00.3576653","CreatedDate":"2020-08-03T14:44:09.2787286","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1603","EvidenceAssessmentGroup":"BMJ","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10160"}]},"ETag":"01000000-0000-001F-0000-00000002F370","Reference":"GID-NG10160","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Type 2 diabetes in adults: management (update)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-25T12:56:58.678783","FirstGoLiveDate":"2019-10-15T08:05:06.032695","CreatedDate":"2019-10-15T08:03:13.6931244","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/TA582"}]},"ETag":"01000000-0000-001F-0000-00000002F371","Reference":"TA582","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Cabozantinib for treating advanced hepatocellular carcinoma after prior therapy [ID1243]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2019-05-24T00:00:00","LastModifiedDate":"2021-06-18T17:32:48.4943747","FirstGoLiveDate":"2018-01-19T06:00:01.6474119","CreatedDate":"2018-01-12T14:43:12.6963425","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1243","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT567"}]},"ETag":"01000000-0000-001F-0000-00000002F3DA","Reference":"GID-MT567","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"GID-MT567 Evoke Spinal Cord Stimulator for managing chronic neuropathic or ischaemic pain","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-10-04T00:00:00","LastModifiedDate":"2021-06-25T17:20:58.695563","FirstGoLiveDate":"2021-06-16T14:23:48.2562906","CreatedDate":"2021-06-08T16:03:57.6409792","DevelopedAs":null,"RelevantTo":null,"IdNumber":"567","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10123"}]},"ETag":"01000000-0000-001F-0000-00000002F6EC","Reference":"GID-NG10123","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Pelvic floor dysfunction: prevention and non-surgical management","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-12-09T00:00:00","LastModifiedDate":"2021-06-28T00:02:54.6108675","FirstGoLiveDate":"2018-09-19T10:47:57.716772","CreatedDate":"2018-09-19T10:44:30.8112287","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-DG10045"}]},"ETag":"01000000-0000-001F-0000-00000002F6EE","Reference":"GID-DG10045","ProjectType":"DG","ProductTypeName":"Diagnostics guidance","Process":"DT","Title":"LiverMultiScan MRI imaging software for the diagnosis and characterisation of non-alcoholic fatty liver disease (provisional title)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-10-26T00:00:00","LastModifiedDate":"2021-06-28T01:02:54.4859108","FirstGoLiveDate":"2021-06-28T01:02:54.4859108","CreatedDate":"2021-06-07T10:13:11.487362","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10159"}]},"ETag":"01000000-0000-001F-0000-00000002F763","Reference":"GID-NG10159","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Type 1 diabetes in adults: diagnosis and management (update)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-07-21T00:00:00","LastModifiedDate":"2021-06-28T10:29:54.4981804","FirstGoLiveDate":"2019-10-15T08:02:30.2521685","CreatedDate":"2019-10-15T08:01:06.9747979","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10122"}]},"ETag":"01000000-0000-001F-0000-00000002F7EC","Reference":"GID-NG10122","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Heart valve disease presenting in adults: investigation and management","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-10-27T00:00:00","LastModifiedDate":"2021-06-28T14:20:54.5120999","FirstGoLiveDate":"2018-08-29T08:32:03.0370958","CreatedDate":"2018-08-29T08:28:26.0520258","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10098"}]},"ETag":"01000000-0000-001F-0000-00000002F88E","Reference":"GID-NG10098","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Obstructive sleep apnoea/hypopnoea syndrome and obesity hypoventilation syndrome in over 16s","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-08-20T00:00:00","LastModifiedDate":"2021-06-28T17:21:19.7299986","FirstGoLiveDate":"2017-12-06T08:32:06.6912393","CreatedDate":"2017-12-06T08:25:58.7835354","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10470"}]},"ETag":"01000000-0000-001F-0000-00000002F960","Reference":"GID-TA10470","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Crizanlizumab for preventing sickle cell crises in sickle cell disease [ID1406]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-09-22T00:00:00","LastModifiedDate":"2021-06-29T08:53:55.3457666","FirstGoLiveDate":"2019-03-29T06:00:41.2856364","CreatedDate":"2019-03-22T12:43:26.8104815","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1406","EvidenceAssessmentGroup":"KSR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-HST10043"}]},"ETag":"01000000-0000-001F-0000-00000002F971","Reference":"GID-HST10043","ProjectType":"HST","ProductTypeName":"Highly specialised technology","Process":"HST","Title":"Odevixibat for progressive familial intrahepatic cholestasis [ID1570]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-01-22T00:00:00","LastModifiedDate":"2021-06-29T09:47:55.3607611","FirstGoLiveDate":"2020-05-13T09:54:42.9978029","CreatedDate":"2020-05-13T09:51:51.9828712","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1570","EvidenceAssessmentGroup":"ScHARR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10217"}]},"ETag":"01000000-0000-001F-0000-00000002F97F","Reference":"GID-IPG10217","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"External support of the aortic root using mesh for people with Marfan syndrome","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-29T10:20:55.3575924","FirstGoLiveDate":"2021-06-29T10:14:55.3668709","CreatedDate":"2021-06-29T10:09:32.4062725","DevelopedAs":null,"RelevantTo":null,"IdNumber":"885","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10584"}]},"ETag":"01000000-0000-001F-0000-00000002F986","Reference":"GID-TA10584","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Olaparib for previously treated, hormone-relapsed metastatic prostate cancer with homologous recombination repair gene mutations [ID1640]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-29T10:56:55.3496635","FirstGoLiveDate":"2019-12-18T09:18:53.2682887","CreatedDate":"2019-12-18T09:16:10.0952822","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1640","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10218"}]},"ETag":"01000000-0000-001F-0000-00000002F98C","Reference":"GID-IPG10218","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"YAG laser vitreolysis for symptomatic vitreous floaters","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-29T11:11:55.3435141","FirstGoLiveDate":"2021-06-29T11:11:55.3435141","CreatedDate":"2021-06-29T11:08:20.3948224","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1860","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10207"}]},"ETag":"01000000-0000-001F-0000-00000002F990","Reference":"GID-IPG10207","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Extra-corporeal shockwave lithotripsy for calcific tendonitis (teninopathy) of the shoulder","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-29T11:15:19.7036953","FirstGoLiveDate":"2021-06-29T11:15:19.7036953","CreatedDate":"2020-12-22T14:12:14.97785","DevelopedAs":null,"RelevantTo":null,"IdNumber":"148","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10219"}]},"ETag":"01000000-0000-001F-0000-00000002F996","Reference":"GID-IPG10219","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Percutaneous ultrasound-guided microwave ablation for symptomatic benign thyroid nodules","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-29T11:18:19.6932417","FirstGoLiveDate":"2021-06-29T11:18:19.6932417","CreatedDate":"2021-06-29T11:16:48.1094195","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1868","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10206"}]},"ETag":"01000000-0000-001F-0000-00000002F99E","Reference":"GID-IPG10206","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Transvenous obliteration for gastric varices","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-29T11:20:55.3583961","FirstGoLiveDate":"2020-12-22T14:11:14.7902199","CreatedDate":"2020-12-22T14:04:57.151268","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1865","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10220"}]},"ETag":"01000000-0000-001F-0000-00000002F9A4","Reference":"GID-IPG10220","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Insertion of a balloon device to disimpact an engaged fetal head prior to emergency caesarean section","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-29T11:24:19.7008883","FirstGoLiveDate":"2021-06-29T11:24:19.7008883","CreatedDate":"2021-06-29T11:21:26.9518989","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1217","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10211"}]},"ETag":"01000000-0000-001F-0000-00000002F9AC","Reference":"GID-IPG10211","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Trabeculectomy with biodegradable collagen matrix implant for glaucoma","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-29T11:26:55.3677521","FirstGoLiveDate":"2021-01-15T14:38:40.6163736","CreatedDate":"2021-01-15T14:24:36.5960475","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1866","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10209"}]},"ETag":"01000000-0000-001F-0000-00000002F9B5","Reference":"GID-IPG10209","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Laparoscopic insertion of a magnetic titanium ring for gastro-oesophageal reflux disease","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-29T11:29:55.3323138","FirstGoLiveDate":"2020-12-22T14:26:14.7553346","CreatedDate":"2020-12-22T14:24:17.0340976","DevelopedAs":null,"RelevantTo":null,"IdNumber":"973","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10210"}]},"ETag":"01000000-0000-001F-0000-00000002FA10","Reference":"GID-IPG10210","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Transcutaneous Trigeminal Nerve Stimulation for ADHD","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-29T11:30:19.7153777","FirstGoLiveDate":"2021-06-29T11:30:19.7153777","CreatedDate":"2020-12-22T14:28:09.442404","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1782","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10221"}]},"ETag":"01000000-0000-001F-0000-00000002FA16","Reference":"GID-IPG10221","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Percutaneous transluminal renal sympathetic denervation for resistant hypertension","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-29T11:36:19.713309","FirstGoLiveDate":"2021-06-29T11:36:19.713309","CreatedDate":"2021-06-29T11:33:43.4491401","DevelopedAs":null,"RelevantTo":null,"IdNumber":"923","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10208"}]},"ETag":"01000000-0000-001F-0000-00000002FA17","Reference":"GID-IPG10208","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Image-guided cryoablation of peripheral neuroma for chronic pain","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2020-12-22T14:24:17.9745957","FirstGoLiveDate":"2020-12-22T14:24:17.9745957","CreatedDate":"2020-12-22T14:21:48.0221576","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1852","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10850"}]},"ETag":"01000000-0000-001F-0000-00000002FA2E","Reference":"GID-TA10850","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Dostarlimab with carboplatin and paclitaxel for treating recurrent or advanced endometrial cancer [ID3968]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-29T15:17:55.3546837","FirstGoLiveDate":"2021-06-29T15:17:55.3546837","CreatedDate":"2021-06-29T15:15:15.3066521","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3968","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10851"}]},"ETag":"01000000-0000-001F-0000-00000002FA39","Reference":"GID-TA10851","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Lenvatinib with pembrolizumab for untreated recurrent or advanced endometrial cancer [ID3966]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-29T15:20:55.3657422","FirstGoLiveDate":"2021-06-29T15:20:55.3657422","CreatedDate":"2021-06-29T15:18:06.9148383","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3966","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10852"}]},"ETag":"01000000-0000-001F-0000-00000002FA3A","Reference":"GID-TA10852","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Melphalan for conditioning treatment before allogeneic haematopoietic stem cell transplant in haematological diseases [ID3969]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-29T15:20:55.4126159","FirstGoLiveDate":"2021-06-29T15:20:55.4126159","CreatedDate":"2021-06-29T15:19:36.960922","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3969","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10169"}]},"ETag":"01000000-0000-001F-0000-00000002FB65","Reference":"GID-IPG10169","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Coronary sinus stent insertion for refractory angina","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-30T10:56:57.886434","FirstGoLiveDate":"2020-04-16T15:53:56.3835464","CreatedDate":"2020-04-16T15:52:07.795896","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1822","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10168"}]},"ETag":"01000000-0000-001F-0000-00000002FB69","Reference":"GID-IPG10168","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Restorative Neurostimulation to Activate the Lumbar Multifidus for chronic mechanical low back pain","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-30T10:57:22.9739188","FirstGoLiveDate":"2020-04-16T15:53:56.3210339","CreatedDate":"2020-04-16T15:48:02.5716612","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1790","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10782"}]},"ETag":"01000000-0000-001F-0000-00000002FBC7","Reference":"GID-TA10782","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"CDF Review","Title":"Niraparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer(CDF review TA528) [ID1644]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-10-20T00:00:00","LastModifiedDate":"2021-06-30T11:56:57.8902784","FirstGoLiveDate":"2021-01-15T14:20:40.601878","CreatedDate":"2021-01-15T14:19:21.3944302","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1644","EvidenceAssessmentGroup":"BMJ","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10170"}]},"ETag":"01000000-0000-001F-0000-00000002FBD9","Reference":"GID-NG10170","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"PHG","Title":"Integrated health and social care for people experiencing homelessness\r\n","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-03-16T00:00:00","LastModifiedDate":"2021-06-30T14:11:57.9289092","FirstGoLiveDate":"2020-02-27T16:49:06.0044792","CreatedDate":"2020-02-25T16:19:29.0141841","DevelopedAs":"PH","RelevantTo":"PH","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10177"}]},"ETag":"01000000-0000-001F-0000-00000002FBDF","Reference":"GID-NG10177","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Hypertension in adults: diagnosis and management (update)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2023-04-19T00:00:00","LastModifiedDate":"2021-06-30T14:14:57.8815018","FirstGoLiveDate":"2020-08-12T15:01:18.181049","CreatedDate":"2020-08-12T14:56:22.0193461","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10165"}]},"ETag":"01000000-0000-001F-0000-00000002FBF8","Reference":"GID-NG10165","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Barrett's oesophagus: medical management, endoscopic treatment, follow up and stage 1 adenocarcinoma","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2023-01-23T00:00:00","LastModifiedDate":"2021-06-30T15:29:57.8836656","FirstGoLiveDate":"2020-01-09T11:59:19.623121","CreatedDate":"2020-01-09T11:56:17.8270837","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10118"}]},"ETag":"01000000-0000-001F-0000-00000002FC59","Reference":"GID-NG10118","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Chronic kidney disease: assessment and management (update)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-08-25T00:00:00","LastModifiedDate":"2021-06-30T15:57:22.9848971","FirstGoLiveDate":"2018-06-28T14:25:31.1546386","CreatedDate":"2018-06-28T14:23:25.5538842","DevelopedAs":"CG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MIB10240"}]},"ETag":"01000000-0000-001F-0000-00000002FC5A","Reference":"GID-MIB10240","ProjectType":"MIB","ProductTypeName":"Medtech innovation briefings","Process":"MIB","Title":"Immunoscore for predicting colon cancer relapse","Status":"InProgress","ProjectGroup":"Advice","PublishedDate":"2021-08-03T00:00:00","LastModifiedDate":"2021-06-30T16:28:41.0080511","FirstGoLiveDate":null,"CreatedDate":"2021-04-14T12:54:33.7264726","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10094"}]},"ETag":"01000000-0000-001F-0000-00000002FC62","Reference":"GID-QS10094","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Perioperative care","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":"2022-04-26T00:00:00","LastModifiedDate":"2021-06-30T17:02:58.0317206","FirstGoLiveDate":"2018-07-24T15:21:32.6312039","CreatedDate":"2018-07-24T15:18:42.5418438","DevelopedAs":null,"RelevantTo":null,"IdNumber":"0","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10810"}]},"ETag":"01000000-0000-001F-0000-00000002FD19","Reference":"GID-TA10810","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"CDF Review","Title":"Atezolizumab for untreated PD-L1-positive locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (CDF Review of TA492) [ID3777]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-10-22T00:00:00","LastModifiedDate":"2021-07-01T08:38:57.9037483","FirstGoLiveDate":"2021-02-12T14:17:23.783905","CreatedDate":"2021-02-12T14:15:55.8904301","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3777","EvidenceAssessmentGroup":"SHTAC","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10113"}]},"ETag":"01000000-0000-001F-0000-00000002FD32","Reference":"GID-NG10113","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"SC","Title":"Disabled children and young people up to 25 with severe complex needs: integrated service delivery and organisation across health, social care and education","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-01-19T00:00:00","LastModifiedDate":"2021-07-01T09:59:57.9116032","FirstGoLiveDate":"2018-06-19T15:37:46.2375544","CreatedDate":"2018-06-19T15:30:15.2533566","DevelopedAs":"SC","RelevantTo":"SC","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10105"}]},"ETag":"01000000-0000-001F-0000-00000002FD33","Reference":"GID-NG10105","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Rehabilitation after traumatic injury","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-01-18T00:00:00","LastModifiedDate":"2021-07-01T09:59:57.9429131","FirstGoLiveDate":"2018-03-07T10:45:37.735066","CreatedDate":"2018-03-07T10:43:22.4876776","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10151"}]},"ETag":"01000000-0000-001F-0000-00000002FD48","Reference":"GID-NG10151","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Gout: diagnosis and management","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-06-13T00:00:00","LastModifiedDate":"2021-07-01T10:02:57.9184446","FirstGoLiveDate":"2019-07-04T12:02:08.1750229","CreatedDate":"2019-07-04T11:53:51.4031459","DevelopedAs":"CG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10173"}]},"ETag":"01000000-0000-001F-0000-00000002FD5C","Reference":"GID-NG10173","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Ectopic pregnancy and miscarriage: diagnosis and initial management (update)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-01T10:05:58.0203711","FirstGoLiveDate":"2020-06-15T08:07:22.2767677","CreatedDate":"2020-06-15T07:56:22.0298598","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10193"}]},"ETag":"01000000-0000-001F-0000-00000002FD69","Reference":"GID-NG10193","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Otitis media with effusion in under 12s: surgery","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2023-12-07T00:00:00","LastModifiedDate":"2021-07-01T10:08:57.8938693","FirstGoLiveDate":"2021-03-18T10:19:47.3474053","CreatedDate":"2021-03-18T09:37:42.1546253","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10630"}]},"ETag":"01000000-0000-001F-0000-00000002FD70","Reference":"GID-TA10630","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Tepotinib for treating advanced non-small-cell lung cancer with MET gene alterations [ID3761]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-03-23T00:00:00","LastModifiedDate":"2021-07-01T11:02:57.8984181","FirstGoLiveDate":"2020-03-10T13:31:33.0749156","CreatedDate":"2020-03-10T13:30:51.4812306","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3761","EvidenceAssessmentGroup":"KSR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10141"}]},"ETag":"01000000-0000-001F-0000-00000002FD78","Reference":"GID-QS10141","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Colorectal cancer (QS update)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-02-01T00:00:00","LastModifiedDate":"2021-07-01T11:20:57.8952822","FirstGoLiveDate":"2020-01-20T12:22:29.7852336","CreatedDate":"2020-01-20T12:19:48.0277756","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10812"}]},"ETag":"01000000-0000-001F-0000-00000002FDDD","Reference":"GID-TA10812","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Lorlatinib for untreated ALK-positive advanced non-small-cell lung cancer [ID3896]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-04-27T00:00:00","LastModifiedDate":"2021-07-01T11:47:57.9030137","FirstGoLiveDate":"2021-02-23T12:10:16.6495755","CreatedDate":"2021-02-23T12:09:35.5558719","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3896","EvidenceAssessmentGroup":"UY","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10698"}]},"ETag":"01000000-0000-001F-0000-00000002FDE6","Reference":"GID-TA10698","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Retifanlimab for treating anal canal squamous cell carcinoma after platinum-based chemotherapy [ID3815]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-06-04T11:05:38.8581511","FirstGoLiveDate":"2020-07-08T12:42:01.1113726","CreatedDate":"2020-07-08T12:40:34.7718479","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3815","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10583"}]},"ETag":"01000000-0000-001F-0000-00000002FDF4","Reference":"GID-TA10583","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pembrolizumab with chemotherapy and surgery for treating resectable gastric or gastro-oesophageal junction cancer [ID2696]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-01T14:32:56.5463284","FirstGoLiveDate":"2019-12-16T11:16:03.1970254","CreatedDate":"2019-12-16T11:14:58.4462224","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2696","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10649"}]},"ETag":"01000000-0000-001F-0000-00000002FEC3","Reference":"GID-TA10649","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Bimekizumab for treating moderate to severe chronic plaque psoriasis [ID2692]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-09-22T00:00:00","LastModifiedDate":"2021-07-01T22:20:56.419185","FirstGoLiveDate":"2020-05-13T09:27:43.001154","CreatedDate":"2020-05-13T09:24:51.911871","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2692","EvidenceAssessmentGroup":"SHTAC","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10142"}]},"ETag":"01000000-0000-001F-0000-00000002FF97","Reference":"GID-NG10142","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"PHG","Title":"Reducing sexually transmitted infections","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-06-08T00:00:00","LastModifiedDate":"2021-07-02T12:23:56.433076","FirstGoLiveDate":"2019-02-25T17:38:42.5950903","CreatedDate":"2019-02-25T17:34:50.6201352","DevelopedAs":"PH","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-DG10040"}]},"ETag":"01000000-0000-001F-0000-00000002FF9B","Reference":"GID-DG10040","ProjectType":"DG","ProductTypeName":"Diagnostics guidance","Process":"DT","Title":"PlGF-based testing to help diagnose suspected pre-eclampsia (update of DG23)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-02T12:24:29.6528611","FirstGoLiveDate":"2020-09-14T01:02:34.155922","CreatedDate":"2020-09-04T11:31:47.2979454","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10808"}]},"ETag":"01000000-0000-001F-0000-00000002FFC4","Reference":"GID-TA10808","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Dapagliflozin for treating chronic kidney disease [ID3866]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-01-05T00:00:00","LastModifiedDate":"2021-07-02T14:08:56.3918751","FirstGoLiveDate":"2021-02-03T14:31:52.6430057","CreatedDate":"2021-02-03T14:29:22.1749067","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3866","EvidenceAssessmentGroup":"ScHARR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10651"}]},"ETag":"01000000-0000-001F-0000-00000002FFCB","Reference":"GID-TA10651","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Pegcetacoplan for treating paroxysmal nocturnal haemoglobinuria [ID3746]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-02-02T00:00:00","LastModifiedDate":"2021-07-02T14:17:56.4225697","FirstGoLiveDate":"2020-05-13T09:33:43.0187291","CreatedDate":"2020-05-13T09:31:11.3006365","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3746","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10674"}]},"ETag":"01000000-0000-001F-0000-0000000303A1","Reference":"GID-TA10674","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"CDF Review","Title":"Abemaciclib with fulvestrant for treating hormone receptor-positive, HER2-negative advanced breast cancer after endocrine therapy [ID2727]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-09-15T00:00:00","LastModifiedDate":"2021-07-05T10:59:58.858403","FirstGoLiveDate":"2020-06-24T00:01:35.6179678","CreatedDate":"2020-06-17T10:08:34.6370422","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2727","EvidenceAssessmentGroup":"BMJ","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10228"}]},"ETag":"01000000-0000-001F-0000-0000000303A8","Reference":"GID-NG10228","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Falls in older people: assessing risk and prevention","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2024-03-01T00:00:00","LastModifiedDate":"2021-07-05T11:08:58.7721676","FirstGoLiveDate":"2021-06-28T12:26:54.4957242","CreatedDate":"2021-06-28T12:22:23.3770556","DevelopedAs":"CG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10820"}]},"ETag":"01000000-0000-001F-0000-00000003041B","Reference":"GID-TA10820","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Finerenone for treating chronic kidney disease in people with type 2 diabetes [ID3773]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-05-04T00:00:00","LastModifiedDate":"2021-06-29T09:41:55.3495848","FirstGoLiveDate":"2021-03-03T11:01:04.329404","CreatedDate":"2021-03-03T10:55:34.3309583","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3773","EvidenceAssessmentGroup":"PenTAG","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10775"}]},"ETag":"01000000-0000-001F-0000-00000003042A","Reference":"GID-TA10775","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Oral azacitidine for maintenance treatment of acute myeloid leukaemia after induction therapy [ID3892]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-05T13:53:58.7768986","FirstGoLiveDate":"2020-12-04T16:07:50.7403985","CreatedDate":"2020-12-04T16:05:19.9324306","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3892","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10719"}]},"ETag":"01000000-0000-001F-0000-000000030432","Reference":"GID-TA10719","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Empagliflozin for treating chronic heart failure with reduced ejection fraction [ID3826]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-02-02T00:00:00","LastModifiedDate":"2021-07-05T13:59:58.7680397","FirstGoLiveDate":"2020-08-13T13:41:34.8453233","CreatedDate":"2020-08-13T13:39:19.6115292","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3826","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10658"}]},"ETag":"01000000-0000-001F-0000-0000000304BE","Reference":"GID-TA10658","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Cabotegravir and rilpivirine for treating HIV-1 [ID3766]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-10-20T00:00:00","LastModifiedDate":"2021-07-05T16:57:39.1908647","FirstGoLiveDate":"2020-05-13T10:45:43.0008806","CreatedDate":"2020-05-13T10:42:32.1339341","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3766","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10639"}]},"ETag":"01000000-0000-001F-0000-0000000304C5","Reference":"GID-TA10639","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Sotorasib for previously treated KRAS G12C mutated, locally advanced or metastatic non-small-cell lung cancer [ID3780]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-03-09T00:00:00","LastModifiedDate":"2021-07-05T16:59:58.7967705","FirstGoLiveDate":"2020-04-01T11:11:20.5495872","CreatedDate":"2020-04-01T11:08:32.3472943","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3780","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10537"}]},"ETag":"01000000-0000-001F-0000-0000000304CB","Reference":"GID-TA10537","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"CDF Review","Title":"Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancer (CDF Review TA600) ID1683","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-05T17:00:39.2050851","FirstGoLiveDate":"2019-09-26T13:32:15.1638246","CreatedDate":"2019-09-26T13:30:23.8046436","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1683","EvidenceAssessmentGroup":"ScHARR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10182"}]},"ETag":"01000000-0000-001F-0000-0000000305AE","Reference":"GID-NG10182","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Weight Management: preventing, assessing and managing overweight and obesity (update)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2023-06-22T00:00:00","LastModifiedDate":"2021-07-06T11:26:59.613732","FirstGoLiveDate":"2020-12-02T11:28:48.8322328","CreatedDate":"2020-12-02T11:25:33.5676908","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10087"}]},"ETag":"01000000-0000-001F-0000-00000003060E","Reference":"GID-QS10087","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Neonatal parenteral nutrition","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-03-22T00:00:00","LastModifiedDate":"2021-07-06T12:21:39.2164435","FirstGoLiveDate":"2018-07-24T15:15:58.592575","CreatedDate":"2018-07-24T14:41:48.3265353","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10121"}]},"ETag":"01000000-0000-001F-0000-00000003068E","Reference":"GID-NG10121","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"PHG","Title":"Looked-after children and young people","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-10-20T00:00:00","LastModifiedDate":"2021-07-06T16:38:59.6939895","FirstGoLiveDate":"2018-08-22T11:19:31.2110758","CreatedDate":"2018-08-22T10:18:12.1093461","DevelopedAs":"PH","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10650"}]},"ETag":"01000000-0000-001F-0000-00000003075C","Reference":"GID-TA10650","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Berotralstat for preventing acute attacks of hereditary angioedema [ID1624]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-08-25T00:00:00","LastModifiedDate":"2021-07-07T10:15:42.8541337","FirstGoLiveDate":"2020-05-13T09:30:42.988331","CreatedDate":"2020-05-13T09:28:27.2354323","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1624","EvidenceAssessmentGroup":"UA","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10181"}]},"ETag":"01000000-0000-001F-0000-00000003076D","Reference":"GID-NG10181","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Rehabilitation for Chronic Neurological Disorders Including Traumatic Brain Injury","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2023-08-02T00:00:00","LastModifiedDate":"2021-07-07T10:44:59.6082003","FirstGoLiveDate":"2020-11-20T16:34:34.0866178","CreatedDate":"2020-11-20T16:30:43.1650966","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10792"}]},"ETag":"01000000-0000-001F-0000-0000000307DC","Reference":"GID-TA10792","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Maribavir for treating refractory or resistant cytomegalovirus infection after transplant [ID3900]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-07T14:29:59.5884229","FirstGoLiveDate":"2021-01-27T12:07:42.1715603","CreatedDate":"2021-01-27T12:06:53.9684226","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3900","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10840"}]},"ETag":"01000000-0000-001F-0000-0000000307E3","Reference":"GID-TA10840","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Cannabidiol for treating seizures caused by tuberous sclerosis complex ID1416","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-07T14:35:59.5749887","FirstGoLiveDate":"2021-04-19T11:00:09.2209409","CreatedDate":"2021-04-15T15:47:16.5665204","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1416","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10844"}]},"ETag":"01000000-0000-001F-0000-00000003086B","Reference":"GID-TA10844","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"CDF Review","Title":"Pembrolizumab for adjuvant treatment of resected melanoma with high risk of recurrence (CDF Review of TA553) [ID3776]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-01-26T00:00:00","LastModifiedDate":"2021-07-07T16:06:42.8532012","FirstGoLiveDate":"2021-05-28T15:22:59.02479","CreatedDate":"2021-05-28T15:19:53.5253216","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3776","EvidenceAssessmentGroup":"UL","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10334"}]},"ETag":"01000000-0000-001F-0000-000000030872","Reference":"GID-TA10334","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Betibeglogene autotemcel for treating transfusion-dependent beta-thalassaemia [ID968]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-09-15T00:00:00","LastModifiedDate":"2021-07-07T16:15:00.8942112","FirstGoLiveDate":"2018-03-28T06:00:57.3925585","CreatedDate":"2018-03-21T08:39:22.5175001","DevelopedAs":null,"RelevantTo":null,"IdNumber":"968","EvidenceAssessmentGroup":"UY","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10406"}]},"ETag":"01000000-0000-001F-0000-0000000308D2","Reference":"GID-TA10406","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Fedratinib for disease-related splenomegaly and symptoms in myelofibrosis [ID1501]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-07T21:30:00.8723049","FirstGoLiveDate":"2018-10-22T14:36:19.6793903","CreatedDate":"2018-10-22T14:35:50.9891677","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1501","EvidenceAssessmentGroup":"ScHARR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10671"}]},"ETag":"01000000-0000-001F-0000-0000000308D5","Reference":"GID-TA10671","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"TAG","Title":"Ripretinib for treating advanced gastrointestinal stromal tumours after 3 therapies [ID3805]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-05-25T00:00:00","LastModifiedDate":"2021-07-08T00:03:00.8837504","FirstGoLiveDate":"2020-05-28T11:19:00.6390636","CreatedDate":"2020-05-28T11:17:58.920438","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3805","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10225"}]},"ETag":"01000000-0000-001F-0000-000000030934","Reference":"GID-NG10225","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Familial Ovarian Cancer","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2024-03-13T00:00:00","LastModifiedDate":"2021-07-08T08:24:00.8945906","FirstGoLiveDate":"2021-06-21T13:38:49.387875","CreatedDate":"2021-06-18T16:31:03.4161958","DevelopedAs":"CG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10145"}]},"ETag":"01000000-0000-001F-0000-00000003093D","Reference":"GID-NG10145","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"SC","Title":"Adults with complex needs: social work interventions including assessment, care management and support","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-04-27T00:00:00","LastModifiedDate":"2021-07-08T08:33:00.8927615","FirstGoLiveDate":"2019-04-23T15:25:40.2787187","CreatedDate":"2019-04-23T15:22:21.4369704","DevelopedAs":"SC","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10680"}]},"ETag":"01000000-0000-001F-0000-000000030944","Reference":"GID-TA10680","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":"Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency [ID3791]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-08T09:18:46.3180161","FirstGoLiveDate":"2020-06-18T09:04:26.3227164","CreatedDate":"2020-06-18T09:03:16.628677","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3791","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10824"}]},"ETag":"01000000-0000-001F-0000-000000030951","Reference":"GID-TA10824","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Mavacamten for treating symptomatic obstructive hypertrophic cardiomyopathy [ID3928]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-08T09:21:00.8815924","FirstGoLiveDate":"2021-03-05T14:25:09.8799049","CreatedDate":"2021-03-05T14:23:23.2246366","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3928","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10853"}]},"ETag":"01000000-0000-001F-0000-000000030952","Reference":"GID-TA10853","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Belimumab for treating lupus nephritis [ID2722]","Status":"Proposed","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-08T09:21:00.8972148","FirstGoLiveDate":"2021-07-06T15:17:59.6079591","CreatedDate":"2021-07-06T15:13:29.7420063","DevelopedAs":null,"RelevantTo":null,"IdNumber":"2722","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10164"}]},"ETag":"01000000-0000-001F-0000-0000000309B7","Reference":"GID-NG10164","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Head injury: assessment and early management","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-05-11T00:00:00","LastModifiedDate":"2021-07-08T14:27:46.3266001","FirstGoLiveDate":"2020-01-03T10:47:04.5568933","CreatedDate":"2020-01-03T10:44:30.9995297","DevelopedAs":"CG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10091"}]},"ETag":"01000000-0000-001F-0000-0000000309C0","Reference":"GID-NG10091","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Myalgic encephalomyelitis (or encephalopathy)/chronic fatigue syndrome: diagnosis and management","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-08-18T00:00:00","LastModifiedDate":"2021-07-08T14:36:46.3467111","FirstGoLiveDate":"2017-10-13T14:42:16.6756734","CreatedDate":"2017-10-13T08:28:24.2397031","DevelopedAs":"CG","RelevantTo":null,"IdNumber":"869","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10237"}]},"ETag":"01000000-0000-001F-0000-0000000309C5","Reference":"GID-NG10237","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Hypoadrenalism: acute and long-term management","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2024-04-04T00:00:00","LastModifiedDate":"2021-07-08T15:27:46.3021663","FirstGoLiveDate":"2021-07-08T15:27:46.3021663","CreatedDate":"2021-07-07T16:16:57.8534207","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-DG10044"}]},"ETag":"01000000-0000-001F-0000-000000030A25","Reference":"GID-DG10044","ProjectType":"DG","ProductTypeName":"Diagnostics guidance","Process":"DT","Title":"Software with artificial intelligence derived algorithms for analysing CT brain scans in people with a suspected acute stroke","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-07-20T00:00:00","LastModifiedDate":"2021-07-08T17:03:00.8646859","FirstGoLiveDate":"2021-03-24T01:01:54.092381","CreatedDate":"2021-03-12T14:30:01.7980663","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MIB10256"}]},"ETag":"01000000-0000-001F-0000-000000030A2B","Reference":"GID-MIB10256","ProjectType":"MIB","ProductTypeName":"Medtech innovation briefings","Process":"MIB","Title":"Paige-Prostate an artificial intelligence (AI)-based system for the assessment of cancer in prostate biopsies.","Status":"InProgress","ProjectGroup":"Advice","PublishedDate":"2021-10-05T00:00:00","LastModifiedDate":"2021-07-08T17:37:40.393276","FirstGoLiveDate":null,"CreatedDate":"2021-07-08T17:37:40.3776506","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-APA10017"}]},"ETag":"01000000-0000-001F-0000-000000030A2D","Reference":"GID-APA10017","ProjectType":"APA","ProductTypeName":"Antimicrobial prescribing evidence summary","Process":"APA","Title":"IB10 Sphinotest a rapid point-of-care (POC) immunoassay","Status":"InProgress","ProjectGroup":"Advice","PublishedDate":"2021-10-05T00:00:00","LastModifiedDate":"2021-07-08T17:41:53.439349","FirstGoLiveDate":null,"CreatedDate":"2021-07-08T17:41:53.439349","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":["AMP"]},{"_links":{"self":[{"href":"/project/GID-HST10028"}]},"ETag":"01000000-0000-001F-0000-000000030A87","Reference":"GID-HST10028","ProjectType":"HST","ProductTypeName":"Highly specialised technology","Process":"HST","Title":"OTL-200 for treating metachromatic leukodystrophy [ID1666]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-09T00:03:01.5347931","FirstGoLiveDate":"2019-11-21T06:00:27.9709418","CreatedDate":"2019-11-14T16:22:43.5609148","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1666","EvidenceAssessmentGroup":"UY","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10230"}]},"ETag":"01000000-0000-001F-0000-000000030AF3","Reference":"GID-NG10230","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"COVID-19 rapid guideline","Title":"COVID-19 rapid guideline: Vaccine-induced Immune Thrombocytopenia and Thrombosis (VITT)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-07-29T00:00:00","LastModifiedDate":"2021-07-09T10:09:52.7693389","FirstGoLiveDate":"2021-07-09T10:06:01.3844568","CreatedDate":"2021-07-07T09:36:21.1438422","DevelopedAs":"COV","RelevantTo":"COV","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":["COV"]},{"_links":{"self":[{"href":"/project/GID-TA10618"}]},"ETag":"01000000-0000-001F-0000-000000030B05","Reference":"GID-TA10618","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Selpercatinib for RET fusion-positive advanced non-small-cell lung cancer [ID3743]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-09T11:03:01.409149","FirstGoLiveDate":"2020-01-29T10:04:36.0705024","CreatedDate":"2020-01-29T10:03:38.8051387","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3743","EvidenceAssessmentGroup":"UL","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10554"}]},"ETag":"01000000-0000-001F-0000-000000030B0A","Reference":"GID-TA10554","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Secukinumab for treating plaque psoriasis in children and young people [ID1669]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-10-20T00:00:00","LastModifiedDate":"2021-07-09T11:06:01.4242115","FirstGoLiveDate":"2019-11-25T06:00:22.8446007","CreatedDate":"2019-11-18T11:58:01.018582","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1669","EvidenceAssessmentGroup":"UA","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10846"}]},"ETag":"01000000-0000-001F-0000-000000030B78","Reference":"GID-TA10846","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping [ID1387]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-09T11:48:01.3730864","FirstGoLiveDate":"2021-06-14T14:16:04.0314805","CreatedDate":"2021-06-14T12:59:34.6200812","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1387","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10236"}]},"ETag":"01000000-0000-001F-0000-000000030B8F","Reference":"GID-NG10236","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"NG","Title":"GID-NG10236","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-09T14:44:33.5620648","FirstGoLiveDate":"2021-07-07T15:57:42.8513756","CreatedDate":"2021-07-07T15:56:58.2442169","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10234"}]},"ETag":"01000000-0000-001F-0000-000000030B90","Reference":"GID-NG10234","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"NG","Title":"GID-NG10234","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-09T14:43:28.7966153","FirstGoLiveDate":"2021-07-07T15:36:01.6645189","CreatedDate":"2021-07-07T15:34:13.9790942","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10739"}]},"ETag":"01000000-0000-001F-0000-000000030F2A","Reference":"GID-TA10739","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Aducanumab for treating mild cognitive impairment and mild dementia caused by Alzheimer's disease [ID3763]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-05-25T00:00:00","LastModifiedDate":"2021-07-11T22:36:03.8301198","FirstGoLiveDate":"2020-09-22T14:38:51.3789805","CreatedDate":"2020-09-22T14:32:21.5348385","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3763","EvidenceAssessmentGroup":"UW","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10156"}]},"ETag":"01000000-0000-001F-0000-000000030F82","Reference":"GID-NG10156","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"SC","Title":"Advocacy services for adults with health and social care needs","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-03-30T00:00:00","LastModifiedDate":"2021-06-30T14:11:57.9132965","FirstGoLiveDate":"2019-09-23T12:49:19.5331011","CreatedDate":"2019-09-23T12:46:44.8481304","DevelopedAs":"SC","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10703"}]},"ETag":"01000000-0000-001F-0000-000000030F94","Reference":"GID-TA10703","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Inclisiran for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1647]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-12T10:00:03.5804977","FirstGoLiveDate":"2020-07-13T16:24:15.7487774","CreatedDate":"2020-07-13T16:20:34.3408349","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1647","EvidenceAssessmentGroup":"UW","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-CGWAVE0725"}]},"ETag":"01000000-0000-001F-0000-000000030FA3","Reference":"GID-CGWAVE0725","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Depression in adults: treatment and management (update)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-05-12T00:00:00","LastModifiedDate":"2021-07-12T10:09:03.6340697","FirstGoLiveDate":"2016-03-04T13:15:45.0665179","CreatedDate":"2015-09-18T10:38:31","DevelopedAs":"CG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10378"}]},"ETag":"01000000-0000-001F-0000-00000003107F","Reference":"GID-TA10378","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Sapropterin for treating phenylketonuria [ID1475]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-08-18T00:00:00","LastModifiedDate":"2021-07-12T14:58:12.8132077","FirstGoLiveDate":"2018-08-20T06:00:26.9642269","CreatedDate":"2018-08-14T10:14:42.5659512","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1475","EvidenceAssessmentGroup":"UL","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10608"}]},"ETag":"01000000-0000-001F-0000-0000000310F0","Reference":"GID-TA10608","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Omburtamab for treating relapsed neuroblastoma  [ID1664]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-12T16:12:04.0328846","FirstGoLiveDate":"2020-01-21T13:40:27.4855307","CreatedDate":"2020-01-21T13:38:37.5481823","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1664","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10727"}]},"ETag":"01000000-0000-001F-0000-0000000310F7","Reference":"GID-TA10727","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Enfortumab vedotin for treating locally advanced or metastatic urothelial cancer after 2 therapies [ID3845]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":"2022-03-09T00:00:00","LastModifiedDate":"2021-07-12T17:36:04.0512014","FirstGoLiveDate":"2020-09-07T13:32:19.774649","CreatedDate":"2020-09-07T13:30:13.1658436","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3845","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10559"}]},"ETag":"01000000-0000-001F-0000-000000031151","Reference":"GID-TA10559","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Baloxavir marboxil for treating influenza [ID1537]","Status":"Suspended","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-13T00:01:00.812367","FirstGoLiveDate":"2019-11-27T06:00:22.9684668","CreatedDate":"2019-11-20T09:19:59.0060714","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1537","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT559"}]},"ETag":"01000000-0000-001F-0000-0000000311AD","Reference":"GID-MT559","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"MT539 3C Patch System for treating diabetic foot ulcers","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-01-19T00:00:00","LastModifiedDate":"2021-07-13T09:00:04.2204879","FirstGoLiveDate":"2021-01-15T09:50:40.5884963","CreatedDate":"2021-01-15T08:28:45.0296478","DevelopedAs":null,"RelevantTo":null,"IdNumber":"539","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10090"}]},"ETag":"01000000-0000-001F-0000-0000000311AE","Reference":"GID-QS10090","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Joint replacement (primary): hip, knee and shoulder","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-03-29T00:00:00","LastModifiedDate":"2021-07-13T09:00:04.3298916","FirstGoLiveDate":"2018-07-24T15:00:58.5990982","CreatedDate":"2018-07-24T15:00:01.5343094","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10222"}]},"ETag":"01000000-0000-001F-0000-000000031227","Reference":"GID-NG10222","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Bronchiolitis in Children","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-08-13T00:00:00","LastModifiedDate":"2021-07-13T12:27:04.0495795","FirstGoLiveDate":"2021-06-03T15:32:12.0320667","CreatedDate":"2021-06-03T15:20:40.2990657","DevelopedAs":"CG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10370"}]},"ETag":"01000000-0000-001F-0000-000000031293","Reference":"GID-TA10370","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"TYRX Absorbable Antibacterial Envelope for preventing infection from cardiac implantable electronic devices  [ID1440]","Status":"ImpactedByCOVID19","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-13T15:49:00.8598046","FirstGoLiveDate":"2018-07-30T06:00:52.2013261","CreatedDate":"2018-07-23T10:40:46.0215111","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1440","EvidenceAssessmentGroup":"UA","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10149"}]},"ETag":"01000000-0000-001F-0000-0000000312A3","Reference":"GID-NG10149","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Meningitis (bacterial) and meningococcal septicaemia: recognition, diagnosis and management","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2023-10-19T00:00:00","LastModifiedDate":"2021-07-13T16:31:00.7664743","FirstGoLiveDate":"2019-05-30T15:19:15.7205345","CreatedDate":"2019-05-30T15:14:56.7828539","DevelopedAs":"CG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10153"}]},"ETag":"01000000-0000-001F-0000-0000000312AC","Reference":"GID-NG10153","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Multiple sclerosis in adults: management","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-07-20T00:00:00","LastModifiedDate":"2021-07-13T16:33:05.7631954","FirstGoLiveDate":"2019-08-15T09:04:17.1143081","CreatedDate":"2019-08-15T09:01:38.9118905","DevelopedAs":"CG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10185"}]},"ETag":"01000000-0000-001F-0000-0000000312B3","Reference":"GID-NG10185","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Metastatic spinal cord compression in adults: risk assessment, diagnosis and management","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2023-08-23T00:00:00","LastModifiedDate":"2021-07-13T16:34:00.7588481","FirstGoLiveDate":"2021-01-20T07:25:20.7731211","CreatedDate":"2021-01-20T07:22:12.9533234","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10150"}]},"ETag":"01000000-0000-001F-0000-0000000312C2","Reference":"GID-NG10150","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Thyroid cancer: assessment and management","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-06-22T00:00:00","LastModifiedDate":"2021-07-13T16:36:05.6659738","FirstGoLiveDate":"2019-06-27T14:05:00.9749156","CreatedDate":"2019-06-27T14:01:39.9997369","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10119"}]},"ETag":"01000000-0000-001F-0000-0000000312C5","Reference":"GID-NG10119","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Babies, children and young people's experience of healthcare","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-08-25T00:00:00","LastModifiedDate":"2021-07-13T16:36:05.6972379","FirstGoLiveDate":"2018-07-11T09:02:45.2010649","CreatedDate":"2018-07-11T09:01:00.7943565","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10210"}]},"ETag":"01000000-0000-001F-0000-0000000312C6","Reference":"GID-NG10210","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Gambling: Identification, diagnosis and management","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2024-02-07T00:00:00","LastModifiedDate":"2021-07-13T16:36:05.712858","FirstGoLiveDate":"2021-05-28T14:31:59.0498957","CreatedDate":"2021-05-11T11:24:43.0582151","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-DG10039"}]},"ETag":"01000000-0000-001F-0000-00000003132F","Reference":"GID-DG10039","ProjectType":"DG","ProductTypeName":"Diagnostics guidance","Process":"DT","Title":"SeHCAT (tauroselcholic [75 selenium] acid) for diagnosing bile acid diarrhoea","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-11-17T00:00:00","LastModifiedDate":"2021-07-14T01:01:03.5101997","FirstGoLiveDate":"2020-08-17T01:01:29.3076244","CreatedDate":"2020-08-12T12:29:22.6882678","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10139"}]},"ETag":"01000000-0000-001F-0000-0000000313F8","Reference":"GID-NG10139","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"PHG","Title":"Vaccine uptake in the general population","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-04-06T00:00:00","LastModifiedDate":"2021-07-14T13:16:03.4783431","FirstGoLiveDate":"2019-01-29T09:42:44.8265111","CreatedDate":"2019-01-29T09:39:26.9851174","DevelopedAs":"PH","RelevantTo":"PH","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10781"}]},"ETag":"01000000-0000-001F-0000-000000031401","Reference":"GID-TA10781","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"CDF Review","Title":"Ixazomib with lenalidomide and dexamethasone for treating relapsed or refractory multiple myeloma (CDF review of TA505) [ID1635]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-03-09T00:00:00","LastModifiedDate":"2021-07-14T13:39:05.6475047","FirstGoLiveDate":"2021-01-22T00:01:27.0672229","CreatedDate":"2021-01-15T13:56:12.0733671","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1635","EvidenceAssessmentGroup":"UW","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10140"}]},"ETag":"01000000-0000-001F-0000-000000031477","Reference":"GID-QS10140","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"End of life care (QS update)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-09-02T00:00:00","LastModifiedDate":"2021-07-14T16:57:05.6995005","FirstGoLiveDate":"2019-10-02T15:59:16.6243765","CreatedDate":"2019-10-02T14:52:59.1180225","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-QS10114"}]},"ETag":"01000000-0000-001F-0000-00000003147F","Reference":"GID-QS10114","ProjectType":"QS","ProductTypeName":"Quality standard","Process":"QSD","Title":"Workplace health: long-term sickness absence and capability to work","Status":"ImpactedByCOVID19","ProjectGroup":"Guidance","PublishedDate":"2021-09-02T00:00:00","LastModifiedDate":"2021-07-14T17:00:05.6677686","FirstGoLiveDate":"2018-07-24T16:48:32.8445817","CreatedDate":"2018-07-24T16:46:00.6994505","DevelopedAs":null,"RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10481"}]},"ETag":"01000000-0000-001F-0000-0000000314D9","Reference":"GID-TA10481","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Chlormethine gel for treating mycosis fungoides-type cutaneous T-cell lymphoma [ID1589]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-08-18T00:00:00","LastModifiedDate":"2021-07-15T00:01:03.4916338","FirstGoLiveDate":"2019-05-01T15:00:46.5178294","CreatedDate":"2019-05-01T14:12:30.889809","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1589","EvidenceAssessmentGroup":"UA","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10140"}]},"ETag":"01000000-0000-001F-0000-000000031533","Reference":"GID-NG10140","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"PHG","Title":"Mental wellbeing at work","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-03-02T00:00:00","LastModifiedDate":"2021-07-15T08:30:17.0849014","FirstGoLiveDate":"2019-02-13T13:03:27.352434","CreatedDate":"2019-02-13T12:54:27.1005139","DevelopedAs":"PH","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-MT554"}]},"ETag":"01000000-0000-001F-0000-000000031536","Reference":"GID-MT554","ProjectType":"MTG","ProductTypeName":"Medical technologies guidance","Process":"MT","Title":"GID-MT554 KardiaMobile for the ambulatory detection of atrial fibrillation","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-01-06T00:00:00","LastModifiedDate":"2021-07-15T09:00:15.591479","FirstGoLiveDate":"2020-12-02T15:52:48.8009094","CreatedDate":"2020-12-02T15:41:34.8195513","DevelopedAs":null,"RelevantTo":null,"IdNumber":"554","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10610"}]},"ETag":"01000000-0000-001F-0000-00000003159A","Reference":"GID-TA10610","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Roxadustat for treating anaemia in people with chronic kidney disease [ID1483]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-03-02T00:00:00","LastModifiedDate":"2021-07-15T11:45:15.4515518","FirstGoLiveDate":"2020-01-28T14:29:58.7721304","CreatedDate":"2020-01-22T15:40:35.7077936","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1483","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10736"}]},"ETag":"01000000-0000-001F-0000-00000003159B","Reference":"GID-TA10736","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Icosapent ethyl with statin therapy for reducing the risk of cardiovascular events in adults with elevated triglycerides  [ID3831]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-03-23T00:00:00","LastModifiedDate":"2021-05-27T16:22:51.0948827","FirstGoLiveDate":"2020-09-18T08:42:43.298809","CreatedDate":"2020-09-18T08:40:55.9399617","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3831","EvidenceAssessmentGroup":"KSR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-IPG10153"}]},"ETag":"01000000-0000-001F-0000-00000003159D","Reference":"GID-IPG10153","ProjectType":"IPG","ProductTypeName":"Interventional procedures guidance","Process":"IP","Title":"Maintaining normothermia using temperature modulation devices to improve outcomes after stroke or subarachnoid haemorrhage","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2021-07-28T00:00:00","LastModifiedDate":"2021-02-26T16:10:38.6028475","FirstGoLiveDate":"2020-01-22T17:34:27.5092983","CreatedDate":"2020-01-22T17:33:29.712252","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1784","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10520"}]},"ETag":"01000000-0000-001F-0000-0000000315AD","Reference":"GID-TA10520","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Nintedanib for treating progressive fibrosing interstitial lung disease excluding idiopathic pulmonary fibrosis [ID1599]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-15T13:21:15.454834","FirstGoLiveDate":"2019-07-30T06:00:57.2288075","CreatedDate":"2019-07-23T09:02:48.2708749","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1599","EvidenceAssessmentGroup":"KSR","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10738"}]},"ETag":"01000000-0000-001F-0000-000000031609","Reference":"GID-TA10738","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Avatrombopag in combination for treating chronic immune thrombocytopenia [ID3838]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-15T17:30:15.4459398","FirstGoLiveDate":"2020-09-18T08:47:44.224208","CreatedDate":"2020-09-18T08:44:34.1733304","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3838","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10122"}]},"ETag":"01000000-0000-001F-0000-000000031665","Reference":"GID-TA10122","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA pre-2018","Title":" Abiraterone for treating newly diagnosed high-risk hormone-sensitive metastatic prostate cancer [ID945]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-16T00:01:23.0259589","FirstGoLiveDate":"2016-10-18T00:01:32.7103667","CreatedDate":"2016-10-11T16:01:34.713806","DevelopedAs":null,"RelevantTo":null,"IdNumber":"945","EvidenceAssessmentGroup":"UA","AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10730"}]},"ETag":"01000000-0000-001F-0000-000000031668","Reference":"GID-TA10730","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"177Lu-PSMA-617 for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-09-21T00:00:00","LastModifiedDate":"2021-07-16T00:01:23.0572126","FirstGoLiveDate":"2020-09-07T13:48:06.5053677","CreatedDate":"2020-09-07T13:46:50.7450324","DevelopedAs":null,"RelevantTo":null,"IdNumber":"3840","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-TA10606"}]},"ETag":"01000000-0000-001F-0000-000000031669","Reference":"GID-TA10606","ProjectType":"TA","ProductTypeName":"Technology appraisal guidance","Process":"STA 2018","Title":"Obeticholic acid for treating liver fibrosis in people with steatohepatitis  [ID1645]","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-06-08T00:00:00","LastModifiedDate":"2021-07-16T00:01:23.0884633","FirstGoLiveDate":"2020-01-27T06:00:16.3216903","CreatedDate":"2020-01-20T15:34:36.3101685","DevelopedAs":null,"RelevantTo":null,"IdNumber":"1645","EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10174"}]},"ETag":"01000000-0000-001F-0000-0000000316C9","Reference":"GID-NG10174","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Intrapartum care for healthy women and babies (update)","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2023-03-22T00:00:00","LastModifiedDate":"2021-07-16T08:04:22.9950737","FirstGoLiveDate":"2020-06-15T08:10:22.4005772","CreatedDate":"2020-06-15T08:07:51.6203897","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10097"}]},"ETag":"01000000-0000-001F-0000-0000000316D0","Reference":"GID-NG10097","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Subarachnoid haemorrhage due to ruptured aneurysms","Status":"ImpactedByCOVID19","ProjectGroup":"Guidance","PublishedDate":null,"LastModifiedDate":"2021-07-16T09:16:22.9978789","FirstGoLiveDate":"2017-11-29T12:07:44.0746668","CreatedDate":"2017-11-29T12:04:22.4319367","DevelopedAs":"CG","RelevantTo":"CG","IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]},{"_links":{"self":[{"href":"/project/GID-NG10148"}]},"ETag":"01000000-0000-001F-0000-0000000316D8","Reference":"GID-NG10148","ProjectType":"NG","ProductTypeName":"NICE guideline","Process":"CG","Title":"Self harm: assessment, management and preventing recurrence","Status":"InProgress","ProjectGroup":"Guidance","PublishedDate":"2022-06-29T00:00:00","LastModifiedDate":"2021-07-16T09:30:09.6857564","FirstGoLiveDate":"2019-05-30T10:37:15.5591863","CreatedDate":"2019-05-30T10:22:10.5234366","DevelopedAs":"CG","RelevantTo":null,"IdNumber":null,"EvidenceAssessmentGroup":null,"AreasOfInterestList":[]}]},"ETag":null,"Page":0,"PageSize":2048,"TotalItems":887,"ProjectGroup":"All"}